REGULATION OF GLYCOSYLATION IN MAMMALIAN CELL LINES: INSIGHTS FROM STRUCTURAL GLYCOMICS, ANALYSIS OF GLYCOSYLATION-RELATED GENES AND FUNCTIONAL RNAI SCREENS by ZHANG PEIQING
  
REGULATION OF GLYCOSYLATION IN  
MAMMALIAN CELL LINES:  
INSIGHTS FROM STRUCTURAL GLYCOMICS, 
ANALYSIS OF GLYCOSYLATION-RELATED GENES  















NATIONAL UNIVERSITY OF SINGAPORE 
2011 

 REGULATION OF GLYCOSYLATION IN 
MAMMALIAN CELL LINES:  
INSIGHTS FROM STRUCTURAL GLYCOMICS, 
ANALYSIS OF GLYCOSYLATION-RELATED GENES  












A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF BIOCHEMISTRY 






 I would like to express my heartfelt gratitude to my supervisor, Dr Song 
Zhiwei, for his guidance and patience throughout my graduate study. He brought me 
into the “sweet” field of glycobiology and helped me develop a strong appreciation 
towards science. During my six years working in his group, he always provided 
opportunities for me to venture into new areas of biology and biotech research, yet 
gave me high level of autonomy to think, speculate and work as a young researcher. I 
believe the knowledge and skills that I learned under him will prove to be a vital 
starter’s kit in my next stage of scientific career. 
 
  Members, alumni and attachment students of Expression Engineering Group 
at Bioprocessing Technology Institute (BTI) have always been nice people to work 
with.  I would like to especially highlight the contributions of Diana Tan, Desmond 
Heng, and Wang Tianhua to the Glycosylation Toolbox project. Ryan Haryadi 
isolated the CHO-gmt5 mutant which allowed me to study the structure-function 
relationship of the GDP-fucose transporter. Chan Kah Fai provided exceptional 
technical assistance in IEF and cloning. Helen Pu, our de facto lab manager, keeps 
everything in place and allows us to concentrate on our research with peace of mind. 
Natasha Pereira provided professional and prompt proof readings for all my 
manuscripts. I would like to thank John Goh for the enjoyable scientific or non-
scientific discussions.  
  
 I am indebted to Dr Muriel Bardor and her group members, Gavin, Corrine 
and Boon Tee, at BTI Analytics Group, for their expert assistance in mass 
spectrometry and chromatography experiments described in Chapter 3. I would like to 
acknowledge the inputs from Dr Yang Yuansheng and Mariati on transcript profiling 
of glycogenes in Chapter 4. The RNAi screening project wouldn’t have been possible 
without the collaboration with Dr Frederic Bard at IMCB. He kindly provided the 
kinome/phosphotome siRNA library and granted me the access to their HTS system. 
All the image acquisition and quantification work was performed in his lab at IMCB. I 
would like to also thank his group members, Germaine Goh for her technical 
assistance and insightful discussions and Pankaj Kumar for the invaluable advice on 
data analysis. 
 
 My research journey started with my interview for a master’s program with 
Professor Miranda Yap. I can’t thank her enough for the continued trust and 
encouragement, and the offers of two graduate studentships including the current PhD 
program. I wish her all the best for a speedy recovery. I would like to acknowledge 
the financial support by A*STAR Scientific Staff Development Award throughout my 
four years of PhD study. 
 
 According to the ancient wisdom in the Holy Bible, “Two are better than one; 
because they have a good reward for their labor.” (Ecclesiastes 4:9). I am so grateful 
to have so many wonderful people who helped me one way or another, many of whom 
are not listed here. And of course not forget to mention the unconditional love and 
support from my family, which has allowed me to pursue my dream in glycobiology, 








• Zhang, P., Tan, D. L., Heng, D., Wang, T., Mariati, Yang, Y., and Song, Z. 
(2010) A functional analysis of N-glycosylation-related genes on sialylation of 
recombinant erythropoietin in six commonly used mammalian cell lines, 
Metab Eng 12, 526-536. 
• Zhang, P.*, Haryadi, R.*, Chan, K. F., Teo, G., Goh, J., Pereira, N. A., Feng, 
H., and Song, Z. (2012) Identification of functional elements of the GDP-
Fucose transporter SLC35C1 using a novel CHO mutant, Glycobiology doi: 
10.1093/glycob/cws064. (*: Equal contribution)  
 
Other related publications 
 
• Lingg, N. *, Zhang, P.*, Song, Z, and Bardor, M. (Submitted) The sweet tooth 
of biopharmaceuticals: Importance of recombinant protein glycosylation 
analysis, Biotechnol J (Invited review). (*: Equal contribution) 
• Chan, K. F., Zhang, P., and Song, Z. (2010) Identification of essential amino 
acid residues in the hydrophilic loop regions of the CMP-sialic acid transporter 
and UDP-galactose transporter, Glycobiology 20, 689-701. 
• Goh, J. S., Zhang, P., Chan, K. F., Lee, M. M., Lim, S. F., and Song, Z. (2010) 
RCA-I-resistant CHO mutant cells have dysfunctional GnT I and expression of 
normal GnT I in these mutants enhances sialylation of recombinant 
erythropoietin, Metab Eng 12, 360-368.  
• Lim, S. F., Lee, M. M., Zhang, P., and Song, Z. (2008) The Golgi CMP-sialic 
acid transporter: A new CHO mutant provides functional insights, 





TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ..................................................................................................................... i 
LIST OF PUBLICATIONS .................................................................................................................... ii 
TABLE OF CONTENTS ....................................................................................................................... iii 
SUMMARY............................................................................................................................................ vii 
LIST OF FIGURES ............................................................................................................................... ix 
LIST OF TABLES ................................................................................................................................ xii 
ABBREVIATIONS .............................................................................................................................. xiii 
GRAPHIC SYMBOLS FOR MONOSACCHARIDES .................................................................... xiv 
 
CHAPTER 1: INTRODUCTION ................................................................................ 1 
1.1 Pathways and diversity of glycosylation ............................................................................ 3 
1.1.1 N-Glycosylation .................................................................................................................... 3 
1.1.1.1 N-Glycosylation pathway .................................................................................................... 3 
1.1.1.2 Structural diversity of N-glycans ......................................................................................... 6 
1.1.2 O-Glycosylation .................................................................................................................... 8 
1.1.2.1 O-Glycosylation pathway .................................................................................................... 8 
1.1.2.2 Structural diversity of O-glycans ......................................................................................... 9 
1.2 Impact of glycosylation in cellular physiology ................................................................ 11 
1.2.1 Intracellular functions of N-glycans .................................................................................... 11 
1.2.2 Glycans in extracellular recognition .................................................................................... 12 
1.2.3 Glycosylation in development: Congenital disorders of glycosylation ............................... 14 
1.2.4 Glycosylation change in cancer ........................................................................................... 17 
1.3 Impact of glycosylation in pharmacology ........................................................................ 18 
1.3.1 Sialylation of erythropoietin ................................................................................................ 19 
1.3.2 O-Glycosylation of mucin 1 ................................................................................................ 22 
1.3.3 Non-human glycosylation of biopharmaceuticals causes adverse immune responses ......... 24 
1.4 Regulation and control of glycosylation at the pathway level ........................................ 26 
1.5 Specific aims and organization of the thesis .................................................................... 27 
 
CHAPTER 2: MATERIALS AND METHODS ...................................................... 28 
2.1 Major materials ................................................................................................................. 28 
2.1.2 Antibodies, lectins, and fluorescent probes ......................................................................... 28 
2.1.3 Cell lines and culture media ................................................................................................ 29 
2.2 Core methods ..................................................................................................................... 29 
2.2.1 Cell culture .......................................................................................................................... 29 
2.2.2 Transient transfection using Lipofectamine in well dishes .................................................. 29 
2.2.3 Transient transfection using FuGene 6 in well dishes ......................................................... 30 
2.2.4 Large scale transient expression of Fc fusion proteins ........................................................ 31 
2.2.5 Protein A chromatography ................................................................................................... 32 
2.2.6 SDS-PAGE/Western blotting .............................................................................................. 32 
2.2.7 Isoelectric focusing (IEF) .................................................................................................... 33 
2.2.8 MALDI-TOF mass spectrometry ........................................................................................ 35 
2.2.9 Immunofluorescent cell staining .......................................................................................... 36 
2.2.10 Confocal microscopy ........................................................................................................... 37 
2.2.11 Fluorescence-activated cell sorting (FACS) ........................................................................ 37 
2.2.12 Quantitative RT-PCR (qRT-PCR) ....................................................................................... 38 
2.3 Model molecules ................................................................................................................. 39 
2.3.1 EPO and EPO-Fc for N-glycosylation study ....................................................................... 39 
2.3.2 MUC1-Fc for O-glycosylation study ................................................................................... 41 
 
CHAPTER 3: GLYCOMIC ANALYSIS OF CHO-K1, BHK-21, HEK293, COS-7 
AND 3T3 CELL LINES ............................................................................................. 42 
3.1 Introduction ....................................................................................................................... 42 
3.1.1 Background .......................................................................................................................... 42 
3.1.2 Specific aims and outlines ................................................................................................... 43 
3.2 Experimental procedures .................................................................................................. 44 
iv 
 
3.2.1 Preparation of cells for whole cellular glycomic analysis .................................................... 44 
3.2.2 Protein extraction ................................................................................................................. 45 
3.2.3 Reduction and carboxymethylation ...................................................................................... 45 
3.2.4 Tryptic and PNGase F digestions ......................................................................................... 46 
3.2.5 Separation of released N-glycans from O-glycopeptides ..................................................... 46 
3.2.6 Reductive elimination on O-glycopeptides fractions............................................................ 46 
3.2.7 Permethylation of N- and O-glycans .................................................................................... 47 
3.2.8 Sep-Pak Separation of permethylated glycans ..................................................................... 47 
3.2.9 Mass spectrometry analysis .................................................................................................. 47 
3.2.10 High pH anion exchange chromatography (HPAEC) .......................................................... 48 
3.2.11 Fluorescent staining of intracellular and cell surface Tn antigen by HPA ........................... 49 
3.3 Results ................................................................................................................................. 49 
3.3.1 Structural profiling of endogenous N-glycans by MALDI-TOF .......................................... 49 
3.3.1.1 N-Glycome of CHO-K1 ..................................................................................................... 50 
3.3.1.2 N-Glycome of BHK-21 ...................................................................................................... 54 
3.3.1.3 N-Glycome of HEK293 ...................................................................................................... 59 
3.3.1.4 N-Glycome of COS-7 ......................................................................................................... 63 
3.3.1.5 N-Glycome of 3T3 .............................................................................................................. 67 
3.3.1.6 Main features of N-glycomes of the five cell lines ............................................................. 73 
3.3.2 Structural profiling of endogenous O-glycans by MALDI-TOF .......................................... 75 
3.3.2.1 O-Glycome of CHO-K1 ..................................................................................................... 75 
3.3.2.2 O-Glycome of BHK-21 ...................................................................................................... 76 
3.3.2.3 O-Glycome of HEK293 ...................................................................................................... 77 
3.3.2.4 O-Glycome of COS-7 ......................................................................................................... 78 
3.3.2.5 O-Glycome of 3T3 .............................................................................................................. 79 
3.3.2.6 Main features of O-glycomes of the five cell lines ............................................................. 80 
3.3.3 HPA staining of intracellular and cell surface Tn antigen .................................................... 81 
3.3.4 Structural characterization of N-glycan on recombinant EPO-Fc produced in the five cell 
lines by MALDI-TOF .......................................................................................................... 82 
3.3.4.1 N-Glycan structures of EPO-Fc produced in CHO-K1 ...................................................... 83 
3.3.4.2 N-Glycan structures of EPO-Fc produced in BHK-21 ....................................................... 85 
3.3.4.3 N-Glycan structures of EPO-Fc produced in HEK293 ....................................................... 87 
3.3.4.4 N-Glycan structures of EPO-Fc produced in COS-7 .......................................................... 89 
3.3.4.5 N-Glycan structures of EPO-Fc produced in 3T3 ............................................................... 91 
3.3.4.6 Main features of N-glycosylation of recombinant EPO-Fc in the five cell lines ................ 93 
3.3.5 Comparative analysis of sialylation of EPO-Fc N-glycans by HPAEC ............................... 93 
3.3.6 Expression, purification, and initial O-glycosylation analysis of recombinant MUC1-Fc ... 96 
3.4 Discussion ............................................................................................................................ 99 
3.5 Chapter summary ............................................................................................................. 104 
 
CHAPTER 4: IMPACTS OF GLYCOSYLATION-RELATED GENES ON 
SIALYLATION OF RECOMBINANT EPO IN SIX MAMMALIAN CELL 
LINES .........................................................................................................................105 
4.1 Introduction ...................................................................................................................... 105 
4.1.1 Glycosylation in the context of biopharmaceutical drugs .................................................. 105 
4.1.2 Regulation of N-glycosylation at pathway level ................................................................ 105 
4.1.3 Genetic engineering approaches to enhance sialylation of N-glycans ................................ 107 
4.1.4 Specific aims and outlines .................................................................................................. 108 
4.2 Experimental procedures ................................................................................................. 109 
4.2.1 Transient transfection ......................................................................................................... 109 
4.2.2 IEF/immunoblotting analysis of EPO and EPO-Fc ............................................................ 110 
4.2.3 End-point RT-PCR analysis of heterologous glycogene expression .................................. 110 
4.2.4 Quantitative RT-PCR (qRT-CPR) profiling of endogenous glycogenes ............................ 112 
4.2.4 Thiobarbituric acid assay .................................................................................................... 114 
4.2.5 Lectin precipitation of glycoproteins .................................................................................. 115 
4.3 Results ............................................................................................................................... 115 
4.3.1 Organization and pathway-mapping of the glycosylation toolbox ..................................... 115 
4.3.2 Recombinant EPO produced in the six mammalian cell lines show distinct IEF profiles, due 
to differences in sialylation ................................................................................................ 119 
v 
 
4.3.3 Combinatorial expression of Group B genes from the glycosylation toolbox significantly 
improved recombinant EPO sialylation in HEK293, COS-7, 3T3 and NS0 cells ............. 121 
4.3.4 Sialyltransferases in Group B are responsible for the enhancement of EPO sialylation in 
HEK293, COS-7, 3T3 and NS0 cells ................................................................................ 127 
4.3.5 Overexpression of sialyltransferases and CMP-sialic acid transporter did not change the 
sialylation pattern of recombinant EPO produced by CHO-K1 and BHK-21 cells ........... 131 
4.3.6 Endogenous ST3GalIII and ST3GalIV are expressed at low levels in 3T3 and NS0 cells 133 
4.4 Discussion ......................................................................................................................... 135 
4.5 Chapter summary ............................................................................................................ 140 
 
CHAPTER 5: ELUCIDATION OF STRUCTURE-FUNCTION 
RELATIONSHIP OF GDP-FUCOSE TRANSPORTER ..................................... 141 
5.1 Introduction ..................................................................................................................... 141 
5.1.1 Nucleotide-sugar transporters: phylogeny and sequence alignment .................................. 142 
5.1.2 GDP-fucose transporter and its implications in diseases ................................................... 145 
5.1.3 Structure-function relationship of nucleotide-sugar transporters ....................................... 146 
5.1.4 Specific aims and outlines ................................................................................................. 147 
5.2 Experimental procedures ................................................................................................ 149 
5.2.1 Lectin staining of CHO-K1, CHO-gmt1 and CHO-gmt5 cells .......................................... 149 
5.2.2 Characterization of N-glycans on recombinant EPO-Fc by MALDI-TOF ........................ 149 
5.2.3 Cloning of human GFT and its variants ............................................................................. 150 
5.2.4 Immunofluorescent staining for localization and activity of GFT variants ....................... 152 
5.2.5 FACS analysis of cell surface fucosylation ....................................................................... 153 
5.3 Results ............................................................................................................................... 154 
5.3.1 Endogenous and recombinant N-glycans produced by CHO-gmt5 cell are free of sialic acid 
and fucose .......................................................................................................................... 154 
5.3.2 The human GDP-Fucose transporter is mainly localized to trans-Golgi ........................... 157 
5.3.3 The cytosolic C-terminal tail sequence of GFT is critical for its transport activity but not 
localization to the Golgi .................................................................................................... 158 
5.3.4  344EM345 and a cluster of three Lys residues in the C-terminal tail of GFT have significant 
impacts on the activity of GFT .......................................................................................... 163 
5.3.5 Three conserved Gly residues in the transmembrane helices have differential impacts on the 
activity of GFT .................................................................................................................. 167 
5.4 Discussion ......................................................................................................................... 169 
5.5 Chapter summary ............................................................................................................ 173 
 
CHAPTER 6: RNAi SCREENING OF KINASES AND PHOSPHOTASES TO 
IDENTIFY REGULATOR GENES OF CELL SURFACE GLYCOSYLATION175 
6.1 Introduction ..................................................................................................................... 175 
6.1.1 Regulation of glycosylation: insights from beyond the pathway ....................................... 175 
6.1.2 RNAi screening as a functional assay to discover novel genes and interactions ............... 175 
6.1.3 Specific aims and outlines ................................................................................................. 176 
6.2 Experimental procedures ................................................................................................ 178 
6.2.1 Reverse transfection of siRNA .......................................................................................... 178 
6.2.2 Lectin staining of cell surface glycans ............................................................................... 179 
6.2.3 Automated high-content image acquisition and quantification ......................................... 180 
6.2.4 Data analysis ...................................................................................................................... 181 
6.3 Results ............................................................................................................................... 181 
6.3.1 Proof-of-concept ................................................................................................................ 181 
6.3.3 Primary screens ................................................................................................................. 184 
6.3.3.1 ConA screens ................................................................................................................... 184 
6.3.3.2 AAL screens .................................................................................................................... 187 
6.4 Discussion ......................................................................................................................... 190 
6.5 Chapter summary ............................................................................................................ 193 
 
CHAPTER 7: CONCLUSIONS AND RECOMMENDATIONS ......................... 195 
7.1 Understanding the diversity of glycosylation: Insights from glycomic profiling of host 
cell lines and recombinant glycoproteins ....................................................................... 195 
vi 
 
7.2 Regulation of glycosylation at pathway level: Insights from functional analysis of 
pathway-associated glycogenes ........................................................................................ 197 
7.3 Regulation of glycogene-encoded proteins: Insights from structure-function analysis 
of GDP-fucose transporter ............................................................................................... 198 








 This thesis represents a multifaceted approach to elucidate the regulation 
mechanism of glycosylation in mammalian cell lines. First, N-linked and O-linked 
glycan structures of five commonly used mammalian cell lines, namely CHO-K1, 
BHK-21, HEK293, COS-7 and 3T3, were characterized by a combination of mass 
spectrometric and chromatographic techniques. Such glycomic profiling revealed 
several immunogenic non-human N-glycan structures in BHK-21 and 3T3 cells. The 
cell lines were also shown to have significantly different capabilities in N-glycan 
sialylation, which follows the order: (BHK-21, CHO) > (COS-7, HEK293) > 3T3. 
Significant difference in O-glycosylation was also detected: CHO-K1 was found to 
produce only mono- or di-sialyl T antigen structures whereas the other four cell lines 
were found to produce additional core 2 structures. This glycomic profiling study 
suggests that glycosylation is differentially regulated in cell lines. Second, regulation 
of N-glycosylation at pathway level was functionally investigated by focusing on 
sialylation of recombinant EPO. Thirty one genes that are directly involved in the N-
glycosylation pathway were cloned and heterologously expressed in the 
aforementioned five cell lines as well as NS0 cells. None of these genes could 
enhance EPO sialylation in BHK-21 and CHO-K1 cells. Overexpression of three 
sialyltransferases led to significant enhancement of EPO sialylation in HEK293, COS-
7, 3T3 and NS0 cells. The other glycogenes involved in upstream reaction steps could 
not synergize the effect of these sialyltransferases to further enhance sialylation. 
Transcriptional analysis of endogenous glycogene expression showed a relatively low 
abundance of sialyltransferases ST3GalIII in HEK293, 3T3 and NS0 and relatively 
higher abundance of an upstream glycogene, GlcI. The expression level of ST3GalIII 
in these three cell lines positively correlated to EPO sialylation extent. This study 
viii 
 
represents a pathway-focused functional analysis of glycogenes which supports the 
notion that glycan structural diversity is mainly a consequence of different expressions 
of glycogenes that control terminal modifications. Third, structure-function 
relationship of glycogene-encoded proteins, especially nucleotide-sugar transporters, 
represents a major interest in understanding the regulation of glycogene-encoded 
proteins and possible targets for controlling glycosylation. On the basis of a CHO 
glycosylation mutant of GDP-fucose transporter (GFT), a set of GFT variants were 
functionally analyzed. Through these analyses, we identified a conserved Glu-Met 
motif and a cluster of Lys residues in the C-terminal tail of GFT having a critical 
impact on the transport activity of GFT. In addition, three conserved Gly residues 
located in different transmembrane helices are also essential for GFT activity. These 
elements could represent viable targets for inactivating GFT as a therapeutic approach. 
Finally, functional genomic screening of the kinases and phosphotases in the human 
genome was performed aiming to identify novel genes that control the cell surface 
glycosylation. Using ConA and AAL lectins to specifically label oligomannose-type 
and fucosylated glycans at the cell surface, the primary screening results suggested a 
significant number of genes may play a role in the transition of oligomannose/hybrid-
type glycans to complex-type glycans as well as in fucosylation of glycans. On this 
basis, it is tempting to speculate that multiple kinases and phosphotases can regulate 
the glycosylation process upstream of the glycosylation pathway in response to 
extracellular or intracellular signals. In summary, this multi-layered investigation 
provides a set of essential information for selection of cell lines for biotech application 
as well as promising molecular targets for controlling the glycosylation for enhancing 
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CHAPTER 1: INTRODUCTION 
 
In the post genomic era, it has become increasingly clear that the complexity 
in biological functions is not soely determined by the number of genes per se in a 
genome. This notion is supported by the fact that despite the comparable number of 
genes in human and C. elegans, the biological complexity of human surpasses that of 
C. elegans by many orders of magnitude (Muller and Grossniklaus 2010). The 
increased complexity in biological functions during the evolution is contributed by a 
number of factors such as transcriptional and translational control of gene expression, 
as well as post translation modification of gene products. Post translational 
modification refers to the chemical modification of a protein after its translation. 
Glycosylation is the most prominent type of post translational modification. It refers 
to the enzymatic attachment of carbohydrate moieties to polypeptide or lipid 
backbones. In fact, an early survey of protein sequences in the SWISS-Prot database 
estimated that more than half of all proteins in nature are glycosylated (Apweiler et al. 
1999). 
The carbohydrate moieties, or glycans, can be added to the protein by either N- 
or O-linkage with the former being more common and better understood. In N-
glycosylation, the glycan is attached to an Asn residue within the sequence motif of 
N-X-(S/T) where X can be any amino acid except proline. O-glycosylation is initiated 
with the attachment of a monosaccharide such as mannose (Man), fucose (Fuc), or N-
acetylgalactosamine (GalNAc) to a Ser or Thr residue. O-GalNAc glycosylation, or 
mucin-type O-glycosylation, is the most common among these types of modifications 





Information encoded by different glycans, termed the “sugar code” (Gabius 
2000), is read by intracellular or extracellular glycans-binding proteins (or 
endogenous lectins), which in turn, through other interacting partners and mechanisms, 
creates new cellular functions/responses (Kilpatrick 2002). Glycosylation plays a 
pivotal role both intracellularly and extracellularly. The diverse functions of 
glycosylation range from protein folding (Parodi 2000), intracellular targeting of 
glycoproteins (Helenius and Aebi 2001), enhancing the stability of proteins (Sola and 
Griebenow 2009), cell-cell communication (Stanley and Okajima 2010), pathogen-
host interaction (Skehel and Wiley 2000), development (Haltiwanger and Lowe 2004), 
endocytosis (Weigel and Yik 2002), to cancer immunobiology and metastasis (Dennis 
et al. 1999, Irimura 1994, Taylor-Papadimitriou et al. 2002). Therefore, one major 
objective of glycobiology is to establish the structure-function relationship of glycans. 
Impact of glycosylation on the efficacy of therapeutic glycoproteins has also been 
documented, where there is often a context-dependent preference for different glycan 
structures (Walsh and Jefferis 2006). Hence, a systematic understanding of the 
regulation mechanism for protein glycosylation is crucial for deciphering the sugar 
code as well as effectively controlling this process for drug production and disease 
intervention. 
Unlike the synthesis of nucleic acids and proteins which follows the genetic 
blueprints, glycan structure produced by a cell is not directly encoded in the genome. 
Instead, glycans are synthesized by a series of complex metabolic reactions which 
involve a wide range of precursors, substrates and enzymes. As a result, glycans 
attached to the same protein can exhibit a myriad of structures. In addition, 
glycosylation has also been shown to be dependent on the attached protein, the host 
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cell line and species (Kornfeld and Kornfeld 1985). Therefore, there has been a 
growing appreciation of systematic characterization of glycome, i.e. the collection of 
glycan structures, produced by commonly used cell lines or cell types of research and 
clinical interests (Goetz et al. 2009, North et al. 2010, North et al. 2012). 
Glycosylation analysis of therapeutic glycoproteins provides critical insights with 
respect to the efficacy and safety of such drugs (Walsh and Jefferis 2006). 
Understanding the glycan structures produced in the cultured cells will allow for 
subsequent investigation of the regulation mechanism. 
Insights into the regulation of glycosylation are mainly contributed by 
transcriptional profiling of glycan-related genes (Comelli et al. 2006a, Nairn et al. 
2008) at pathway level. Detailed functional analysis of these genes is lacking, together 
with insights from systems level. 
The following paragraphs begin with an introduction on the structural diversity 
of glycans and pathways for the biosynthesis of such glycan structures. This is 
followed by a brief description of glycan functions on proteins and cells. Next, the 
current understanding of regulation of glycosylation at pathway level is highlighted. 
Finally, specific aims and organization of the thesis are described. 
 
1.1 Pathways and diversity of glycosylation 
1.1.1 N-Glycosylation 
1.1.1.1 N-Glycosylation pathway  
The N-glycosylation pathway is comprised of a series of enzymatic reactions 
with the early part largely conserved in eukaryotes. It is initiated in the ER with the 
formation of dolicol-linked sugar precursor, which is then elaborated to form a 
Glc3Man9GlcNAc2 tetradeca-saccharide (Fig. 1.1). This saccharide is then 
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transferred to an Asn residue within an N-glycosylation sequon (N-X-(S/T)) of a 
nascent polypeptide.  
 
Fig. 1. 1. Assembly of N-glycan precursor in the ER 
The precursor structure of N-glycan is first synthesized at the cytosolic side of the ER 
membrane by the enzymatic attachment of a GlcNAc residue on a dolicol lipid carrier 
(bottom left region). This is followed by the attachment of a second GlcNAc to the 
first GlcNAc and subsequent attachment of five Man residues. The Man5GlcNAc2 
structure is then flipped together with the lipid carrier to the luminal side of ER, 
followed by the attachment of four more Man residues. Finally, the 
Glc3Man9GlcNAc2 N-glycan precursor structure is formed by the attachment of three 
Glc residues. This tetradeca-saccharide is then enzymatically transferred en bloc to an 
Asn residue within a N-X-(S/T) sequon of a nascent polypeptide. The substrates for 
Glc, Man, and GlcNAc are UDP-Glc, GDP-Man, and UDP-GlcNAc, respectively. 
Glycogenes involved in the respectively reaction steps in yeast are shown in italic 
alphanumeric format (e.g. ALG7 for the attachment of the first GlcNAc to the lipid 
carrier). (Adapted from Stanley et al. 2009) 
 
In the ER lumen, initial processing of N-glycan is carried out to remove the 
three terminal Glc residues and one Man residue (Fig. 1.2). These steps are catalyzed 
by α-glucosidases and α-mannosidases, which belong to the dedicated family of 
glycan hydrolases, or glycosidases. The glycoprotein is then targeted to the Golgi 
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apparatus to undergo further processing by α-mannosidases in the cis-Golgi. The 
trimmed N-glycan can be decorated sequentially in the medial- and trans-Golgi with a 
variable content of GlcNAc, Gal and Sia residues by glycosyltransferases with 
specificities towards the respective sugars. The tissue-specific expression of different 
glycosyltransferases, together with the reaction network containing parallel, sequential, 
or competitive steps, ultimately give rise to a diverse collection of N-glycan structures 
carried by membrane or secreted proteins. 
 
Fig. 1. 2. Overview of cellular organization of the N-glycosylation pathway 
Initial trimming of N-glycan removes three Glc and one Man residues. The N-glycan 
undergoes further trimming in the cis-Golgi. Structural diversity arises due to the 
differential branching and chain elongation of N-glycans in the medial- and trans-
Golgi. (Adapted from Stanley et al. 2009) 
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1.1.1.2 Structural diversity of N-glycans  
Three major classes of N-glycans can be found on glycoproteins. The 
oligomannose-type glycan contains only Man residues on top of the two GlcNAc 
residues. In complex-type glycans, the non-reducing terminal region is decorated with 
other types of monosaccharide such as GlcNAc, Gal, or Sia. Hybrid-type glycan 
contains both Man and other monosaccharide at the non-reducing termini. Despite 
such structural difference, a Man3GlcNAc core is preserved in all N-glycans, forming 
the basis for the generation of different terminal structures. 
 
Fig. 1. 3. Examples of oligomannose, complex, and hybrid N-glycan structures 
All N-glycans contain a Man3GlcNAc2 core structure (shown in the boxed area). 
Three types of N-glycans are formed, namely oligomannose-type which contains all 
mannose, complex-type which contains other types of monosaccharide, and hybrid-
type which contains both mannose and other types of monosaccharide, on top of the 
core structure. (Adapted from Stanley et al. 2009) 
 
Structural diversity of N-glycans is further complicated by variations in 
terminal modification, branching, and core fucosylation (Fig. 1.4). This increases the 
total number of possible N-glycan structures by many orders of magnitude. In fact, 
glycomic analysis of cell lines and recombinant glycoproteins revealed a huge 
collection of N-glycan structures with major difference in the number of branches 
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(ranging from two to four), sialic acid content ( typically n = 0 – 4), and presence or 
absence of core fucose (North et al. 2012). 
 
Fig. 1. 4. Examples of bi-, tri- and tetra-antennary complex-type N-glycans 
Note the difference in the number of branches, content of sialic acid residues and core 
fucosylation among the three example structures. Structures were drawn using 
GlycoWorkBench software (Ceroni et al. 2008). 
 
N-glycosylation also displays a species-dependent fashion (Fig. 1.5). In yeast, 
activities of mannosyltransferases add more Man residues leading to the formation of 
highmannose-type of N-glycans. In slime mold, however, the N-glycans exit the Golgi 
with 8 mannose residues. In plant cells, the Man8 glycan is further trimmed to a Man3 
core structure with a bisecting xylose (Xyl) residue. In invertebrates, the N-glycan can 
be core fucosylated by α1,3- or α1,6-linkages at both reducing end GlcNAc residues. 
The terminal modification of N-glycans in mammals is more advanced where the 
GlcNAc can be further linked to Gal, which in turn can be capped by Sia. In addition 
to terminal elongation, mammalian N-glycans can be further branched to form tri- or 





Fig. 1. 5. Species variations of N-glycosylation 
N-glycans produced in yeast are predominantly highmannose type. In slime molds, the 
N-glycans typically contain 8 Man residues. Plant N-glycans are more thoroughly 
trimmed to a Man3GlcNAc core structure with the addition of a bisecting Xyl residue 
and an α1,3-linked core fucose. Invertebrate N-glycans are devoid of Xyl but contains 
two α1,3-linked and one α1,6-linked core fucose residues. Bisecting Xyl and α1,3-




1.1.2.1 O-Glycosylation pathway 
O-Glycosylation is initiated in the cis-Golgi with the attachment of a GalNAc 
residue to a Ser or Thr residue in a protein (Fig. 1.6). Different from N-glycosylation, 
the consensus sequence for such attachment is still unknown, despite evidence 
suggesting the preference of regions rich in Ser/Thr, Pro and Ala for the attachment of 
O-glycans (Jensen et al. 2010, Kirnarsky et al. 1998). The GalNAc residue O-linked to 
Ser/Thr is also known as the Tn antigen. Modification of Tn antigen by a sialic acid 
results in a sialyl-Tn antigen (STn), representing a dead end structure which cannot be 
further modified. Modification of Tn antigen by a Gal residue results in a core 1 
structure, also known as a T antigen. This reaction is catalyzed by a family of 
glycosyltransferases, called polypeptide GalNAc transferases which contain about 20 
isoforms in human (Ten Hagen et al. 2003). These GalNAc transferase isoforms are 
expressed in a tissue-specific fashion and show preference toward different peptide 
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sequences. Because Tn, STn and T antigen structures are exclusively expressed on the 
surface of cancer cells, they are known as tumor-associated antigens or tumor-specific 
O-glycans. Modification of Tn antigen by a GlcNAc residue leads to a core 3 structure. 
GlcNAcylation of core 1 and core 3 structures results in core 2 and core 4 structure, 
respectively. All these core structures can be further processed, leading to extended 
core 1 – 4 structures. 
 
Fig. 1. 6. Biosynthetic pathway of common mammalian O-glycans 
Mucin-type O-glycosylation is initiated with the attachment of a GalNAc residue to 
Ser/Thr. This monosaccharyl structure alone is called Tn antigen. Sialylation of the Tn 
antigen produces a “dead end” structure called STn. Modification of the Tn antigen 
leads to a diverse set of structures with four major types of core structures (colored 
clades). Enzymes catalyzing the reactions were mapped into the pathway diagram 
based on their in vitro activity and specificity. (Adapted from Tarp and Clausen 
2008) 
 
1.1.2.2 Structural diversity of O-glycans 
 Structural diversity of O-glycosylation can be in part contributed by terminal 
modification of different core structures (Fig. 1.7). The major difference can be 





Fig. 1. 7. Elaboration of O-glycans by terminal modifications 
Elongation of the core structures leads to a variety of O-glycans with different 
terminal sequences and length of the branches. (Adapted from Marth and Grewal 
2008) 
 
 In addition to the four core structures found in mammals, additional four core 
structures exist, despite less abundantly, in other species (Fig. 1.8). These structures 
differ in the linkages of Gal, GlcNAc, or GalNAc to the Tn antigen. For example, in 
core 8, the Gal residue is α-linked to the GalNAc. In contrast, the Gal is β-linked to 
the GalNAc in core 1 structure. However, these structures (core 5 – 8) are rare in 
mammals especially human. 
 
Fig. 1. 8. Illustrations of 8 core O-glycan structures 
(Adapted from Tarp and Clausen 2008) 
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1.2 Impact of glycosylation in cellular physiology 
Glycans attached to the proteins have critical intracellular and extracellular 
functions that are essential to maintaining the homeostasis of cellular physiology and 
interaction of cells with their surrounding environment. 
 
1.2.1 Intracellular functions of N-glycans 
N-Glycans are attached to the nascent polypeptide co-translationally and play 
an indispensible role in the folding of glycoproteins in the ER and its targeting to the 
Golgi apparatus (Fig. 1.9). The Glc3Man9GlcNAc2 N-glycan is first processed by 
glucosidase I (GlcI) by removing the top (non-reducing end) Glc. This is followed by 
the action of glucosidae II (GlcII) to remove the Glc residue beneath. The 
Glc1Man9GlcNAc2 N-glycan is a cognate structure of two ER lectins, namely the 
membrane bound calnexin (CNX) and the soluble calreticulin (CRT), both associate 
with ERp57. Folding of the sequestrated glycopolypeptide is assisted by ERp57 which 
catalyzes di-sulfide bond formation. The glycoprotein dissociates with the chaperone 
complex and GlcII removes the last Glc residue. The properly folded glycoprotein 
carrying an oligomannose N-glycan is then recognized by an escort protein, ERGIC-
53, which is sorted together with the bound glycoprotein into COPII vesicles for 
anterograde trafficking to the Golgi (reviewed by Helenius and Aebi 2001). 
N-glycans carried by lysosomal hydrolases are essential for targeting of these 
proteins to the lysosome (Fig. 1.2). In this scenario, the non-reducing terminal or 
subterminal Man residues are enzymatically modified in the cis-Golgi by GlcNAc-
phosphate. Removal of the GlcNAc moiety results in the formation of Man-6-
phosphate motif which is recognized in the TGN by the endogenous lectin Man-6-
phosphate receptor. This receptor then escorts the lysosomal hydrolases into clathrin-
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coated vesicles which deliver the hydrolases to the lysosome (reviewed by Dahms et 
al. 2008, Kim et al. 2009).  
 
Fig. 1. 9. N-Glycans assist protein folding and targeting to the Golgi 
The mono-glucosylated N-glycan after the first GlcII treatment binds to calnexin 
(CNX) or calreticulin (CRT). The attached polypeptide is then folded with the aid of 
ERp57, after which the Glc residue is cleaved by glucosidase II. The oligomannose N-
glycan binds to ERGIC-53 and is then targeted to the Golgi. Red triangle: Glc. Brown 
ribbon: polypeptide backbone. (Adapted from Helenius and Aebi 2001) 
 
1.2.2 Glycans in extracellular recognition 
Extracellular functions of glycans are primarily mediated by glycan-binding 
proteins (GBP), also known as endogenous lectins. The chemical features of cell 
surface glycans allow for specific binding of lectins expressed on apposing cells 
(Kishore et al. 1997). Many of the lectins contain activating or inhibitory motifs in 
their cytosolic tails (Angata 2006). Therefore, binding of glycans to such lectins often 
leads to stimulation or inhibition of signaling, especially in the context of immune 
response (Geijtenbeek and Gringhuis 2009). Because glycans are often attached to 
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cell surface receptor molecules such as EGF receptor, glycans can also participate in 
intracellular signaling or trafficking events induced by glycan-lectin binding (Dennis 
et al. 2009). The cell surface glycans can be remodeled by extracellular glycan 
hydralases, such as sialidases that specifically remove sialic acids from the non-
reducing end of glycans. Remodeling of glycan structures enables the dynamic 
regulation of intracellular signaling (Parker and Kohler 2010).  
One prominent example of glycan function in cell migration is the role of cell 
surface carbohydrate, specifically sialyl-Lewis x (sLex) structure in mediating 
leukocyte extravasation (Kuijpers and Roos 1993) (Fig. 1.10). In this process, a 
leukocyte circulating in a blood capillary is transiently in contact with a lectin call P-
selectin expressed on the surface of endothelial cells near the site of inflammation. 
This weak interaction is mediated by sLex structure expressed on the leukocyte surface 
and slows down the leukocyte which then rolls long the capillary lining. Although the 
final capture of the leukocyte is mediated through integrin molecules, the glycan-
lectin interaction provides an essential first contact that functions as a light “brake” 
allowing for efficient adhesion of leukocyte to the endothelium. 
 Cell surface glycans can be exploited by pathogen for specific targeting, entry, 
and exit, into and out of host cells. The two surface antigens, hemagglutinin (HA) and 
neuraminidase (NA) of influenza viruses are in fact a sialic acid-binding lectin and a 
sialidase, respectively. Binding of HA to cell surface sialic acids allows for docking of 
influenza viruses onto host cells. At the end of a virus replication cycle, NA cleaves 
the sialic acids bound to the viral surface, allowing for efficient escape of the virus 
particles from the host cells (reviewed by Skehel and Wiley 2000). The tissue-specific 
expression of glycans provides a molecular basis for tissue- and species-tropism of 
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viruses (van Riel et al. 2006), highlighting the critical impact of glycosylation in host-
pathogen interactions.   
 
 
Fig. 1. 10. Glycan-lectin interaction mediates leukocyte extravasation 
Initial weak interaction between sLex expressed on the leukocyte surface and P-
selectin expressed on the blood endothelial surface slows down the circulating 
leukocyte and allows it to roll along the capillary for final capture by integrin. 
(Adapted from Nelson and Cox 2005) 
 
1.2.3 Glycosylation in development: Congenital disorders of glycosylation 
Because all eukaryotic cell surfaces are covered with glycocalyx, it has been 
long postulated that glycosylation could play a critical role in development. In fact, 
SSEA-1, a well defined marker for embryonic stem cell, is in fact a Lewis x (Lex) 
(Galβ1,4 (Fucα1,3)GlcNAc) structure (Muramatsu and Muramatsu 2004). LeX is not 
expressed in most of the differentiated tissues, except in some immune cells and 
cancer cells. Other evidences arise from targeted mutations of upstream N-




An extreme example underlining the importance of glycosylation in 
development is a rare class of inherited diseases named congenital disorders of 
glycosylation (CDG) (reviewed by Jaeken and Matthijs 2007). The clinical features of 
CDG include embryonic lethality, growth and mental retardation, and facial 
abnormality. CDG are caused by genetic mutations in glycosylation-related genes that 
are involved in assembly of glycans (CDG-I) and processing of glycans (CDG-II). 
The systemic impact of CDG strongly suggests a role of glycosylation in development 
and maintaining physiological homeostasis. Apart from the two genes implicated in 
CDG-Ia and CDG-Ib shown in Fig. 1.1, many other genes involved in N-linked or O-
linked glycosylation or trafficking are implicated in CDG (Table 1.1). These genes 
can be functionally classified as glycosyltransferases, nucleotide-sugar transporters, 
sugar metabolism-related proteins, and COG proteins. Leukocyte adhesion deficiency 
type II (LAD-II) was identified as a genetic defect in GDP-fucose transporter and is 
also known as CDG-IIc (Lubke et al. 2001, Luhn et al. 2001). Such genetic defect led 
to deficiency in fucosylation of glycans, suggesting an indispensable role of the GDP-
fucose transporter in maintaining normal fucosylation level. Structure-function 




Table 1. 1. List of human congenital disorders of glycosylation 
CDG was originally classified into CDG-I (mutation affecting glycan assembly) and 
CDG-II (mutation affecting glycan processing). The rapid expanding CDG family 
now include mutations that affect O-glycosylation and protein trafficking as well. 








1.2.4 Glycosylation change in cancer 
One hallmark of cancer cells is the change in glycosylation. In fact, a majority 
of monoclonal antibodies raised against cancer cells turned out to be specific for 
carbohydrates that are specifically expressed in early developmental stage or cancer 
cells (Feizi 1985). Examples of altered glycosylation include increased sialylation of 
N-linked and O-linked glycans as well as glycosphingolipids (Dennis et al. 1999), 
increased fucosylation of serum alpha-fetaprotein (Aoyagi et al. 1985, Moriwaki et al. 
2007) and aberrant O-glycosylation of mucin (discussed below in Section 1.3.2). 
Perhaps the best characterized type of glycosylation change in cancer is the 
increased branching of N-glycans, which is resulted from upregulation of GlcNAc 
transferase V (GnTV) expression. The inducible expression of GnTV was shown to be 
mediated through its 5’ promoter region by a transcription factor Ets-1 in response to 
stimulation by v-src, H-ras and v-fps (Ko et al. 1999, Pierce et al. 1997).  The enzyme 
GnTV catalyzes the attachment of a GlcNAc that is β1,6-linked to a Man residue in 
the core N-glycan structure (Fig. 1.11). The β1,6-branch is preferentially subjected to 
poly-LacNAc extension. The LacNAc units serve as acceptor structure for 
fucosylation and sialylation. A few hypotheses have been proposed to explain the 
involvement of increased glycan branching in cancer. One theory suggests that 
binding of galectin to the cell surface poly-LacNAc structures cross-links the protein 
carriers (e.g. EGF receptor), and thus creates a lattice-like structure that is resistant to 
endocytosis-mediated downregulation of signaling (Boscher et al. 2011). Another 
postulation states that the β1,6-branch leads to the formation of sialyl-Lewis x (sLex) 
structure which is recognized by endogenous lectins, selectins (Resto et al. 2008, Zen 
et al. 2008). Binding of sLex to selectins is an essential step in leukocyte extravasation 
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(Ebnet and Vestweber 1999). It is possible that cancer cells gain metastatic potential 
by acquiring such interactions.  
 
 
Fig. 1. 11. Increased N-glycan branching by GnTV upregulation in cancer cells  
Upregulation of GnTV increases the β1,6-braching of N-glycans. Such β1,6-branches 
are preferentially elongated by poly-LacNAc structures which are targets of galectin 
binding. The LecNAc repeating units also serve as substrate for the formation of 
sialyl-Lewis x (sLex) epitope which is then recognized by selectins. (Adapted from 
Varki et al. 2009) 
 
1.3 Impact of glycosylation in pharmacology 
A major proportion of biopharmaceutical drugs on the market are 
glycoproteins, including hormones and growth factors, antibodies, and Fc fusion 
proteins (Walsh 2010). A breakthrough discovery of glycosylation in pharmacology 
was made by Ashwin and Morell about 40 year ago (Morell et al. 1971). They found 
the in vivo circulatory half life of human chorionic gonadotropin (hCG) is critically 
dependent on sialylation of the attached N-glycans. In fact, hCG carrying sialylated 
glycans has a half life of a few hours. The desialylated hCG, in sheer contrast, is 
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quickly cleared from blood circulation in less than 10 min. This discovery later led to 
the identification of asialoglycoprotein receptor in the liver, also known as Ashwin-
Morell receptor, which specifically recognizes asialoglycans and mediates the 
clearance of glycoproteins carrying such structures in the liver. It is therefore 
proposed that sialylation of glycoproteins that carry glycans at the outer surface is a 
critical determinant of the in vivo circulatory half lives. This notion is supported by 
observations from a variety of glycoproteins. Most sialylated glycoproteins were 
found to have half lives in the order of a few hours whereas the half lives of 
desialylated glycoproteins were dramatically reduced to a few minutes (Gan 1979, 
Saxena et al. 1997, Sodetz et al. 1977, Watari et al. 1997). Impact of glycosylation on 
in vivo half life is discussed in detail in the context of a major biopharmaceutical drug, 
erythropoietin. 
 
1.3.1 Sialylation of erythropoietin 
 Erythropoietin (EPO) is a glycoprotein hormone that stimulates the 
differentiation of hematopoietic stem cells into red blood cells. Majority of EPO is 
produced in renal peritubular interstitial cells under the control of the transcription 
activator hypoxia-inducible factor-1 (HIF-1) (reviewed by Krantz 1991). HIF-1 
consists of two subunits, an oxygen-sensitive α-subunit that accumulates when cells 
are subjected to low level of oxygen, as well as an oxygen-independent β-subunit. 
Hence, the production of EPO is regulated by tissue oxygenation. EPO is first 
synthesized as a 193 aa polypeptide precursor. The first 27 aa serve as a signal peptide 
and is cleaved upon the translocation of EPO into ER lumen. The C-terminal arginine 
residue is also cleaved during the secretion process. The remaining polypeptide 
consists of 165 aa with an estimated molecular weight of 18.4 kDa. This polypeptide 
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assumes a simple monomeric structure when fully folded, with about 50% sequence 
forming 4 α-helices connected by loops and compacted by two disulphide bonds.  
There are three N-glycosylation and one O-glycosylation sites (Fig. 1.12). The mature 
EPO has an apparent molecular weight ranging from 20 kDa to around 40 kDa. The 
attached carbohydrate can account for as much as half of the molecular weight of EPO. 
The N-glycans attached to EPO can display a variety of structures, including bi-, tri- 
and tetra-antennary glycans with different terminal sequences. The O-glycan, on the 
other hand, is typically a core 1 structure with up to two sialic acid residues.  
 
 
Fig. 1. 12. A computer model of human EPO with the attached glycans 
Computer models of N-linked (blue) and O-linked (purple) glycans were docked onto 
the crystal structure of a human EPO molecule. EPO contains primarily α-helices (red 
ribbons) which are connected by loops (green lines). The three N-glycans and one O-
glycan are projected from the outer surface of EPO and dramatically increase its 
hydrodynamic volume.   
 (Adapted from the website: http://glycam.ccrc.uga.edu/ccrc/) 
 
The major application of EPO in medicine is for the treatment of renal anemia 
(Eschbach et al. 1989). In kidney diseases that destroy the source of EPO production, 
administration of EPO increases the level of red blood cells. Due to the huge demand 
worldwide, EPO has been ranked one of the top biopharmaceutical drug since late 
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1990’s with annual sales exceeding 7 billion US dollars in 2009 (Walsh 2010). The 
current paradigm for the production of EPO is to clone the gene (usually the cDNA) 
encoding the human EPO and express it in a mammalian cell line that is capable of 
producing “human-like” glycan structures. The recombinant EPO is secreted into the 
conditioned media, purified and made into the final drug formulation. The most 
common host cell lines include Chinese hamster ovary (CHO), baby hamster kidney 
(BHK-21) (Nimtz et al. 1993, Nimtz et al. 1995), and human fibrosarcoma HT-1090 
in which the endogenous EPO gene was activated by a transfected viral promoter 
(Deicher and Horl 2004). 
Glycosylation critically modulates the in vivo bioactivity of EPO by affecting 
its circulatory half life. In fact, early studies showed that sialylated EPO had a half life 
of about 3 hours while that of the desialylated EPO was only about 2 min (Fukuda et 
al. 1989, Spivak 1989). Due to the impact of glycans on drug efficacy and half life, it 
is necessary to thoroughly characterize the glycan structures of glycoprotein drugs and 
ensure its consistency for the compliance to regulatory requirements (FDA 1996). 
Because of such requirement, recombinant EPO produced in cultured cells has to 
undergo extensive purification to remove undersialylated glycoforms to ensure 
consistent and optimal efficacy. Hence, enhancing the sialylation of EPO not only 
improves the efficacy of EPO as a therapeutic agent, but also increases the yield of 
“druggable” EPO from cell culture. In fact, there have been numerous reports on 
different approaches to enhance EPO sialylation. These efforts represent strategies 
mainly focusing on the following aspects: process control, protein engineering, and 
genetic engineering of host cell lines (reviewed by Hossler et al. 2009). From an 
engineering point of view, genetic engineering represents the most robust and 
amenable approach, as it does not require for more sophisticated process 
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instrumentation, and that the engineered cell line can be applied as a host line for not 
one but many glycoproteins. Enhancing EPO sialylation by systematically targeting 
the N-glycosylation pathway is the central theme of Chapter 4.  
 
1.3.2 O-Glycosylation of mucin 1  
 Mucins are a family of large, heavily glycosylated proteins that are bound to 
the surface or secreted to the extracellular matrix of glandular epithelial cells. A 
common feature among all mucin molecules is the presence of variable number of 
tandem repeats (VNTR) which carry multiple O-GalNAc glycosylation sites within 
each repeating unit. Therefore, a mucin protein can contain hundreds of O-glycans. 
The attached O-glycans modulate the biophysical properties of the mucin protein and 
allows for strong retention of water and salts to the mucin layer at the apical surface of 
epithelium, and as a result, provides a physical barrier against pathogens (Fig. 1.13). 
One of the best studied mucin molecules is mucin 1 (MUC1) which is 
ubiquitously expressed in many glandular epithelia, including those in breast, prostate, 
and saliva glands. MUC1 is normally expressed at the apical surface of these cells and 
decorated with extended O-glycans. 
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Fig. 1. 13. Topology, molecular assembly and oligomerization of mucin molecules 
Mucins are heavily O-glycosylated in the VNTR region. a) Topologies of MUC1 and 
MUC2. b) processing of mucins along the secretory pathway. Mucins are N-
glycosylated in the ER, where they are also cleaved or form dimmers. Following O-
glycosylation in the Golgi, mucins are sent to the cell surface. c) Mucin molecules 
form either linear or networked complex at the cell surface. (Adapted from 
McGuckin et al. 2011) 
 
However, in many types of adenocarcinomas, including breast cancer, prostate 
cancer, ovarian cancer, etc., due to the loss of membrane polarity, MUC1 is expressed 
in all surfaces of a cell at upregulated level and can be secreted into the blood stream 
(Brockhausen 2006). In fact, MUC1 circulated in the blood can be detected in some 
late-stage cancer patients (Bon et al. 1999). In addition, the O-glycosylation profile of 
MUC1 in cancer was found to be dramatically altered, leading to the production of 
shorter, truncated O-glycans including Tn, sialyl-Tn (STn), T structures which were 
not found on MUC1 in healthy controls. This observation led to the proposal of using 
MUC1 protein or peptide with such aberrant O-glycan structure as cancer vaccines. 
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Several lines of evidence strongly support such speculation:  i) autoantibodies against 
Tn-MUC1 and STn-MUC1 glycopeptide were detected in patients of breast-, prostate-, 
or ovarian cancer (Wandall et al. 2010), suggesting the strong immunogenicity of such 
O-glycosylated MUC1 glycopeptides; ii) Tn-MUC1 can be selectively taken up by 
dendritic cells (Napoletano et al. 2007) and induced strong humoral (IgG) response in 
both mice (Tarp et al. 2007) and cancer patients (Sabbatini et al. 2007). Therefore, a 
cell line capable of producing recombinant MUC1 with Tn and STn O-glycan 
structures is preferred (Storr et al. 2008). O-Glycomic analysis of total cellular 
proteins and recombinant MUC1 in five mammalian cell lines described in Chapter 3 
is part of our effort to evaluate the applicability of these lines in producing 
recombinant MUC1 for vaccine purposes. 
 
1.3.3 Non-human glycosylation of biopharmaceuticals causes adverse immune 
responses 
 A potential problem with recombinant production of glycoproteins using 
animal cell lines is non-human glycosylation. Because of the differential glycosylation 
machinery in human and other animals, glycan structures/epitopes normally absent in 
the human glycome can be produced in other species or cell lines. When these cell 
lines are applied to the production of recombinant therapeutic glycoproteins for 
human use, the non-human glycans can be recognized by the immune system as 
“foreign” despite being attached to a human protein sequence. Two prominent 
examples highlighting the immunogenicity of non-human glycosylation are N-
glycolylneuraminic acid (Neu5Gc) and galactose α1,3-linked to another galactose 
residue (Galα(1,3)Gal) (Fig. 1.14). Neu5Gc is synthesized from N-acetylneuraminic 
acid (Neu5Ac) by the enzyme CMP-Neu5Ac hydroxylase (CMAH) (Padler-Karavani 
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and Varki 2011). It is present in all animals except human due to the inactivation of 
the CMAH gene in human during the evolution. Antibodies against Neu5Gc are 
present in the human blood (Nguyen et al. 2005). Administration of therapeutic 
glycoproteins containing Neu5Gc will provoke the immune response, resulting in 




Fig. 1. 14. Illustrations of glycans containing Neu5Gc and α3-Gal epitopes 
1: Galα(1,3)Gal on an N-glycan, 2: Neu5Gc on N- and O-glycan 
 
 Galα(1,3)Gal represents the major xenoantigen, identified during 
transplantations of pig organs to human which were often accompanied by rapid 
rejection of the xenografts (Galili 2006). Later it was realized that this di-saccharide 
epitope is not expressed in old world primates including human. Because of the 
expression of α-Gal epitopes by human gut flora, there are abundant circulating 
antibodies against Galα(1,3)Gal in the human blood, which constitutes about 1% of all 
circulating antibodies (Kirkeby and Moe 2001). As an effort to reduce the xenograft 
rejection, α3-galactosyltransferase, the enzyme responsible for the formation of α3-
Gal, was targeted, leading to the production of α-Gal-deficient transgenic pigs (Osman 
et al. 1997). The fact that murine cell lines produce abundant α3-Gal structures raises 
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safety concern when these cell lines are used for the production of recombinant 
glycoproteins. 
 Taken together, the presence of nonhuman glycosylation in many cell lines 
and the adverse immune response such structures are capable of invoking underline 
the importance of systematically analyzing all the glycan structures that a cell line is 
capable of producing. In this study, glycomic profiles of five commonly used 
mammalian cell lines were analyzed toward this effort (Chapter 3). 
 
1.4 Regulation and control of glycosylation at the pathway level 
The critical impact of glycosylation on cellular physiology and efficacy and 
safety of glycoprotein-based drugs prompts an understanding of regulation mechanism 
for this process. Insights of the glycosylation regulation can shed light on molecular 
targets for controlling the glycosylation for disease intervention as well as enhancing 
drug efficacy. Our current understanding of the regulation mechanism is largely based 
on the evidence that glycosyltransferases often show tissue- or organism-specific 
patterns. Using a microarray approach, Comelli et al. (2006a) analyzed the expression 
profile of a focused set of glycogenes in different tissues, and found that genes 
involved in the early steps of the glycosylation pathway were expressed at higher 
levels than genes involved in the late steps of the pathway. Similar results were 
obtained by another group using quantitative PCR approach (Nairn et al. 2008). In 
addition, a positive correlation between glycogene expression level and the relative 
abundance of its product glycan was established in most of the cases. However, due to 
the lack of functional data, it is difficult to conclude that glycogenes expressed at high 
levels are indeed expressed at “sufficient” levels. Functional overexpression of such 
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genes and assessing the accompanying glycosylation profile represents a strategy to 
validate such transcriptional profiling-based results (presented in Chapter 4).  
 
1.5 Specific aims and organization of the thesis 
This thesis represents a multifaceted approach to understand how the process 
of glycosylation is regulated in mammalian cell lines. The first objective (Chapter 3) 
is to show, in detail, the difference of N-linked and O-linked glycosylation in different 
cell lines. Glycomic profiling of these cell lines also provides a vital set of data for the 
selection of a cell line capable of producing favorable glycoforms. On the basis of the 
identified differential glycosylation, the second objective (Chapter 4) is to understand 
how N-glycosylation is regulated by different components (glycogenes) of its 
biosynthetic pathway. By systematic functional overexpression, impact of each 
glycogene on glycosylation, specifically sialylation of N-glycans, is elucidated. The 
differential impacts of glycogenes on glycosylation can help prioritize the target 
glycogenes for glycoengineering of host cell lines. Regulation of localization and 
activity of glycosylation-related proteins can also affect the functional outcome of 
glycosylation. Hence, the third objective is to establish the structure-function 
relationship of nucleotide-sugar transporters using GDP-fucose transporter as an 
example (Chapter 5). Finally, as an effort to identify novel genes that regulate cell 
surface glycosylation, functional RNAi screens are explored (Chapter 6). Although 
essential validations are to be followed up, the primary screening results strongly 
suggest a number of genes act upstream of the glycosylation pathway to affect the cell 






CHAPTER 2: MATERIALS AND METHODS 
 
The chapter includes common materials and core methods used throughout 
this study. Short protocols of major experiments were listed here for the purpose of 
quick reference. Information on design and molecular cloning of model molecules is 
also presented. 
 
2.1 Major materials 
2.1.2 Antibodies, lectins, and fluorescent probes 
Information on major antibodies, lectins, and other fluorescent probes used in 
this study is summarized in Table 2.1. 
Table 2.1. List of antibodies, lectins and fluorescent probes 
Antibody Conjugate Source 
Anti-HA - Sigma (St. Louis, MO) 
Anti-giantin - Abcam (Cambridge, UK) 
Anti-GM130 - Abcam (Cambridge, UK) 
Anti-B4GalTI - Sigma (St. Louis, MO) 
Anti-ManII - Abcam (Cambridge, UK) 
Anti-TGN46 - Abcam (Cambridge, UK) 
Anti-EPO* - ATCC (Manssas, VA) 
Anti-mouse IgG HRP Jackson ImmunoResearch  
Anti-mouse IgG AlexaFluor 488 Invitrogen (Eugene, OR) 
Anti-rabbit IgG AlexaFluor 594 Invitrogen (Eugene, OR) 
Anti-rabbit IgG AlexaFluor 647 Invitrogen (Eugene, OR) 
Lectin Conjugate Source 
PNA FITC EY Labs (St. M 
HPA Alexa Fluor 488 Invitrogen (Eugene, OR) 
SNA - EY Labs (San Mateo, CA) 
MAA - EY Labs (San Mateo, CA) 
AAL Biotin Vector Labs (Burlingame, CA) 
ConA AlexaFluor 488 Invitrogen (Eugene, OR) 
Other probe Conjugate Source 
Hoechst 33342 - Invitrogen (Eugene, OR) 
Streptavidin Cy3 Vector Labs (Burlingame, CA) 
Streptavidin AlexaFluor 647 Invitrogen (Eugene, OR) 
* Hybridoma was purchased from ATCC. Anti-EPO antibody was produced in house. 
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2.1.3 Cell lines and culture media 
CHO-K1, BHK-21, HEK293, COS-7, 3T3, and HeLa cells were purchased 
from American Type Cell Collection (ATCC) (Manssas, VA). NS0 cells were 
purchased from ECACC (UK). All these seven cell lines were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 
(both from Invitrogen, Auckland, CA) in a humidified 37oC incubator with 5% CO2. 
Lec1, Lec8, and Lec23 cells were kindly provided by Dr. P. Stanley (Albert Einstein 
College of Medicine, NY) and cultured in MEM-α medium (Invitrogen, Auckland, 
CA) supplemented with 10% FBS and 40 µg/ml (final concentration) of L-proline 
(Sigma, St. Louis, MO). CHO-gmt1 and CHO-gmt5 cell lines were isolated in this lab 
and cultured in DMEM supplemented with 10% FBS. 
 
2.2 Core methods 
2.2.1 Cell culture 
All cell lines were cultured in tissue culture-treated T-flasks or well plates. 
Upon reaching confluence, cells were detached from the surface by incubating in 0.25% 
trypsin-EDTA for 1 – 5 min at room temperature. Trypsinization was stopping adding 
complete culture medium (basal medium + 10% FBS). A small volume of the cell 
suspension was left in the flask and mixed with fresh complete culture medium. Cells 
were then incubated in a humidified CO2 incubator and periodically passaged every 3 
– 4 days.  
 
2.2.2 Transient transfection using Lipofectamine in well dishes 
Lipofectamine-mediated plasmid transfection was done according to 
manufacturer’s instructions with slight modifications. Briefly, cells at mid-log phase 
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were harvested by trypsinization, pelleted by centrifugation (1000 rpm, 5 min) using 
Sorvall RT+ centrifuge (Thermo Scientific, Germany). The cell pellet was then 
resuspended in fresh complete culture media. Viable cell density (VCD) was 
measured by a Cedex cell counter (Innovatis), and the cell suspension was diluted in 
fresh complete culture medium to optimal seeding density. For COS-7, the optimal 
seeding density is 3 × 105 cells/ml, while for all the other cell lines the optimal 
seeding density is 2 × 105 cells/ml. For transfection in a 12-well plate, 1 ml of the 
diluted cell suspension was added into each well. The plate was then incubated in the 
incubator overnight. Next day, 4 µl of Lipofectamine 2000 reagent (Invitrogen, 
Carlsbad, CA) was diluted in 100 µl of Opti-MEM medium (Invitrogen, Auckland, 
CA) in a microcentrifuge tube. In another tube, 2 µg of plasmid DNA was diluted in 
100 µl of Opti-MEM medium. Both tubes were incubated at room temperature for 5 
min. Contents of the two tubes were then combined, thoroughly mixed by votexing 
and incubated for 20 min at room temperature. The mixture ( ~200 µl) was then added 
in a dropwise fashion into one well of a 12-well plate. The plate was then transferred 
to a 37 oC humifidied incubator with 5% CO2. After incubation for about 6 hrs, the 
medium was carefully aspirated without disturbing the cell layer and replaced with 1 
ml of fresh complete culture medium. The plate was further incubated in the incubator 
for 2 – 3 days until further analysis. 
 
2.2.3 Transient transfection using FuGene 6 in well dishes 
FuGene 6-mediated plasmid transfection was done according to 
manufacturer’s instructions with slight modifications. Briefly, cells were harvested, 
counted and diluted as described in Section 2.2.2 to 1×105 cells/ml. For transfection in 
a 12-well plate, 1 ml of the diluted cell suspension was added into each well. The 
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plate was then incubated in the incubator overnight. Next day, 3 µl of FuGene 6 
reagent (Roche, Indianapolis, IN) was diluted in 50 µl of Opti-MEM medium 
(Invitrogen, Auckland, CA) and incubated for 5 min at room temperature. 1 µg of 
plasmid DNA was then added and the tube was vortexed. After 20 min incubation at 
room temperature, the mixture was added in a dropwise fashion into one well of a 12-
well plate. The plate was then transferred to a 37 oC humidified incubator with 5% 
CO2 for typically 1 – 3 days until further analysis. 
 
2.2.4 Large scale transient expression of Fc fusion proteins 
 Cells were seeded at appropriate density into ten T175 flasks (35 ml of cell 
suspension per flask) and cultured overnight. Next day, cells were transfected by 
Lipofectamine with a construct encoding an Fc fusion protein following the 
procedures described in Section 2.2.2. The amounts of Lipofectamine reagent, plasmid 
DNA, and diluents (Opti-MEM) were proportionally scaled up by surface area of the 
cell culture flasks. 6 hrs after transfection, medium was carefully aspirated and 
replaced with a protein-free medium, HyQ PF CHO (HyClone, Logan, UT) 
supplemented with 2 mg/ml sodium bicarbonate and 6 mM L-glutamine. The purpose 
of using a protein-free medium for transient expression of recombinant Fc fusion 
proteins is to minimize the contamination of Fc fusion proteins by bovine IgG 
molecules that are present in the FBS, which can be co-purified together with Fc 
fusion proteins by Protein A chromatography. Three days after transfection, 
conditioned media were collected and centrifuged to remove cell debris as well as 





2.2.5 Protein A chromatography 
 Purification of Fc fusion proteins was performed using an Akta FPLC system 
and a 5 ml HiTrap Protein A HP column (both from GE Healthcare, Uppsala, 
Sweden). The column was first washed in water and equilibrated with 20 mM sodium 
phosphate buffer (pH 7.0). Conditioned medium (typically about 300 ml) was filtered 
by a filter unit (0.4 µm cutoff) and then slowly loaded onto the column at 2 ml/min. 
Flow-through was collected for analysis of binding efficiency. After sample loading, 
the column was washed extensively with the phosphate buffer at 5 ml/min until the 
absorbance at 280 nm wavelength reached the baseline. The column was further 
washed with 5 – 10 column volumes (i.e. 25 – 50 ml) of the phosphate buffer. Finally, 
bound proteins were eluted with elution buffer (0.1 M glycine-HCl, pH 2.7) at 2 
ml/min. The eluate was collected at 2 ml per fraction and immediately neutralized 
with a 1/20 volume (i.e. 100 µl per fraction) of neutralization buffer (1 M Tris, pH 
9.0). Fractions corresponding to the major elution peak area were pooled and stored at 
– 20 oC for further analysis. To avoid cross contamination, a fresh Protein A column 
was used for each sample. 
 
2.2.6 SDS-PAGE/Western blotting 
Protein samples (typically 10 – 30 µl) were mixed with reducing or non-
reducing sample buffer (Thermo Scientific, Rockford, IL) in a 4:1 (v/v) ratio and 
boiled at 95oC for 10 min. Samples were then loaded onto a 10-well bis-tris gel (for 
small- or medium-sized proteins such as EPO) or tris-acetate gel (for large proteins 
such as EPO-Fc and MUC1-Fc) (both from Invitrogen, Auckland, CA). 
Electrophoresis was performed at 100 – 130 V and stopped when the target protein 
was optimally separated. 
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Gel was removed from the cassette and electro-blotted against a PVDF 
membrane at 100 V for 75 min. After blotting, the membrane was blocked with 5% 
milk in PBS for 10 min. Monoclonal Anti-EPO antibody was added in 1:1000 dilution 
and incubated at 4oC overnight. The membrane was then washed 3 times (10 min each) 
in PBS containing 0.1% Tween 20 and then blocked again in 5% milk in PBS for 10 
min. Secondary antibody, horse radish peroxidase-conjugated goat anti-mouse IgG 
antibody (Jackson ImmunoResearch, West Grove, PA), was added in 1:10000 dilution. 
The membrane was wash three times and briefly incubated with ECL 
chemiluminescent detection substrate (GE Healthcare, Bucks, UK) and imaged on X-
ray films (Roche, Manheim, Germany) using a Kodak X-ray film processor at 
different exposure times. Typically, three exposure times were used to capture images 
below, within and above detection range. Images that are within the visual dynamic 
range were chosen to produce the final figures. Each IEF experiment was repeated at 
least three times and consistent results were obtained.  
 
2.2.7 Isoelectric focusing (IEF) 
Conventional IEF gel involves the addition of free ampholytes with a range of 
pKa values in the polyacrylamide gel matrix (Chuan et al. 2006, Lasne et al. 2002). 
The pH gradient is form by pre-focusing the ampholytes before applying the sample. 
Because the ampholytes are free molecules, change in the pH gradient can occur 
during the IEF process (typically 3 – 4 hours), resulting in drifting and/or distortion of 
bands. In this study, immobilized pH gradient (IPG) IEF (Lim et al. 2008, Schriebl et 
al. 2007) was employed due to its advantages over conventional IEF in terms of 
minimal drifting and band distortion. In IPG gel, acrylamido molecules with 
derivatized side chains are mixed with acrylamide solution. These acrylamido 
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molecules will be incorporated into the gel matrix and therefore form an immobilized 
pH gradient. First, two reservoirs of gel solutions were prepared by mixing different 
immobiline solutions (i.e. acrylamido solutions with different pKa values) (Table 2.2). 
Then, the gel solutions were separately filled into two chambers of a gel gradient 
mixer and slowly mixed and injected into a glass cassette. The gel was left at room 
temperature after casting and then transferred to a 50 oC oven for 2 hours to set. Then 
the gel was taken out from the glass cassette and washed 4 ×15 min in water, followed 
by a 15 min wash with 1.5 % glycerol in water. After washing, the gel was dried 
overnight in a 50oC oven and then stored in a -20oC freezer.  
 
Table 2.2. Recipes for basic and acidic solutions for a pH 3 – 10 gel 
Basic and acidic solutions are separately prepared by mixing different amount of 
immobiline solutions in addition to other gel components. 
Tetramethylethylenediamine (TEMED) and ammonium persulfate (APS) are added 
right before the two solutions are mixed together and injected into the glass cassette.  
 
Immobiline (pKa) Basic solution (µl) Acidic solution (µl) 
1 - 1066 
3.6 311 311 
4.6 282 282 
6.2 305 305 
7.0 288 288 
8.5 284 284 
9.3 321 321 
>12 499 - 
Acrylamide/Bis 2.5 ml 2.5 ml 
Glycerol - 3 ml 
Deionized H2O Top up to 15 ml Top up to 15 ml 
TEMED 12 µl 12 µl 
APS* (40%) 15 µl 15 µl 
 
Before an IEF experiment, the dried IPG gel was re-hydrated in 25 ml of 
denaturing solution containing 6 M urea, 0.5 g CHAPS, 0.04 g DTT and 0.5 ml 
Pharmalyte pH 3 – 10 solution (GE Healthcare, Uppsala, Sweden) and 100 µl of 0.1% 
bromophenol blue in water. 
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Samples (typically 10 – 40 µl) were topped up with water to 40 µl, mixed with 
an equal volume of IPG buffer 3 – 10 (GE Healthcare, Uppsala, Sweden) and loaded 
into sample loading cups. The IEF running condition is as follows: 0 – 300 V gradient 
in 1 min; 300 V for 15 min; 300 – 3000 V gradient in 3 hours, and finally 3100V for 1 
hour. After focusing, the gel was briefly rinsed in water and then 0.7% acetic acid. 
The gel was electro-blotted against a PVDF membrane (60 V for 60 min). Immuno-
detection of target protein on the PVDF membrane follows the Western blot 
procedures described in Section 2.2.6. 
 
2.2.8 MALDI-TOF mass spectrometry 
Structural characterization of N-linked and O-linked glycans described in 
Chapter 3 and Chapter 5 was performed using matrix-assisted laser desorption 
ionization/time-of-flight mass spectrometry (MALDI-TOF MS). The method was 
documented in detail in Chapter 3 and the experimental outlines are highlighted here. 
For the analysis of whole cellular N- and O-glycomes, cells were cultured to mid log 
phase, washed and scraped from cell culture flasks. Proteins were extracted from the 
cell pellet, digested by trypsin and carboxy-reduced. N-glycans were released from the 
glycopeptides with protein N-glycanase F (PNGase F) and then separated from the 
peptides using a Sep-Pak C18 column. O-glycans that were still conjugated to the 
peptides were liberated by reductive elimination (North et al. 2009). To allow for 
efficient ionization, N- and O-glycans were derivatized by chemical permethylation 
(Ciucanu 2006, Dell et al. 1994) and cleaned up using a Sep-Pak C18 column. Finally, 
permethylated glycan samples were analyzed using a 5800 MALDI0TOF/TOF mass 
spectrometer in positive reflectron mode. For analysis of glycan structures carried by 
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purified EPO-Fc and MUC1-Fc, the procedures started with tryptic digest of proteins 
directly.  
 
2.2.9 Immunofluorescent cell staining 
Cells were seeded at optimal density (typically 1×105 cells/ml) into well plates 
with cover slips at the bottom. After overnight culture, cells were transfected using 
FeGene6 (Section 2.2.3) and incubated overnight. Two days after transfection, cells 
were washed with PBS, fixed with 4% paraformaldehyde (PFA) (diluted from 16% 
methanol-free PFA from Thermo Scientific (Rockford, IL)) in PBS for 10 min and 
permeabilized by 0.1% Triton X-100 (Sigma, St. Louis, MO) in PBS for 5 min. After 
washing with PBS twice, cells were blocked with either 10% normal goat serum 
(Invitrogen, Eugene, OR) or Carbo-Free blocking solution (Vector Laboratories, 
Burlingame, CA) for experiments involving lectin labeling for 30 min. Cells were 
then briefly rinsed with PBS and incubated with PBS containing 1% BSA and primary 
antibodies or lectins at appropriate dilutions for 30 min - 2 hours. The coverslips were 
then washed three times in PBS and incubated with fluorescently conjugated 
secondary antibodies or other probes at appropriate dilutions. In all experiments, 
Hoechst 33342 (Invitrogen, Eugene, OR) at 2 µg/ml (final concentration) was 
included in the secondary antibody mixture to stain the nuclei. Finally, the coverslips 
were washed four times in PBS and then mounted onto glass slides using ProlongGold 
antifade medium (Invitrogen, Eugene, OR) and stored at room temperature overnight 
before long-term storage at 4oC. The slides were analyzed by either a Carl Zeiss 





2.2.10 Confocal microscopy 
Fluorescent micrographs were taken as 12-bit grayscale images using a Carl 
Zeiss LSM 510 META confocal microscope equipped with appropriate laser lines, a 
63× PLAN-apochromat objective (1.40 NA) immersed in oil, and a photomultiplier 
tube (PMT) detector. Typically, the pinhole size was set at 1 Airy Unit (AU) of the 
longest emission wavelength. When qualitative comparison of fluorescence intensity 
was required, images were acquired under constant imaging parameters including 
detector gain, offset, scanning speed, etc. Representative areas of interest were 
cropped with LSM Image Brower software without any post-acquisition adjustment 
(except coloration of the grayscale images) and used to produce the final figures.  
 
2.2.11 Fluorescence-activated cell sorting (FACS) 
FACS was employed for analysis of cell surface fucosylation in Chapter 5. 
CHO-gmt5 cells were transfected with different GFT constructs in 12-well plates 
using FuGene6 (Section 2.2.3). Two days after transfection, cells were briefly rinsed 
with PBS and harvested using PBS containing 2 mM EDTA. After washing with PBS, 
cells were fixed with 4% PFA (diluted from 16% methanol-free PFA, Thermo 
Scientific) in PBS for 10 min. After washing with PBS twice, cells were incubated 
with Carbo-Free blocking solution  for 30 min, and then incubated with PBS 
containing 1% BSA and 5 µg/ml biotinylated AAL for 30 min. After 2 washes with 
PBS, cells were incubated in PBS containing 1% BSA and 5 µg/ml Cy3-conjugated 
streptavidin for 30 min. Finally, cells were washed twice in PBS and analyzed by a 





2.2.12 Quantitative RT-PCR (qRT-PCR) 
qRT-PCR technique was employed to determine and compare the expression 
level of endogenous glycogenes in different cell lines. The protocol was adapted from 
a previously published method with some modifications (Nairn et al. 2008). Briefly, 
total RNA was extracted from cultured cells using RNeasy Mini kit (Qiagen, Hilden, 
Germany). First strand cDNA was synthesized from 5 µg of total RNA using Moloney 
murine leukemia virus reverse transcriptase (MMLV-RT) and oligo dT(15) (both from 
Promega, Madison, WI). Specific primer pairs for selected glycogenes were designed 
using Primer3 web site (Koressaar and Remm 2007, Rozen and Skaletsky 2000) based 
on the following criteria: primer length 19 – 21 bp, product size 100 – 150 bp, Tm 59 – 
61 oC. Primer specificity was confirmed by melting curve analysis (indicated by a 
single peak) and agarose gel electrophoresis (indicated by a single band of expected 
size).  
PCR amplification was performed using ABI Prism 7000 qRT-PCR Detection 
System (Applied Biosystems, Foster City, CA). For each reaction of 25 µl, 12.5 µl of 
2× SYBR Green PCR mastermix (Applied Biosystems) was mixed with 12.5 µl 
cDNA (from 5 µg of total RNA) and 364 nM (final concentration) of forward and 
reverse primers. PCR reaction conditions were as follows: 95 oC for 10 min, followed 
by 40 cycles of 95 oC for 15 s and 60 oC for 60 s. Threshold cycle (Ct) was determined 
using ABI Prism 7000 SDS program (Applied Biosystems). All reactions were run in 
triplicates. Primer amplification efficiencies were analyzed by serially diluting the 
cDNA samples. The corresponding average Ct values were plotted against log (cDNA 
amount) and fitted to a linear curve with R2 close to 1. Primer efficiency (E) was 
calculated based on the slope of the linear curve (S) using the following equation: 
110 /1 −= − SE
                                                                                                   Equation 1 
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Efficiencies of all primers were found to be within the range of 1±0.1. Relative 
transcript abundance was calculated by transforming the average Ct values to 2-Ct and 
normalizing to a house keeping gene, β-actin (ActB) (2-∆Ct). 
 
2.3 Model molecules 
 EPO, EPO-Fc and MUC1-Fc were chosen as model molecules to specifically 
analyze the glycosylation of secreted proteins. These glycoproteins critically depend 
on the attached glycans for in vivo bioactivity or immunogenicity. Therefore, 
systematic characterization of their glycosylation in different cell lines and 
investigation of mechanism that regulate such glycosylation will provide a framework 
for glycoengineering of the host cell lines.     
 
2.3.1 EPO and EPO-Fc for N-glycosylation study 
 The protein sequence of erythropoietin (EPO) contains three N-linked and one 
O-linked glycosylation sites (Fig. 2.1). The dense glycosylation makes EPO an ideal 
molecule for studying glycosylation. N- and O-glycans can be cleaved from the EPO 
protein backbone by enzymatic or chemical treatment and analyzed by mass 
spectrometry or chromatography-based methods (Fibi et al. 1995, Hokke et al. 1995, 
Shahrokh et al. 2011). Sialylation of glycans carried by EPO can be qualitatively 
assessed by a rapid and sensitive method for analyzing the sialylation of EPO is 
isoelectric focusing (IEF) (Lasne and de Ceaurriz 2000, Lim et al. 2008, Schriebl et al. 
2007). Previously, we cloned the cDNA sequence for human EPO into a mammalian 
expression vector, pcDNA3.1(+) using EcoRI/XhoI restriction sites (Lim et al. 2008). 
This construct was extensively used in Chapter 4 for functional analysis of glycogenes 







Fig. 2. 1. Protein sequence of human EPO 
The signal peptide of EPO was shown in gray and italics. The N-glcosylation sites on 
EPO were shown in red. The O-glycosylation site was shaded in yellow. 
 
 Characterization of glycan structure by mass spectrometry requires 
purification of the protein to high homogeneity. Purification of EPO typically relies on 
multi-step chromatographic techniques (Broudy et al. 1988). To allow for rapid and 
efficient purification of recombinant EPO from crude conditioned media, a human 
IgG Fc domain was genetically tagged to EPO (Fig. 2.2). The presence of the Fc 
domain enables a single-step purification of the resultant EPO-Fc by Protein A 
chromatography (Schriebl et al. 2006). The potential N-glycosylation site in the Fc 
region, Asn297, was mutated to Ala. In addition, the O-glycosylation site within the 
EPO sequence, Ser126, was mutated to Val. Therefore, the EPO-Fc fusion protein 
carried only three N-glycans and no O-glycan. cDNA sequence of this model 










Fig. 2. 2. Protein sequence of EPO-Fc fusion protein 
The signal peptide of EPO was shown in gray and italics. The N-glycosylation sites on 
EPO were shown in red. The O-glycosylation site was mutated to Val (green shaded). 
The sequence for human IgG1 Fc include the hinge region was shaded in gray. The N-






2.3.2 MUC1-Fc for O-glycosylation study 
 Mucin 1 (MUC1) is a large, heavily O-glycosylated protein that is either 
bound to the apical surface of endothelial cells or secreted into the extracellular space 
(Tarp and Clausen 2008). The O-glycans are predominantly located in the variable 
number of tandem repeats (VNTR) region. We cloned the N-terminal region of MUC1, 
including the signal peptide and six tandem repeats, which is then fused to the human 
IgG1 Fc region with the N297A mutation (Fig. 2.3). cDNA sequence for the MUC1-
Fc fusion protein was cloned into pcDNA3.1(+) vector using HindIII/XhoI sites, and 
expressed in different mammalian cell lines. The fusion protein secreted into the 
conditioned media was purified by Protein A chromatography for MALDI-TOF 












Fig. 2. 3. Protein sequence of MUC1-Fc fusion protein 
The signal peptide of MUC1 was shown in gray and italics. The potential O-
glcosylation sites on MUC1 were shown as red and bolded letters. Tandem repeating 
sequences (HGVTSAPDTRPAPGSTAPPA) were alternately highlighted in cyan and 
yellow. Note the presence of potential O-glycosylated Ser or Thr outside these tandem 
repeats. The sequence for human IgG1 Fc including the hinge region was shaded in 
gray. The N-glycosylation site on Fc Asn297 (IgG1 numbering) was mutated to Ala 







CHAPTER 3: GLYCOMIC ANALYSIS OF CHO-K1, 




Proteins secreted into the extracellular space as well as those expressed on the 
cell surface are often modified with carbohydrate moieties. The attached 
carbohydrates or glycans critically modulate the properties and biological functions of 
the proteins and the cell. Impact of glycosylation on in vivo bioactivity of recombinant 
glycoprotein drugs mainly lies in three aspects: i) in vivo circulatory half-lives of 
many glycoprotein drugs are primarily determined by sialylation extent of glycans 
(Morell et al. 1971, Sinclair and Elliott 2005), ii) glycan structure of IgG Fc critically 
determines the affinity of IgG toward Fc receptor for effector function (Anthony et al. 
2008, Kaneko et al. 2006, Peipp et al. 2008), iii) glycans attached to protein drugs 
sometimes facilitate the targeting and delivery of the drugs as exemplified by 
oligomannose-type glycan on the drug Cerezyme for effectively targeting to 
macrophage (Hoppe 2000). N- and O-glycans decorating the membrane-bound cell 
surface proteins also have profound effects on the cell, including: i) modulating the 
interaction of the cell with an apposing cell that expresses glycan-binding proteins to 
decipher the information encoded by the glycan structures, and thus leading to a wide 
range of physiological and pathological responses including cancer metastasis (Varki 
et al. 2009), development (Haltiwanger and Lowe 2004), and cell migration (Kuijpers 
and Roos 1993), ii) critically participating in the host-pathogen recognition process 
such as binding of influenza virus to sialic acids found on cell surface glycoproteins 
(Skehel and Wiley 2000). 
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Clearly, it is of paramount importance to systematically analyze the glycome, 
i.e. the collection of N- and O-linked glycans, of cells relevant to recombinant 
glycoprotein production as well as experimental research. Recent advances in mass 
spectrometry and chromatography have seen tremendous progresses in understanding 
the glycomic profiles of many important cell lines and tissues (North et al. 2010, 
North et al. 2012), mainly driven by the establishment and maturation of mass-
assisted laser desorption/ionization (MALDI) mass spectrometry technology (Harvey 
2011). MALDI is a soft ionization method which results in minimal fragmentation of 
glycan species. Glycans are usually permethylated and analyzed in positive ion mode. 
MALDI ionization results in predominantly singly charged molecular ion [M+Na]+ 
and a putative glycan structure matching the mass-to-charge ratio (m/z) is assigned 
based on knowledge of the biosynthetic pathway. Mass spectra of glycans also allow 
for semi-quantitative comparison of relative abundances of different glycans, provided 
they are within a short mass range of the same spectrum (Wada et al. 2007). Mass 
spectrometry technique can be complemented by other method, including high 
performance liquid chromatography for separation and quantification of glycans, 
lectin labeling of glycans for structural insights, which together can provide 
comprehensive information on the glycome. 
 
3.1.2 Specific aims and outlines 
This study aims to characterize the glycomes of five commonly used 
mammalian cell lines, namely CHO-K1, BHK-21, HEK293, COS-7 and 3T3, as well 
as the glycan structures on recombinant glycoproteins, EPO-Fc and MUC1-Fc, 
produced by these cell lines. CHO-K1 and its derivative lines are the industrial 
workhorse for the production of majority of glycosylated biopharmaceuticals, 
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including erythropoietin (EPO), antibodies and Fc-fusion proteins (Walsh 2003, 
Walsh 2010). BHK-21 is mainly used to produce EPO (Fibi et al. 1995) and Factor 
VIII (Suiter 2002). HEK293 is often used for transient gene expression (Fliedl and 
Kaisermayer 2011) and production of adenovirus (Zhong et al. 2006). COS-7 and 3T3 
cells have been use to produce recombinant virus for potential vaccine and gene 
therapy applications (Beard et al. 1989, Cohen et al. 1995, Horthongkham et al. 2007, 
Kafri 2004). This study begins with the profiling of N- and O-glycome at whole 
cellular level using MALDI MS. This is followed by N-glycosylation analysis for 
recombinant EPO-Fc produced in the five cell lines. Sialylation extent of EPO-Fc in 
the five cell lines, a parameter that critically determines the bioactivity of glycoprotein 
drugs, was quantitatively compared by a chromatographic method. Finally, 
recombinant MUC1-Fc was also expressed in the five cell lines and purified for the 
characterization of the attached O-glycans. This study provides a systematic collection 
of data as groundwork for selection and engineering of the five cell lines for the 
production of glycoproteins or viral vectors with desired glycoforms yet devoid of 
immunogenetic glycan epitopes. The glycomic data also represents a baseline of 
protein glycosylation status in the cell lines for subsequent investigation of regulation 
mechanism for N-glycosylation at pathway level (Chapter 4). 
 
3.2 Experimental procedures 
3.2.1 Preparation of cells for whole cellular glycomic analysis 
 Cells were revived from the cell bank, passaged for 5 – 8 times and then 
seeded in five T175 flasks and cultured for 2 – 3 days in DMEM supplemented with 
10% FBS (both from Invitrogen, Auckland, CA) until the cells reached mid-log phase. 
Monolayer of cells was washed three times with PBS. Cells were then scraped from 
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the surface and pooled into a 150 ml centrifuge tube. After centrifugation at 4000 rpm 
using a desktop centrifuge (Sorvall RT+, Thermo Scientific, Germany), supernatants 
were carefully discarded and cell pellets were stored at -20 oC for further analysis. 
 
3.2.2 Protein extraction 
1 ml of extraction buffer (25 mM Tris, 150 mM NaCl, 5 mM EDTA, 1% 
CHAPS, pH 7.4) was added to approximately 1 x 107 cells. The cell sample was 
vortexed and then sonicated at high wave strength for 15 min after which it was 
centrifuged at 500 g for 10 min to collect the supernatant. The extraction was repeated 
another time with the remaining cells using 500 µl of extraction buffer. Then, the 
supernatant fractions from the two extractions were pooled together and dialyzed 
against 4 x 1 L of 50 mM ammonia bicarbonate, pH 8.5 at 4 °C for 24 h using 7000 
MWCO dialysis cassette. After 24 h, the sample was removed from the dialysis 
cassette and transferred to a 7 ml Teflon-lined capped amber glass vial for reduction 
and carboxymethylation of the glycoproteins. 
 
3.2.3 Reduction and carboxymethylation 
2 ml of Tris-HCl, pH 8.5 was first added to the sample followed by 
dithiothreitol (2 mg/ml). The sample was then vortexed and incubated at 37 °C for 1 
hr in the dark under rotation at 20 rpm. After 1 hr, iodoacetic acid (10 mg/ml) was 
added to the sample, vortexed and incubated at 37 °C for another 2 hr in the dark 
under rotation at 20 rpm. At the end of 2 hr, the carboxymethylation process was 
terminated by dialyzing the sample against 4 x 1 L of 50 mM ammonium bicarbonate,
 
pH 8.5 at 4 °C for 24 hr using 7000 MWCO dialysis cassette. The sample was 
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removed from the dialysis cassette and transferred to a 7 ml Teflon-lined capped glass 
vial. The sample was then evaporated to dryness N2 sample concentrator. 
 
3.2.4 Tryptic and PNGase F digestions 
The reduced carboxymethylated proteins were digested with 40 µg of modified 
procine trypsin (Cat. No. V5111; Promega) for 16 hr at 37 °C in 50 mM ammonium 
bicarbonate, pH 8.5. The digestion of trypsin was then quenched by incubating the 
sample at 95 °C for 15 min. After the sample has been cooled, 0.01 units of peptide-
N-glycosidase F (PNGase F) (EC No. 3.5.1.52; Prozyme) was added and incubated 
for 16 hr at 37 °C. The products were then purified using Sep-Pak® C18 (Waters) 
cartridge. 
 
3.2.5 Separation of released N-glycans from O-glycopeptides 
The Sep-Pak® C18 cartridge was primed sequentially with 5 ml methanol, 5ml 
deionized water, 5 ml acetonitrile and 5 ml deionized water before the loading of the 
sample directly onto the cartridge. N-glycans from the sample were eluted using 5 ml 
of deionized water and 5 ml of 5% acetic acid. O-glycoproteins were eluted using 5 
ml 50% acetonitrile. All three fractions were evaporated to dryness using N2 sample 
concentrator. 
 
3.2.6 Reductive elimination on O-glycopeptides fractions 
O-glycans were released by adding 400 µl of sodium borohydride (40 mg/ml 
in 0.1 M sodium hydroxide) at 45 °C for 16 hr. The reaction was terminated by 
dropwise addition of glacial acetic acid followed by clean-up using Dowex 50W-
X8(H) 50-100 mesh resin chromatography. O-glycans were eluted using 5 ml of 5% 
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acetic acid and evaporated to dryness using N2 sample concentrator. 500 µl of 10% 
acetic acid in methanol were then added and dried to remove borate (repeated five 
times).  
 
3.2.7 Permethylation of N- and O-glycans 
Sodium hydroxide pellets were crushed using an agate mortar in dimethyl 
sulfoxide and 500 µl of the slurry and 500 µl of iodomethane were added to the dried 
glycan samples in glass tubes. The reaction was allowed to proceed under rotation at 
20 rpm for 2 hr. 1 ml of deionized water was added dropwise to quench the 
permethylation. The permethylated sample was then extracted with 2 ml of 
chloroform and washed several times with deionized water until the chloroform layer 
was clear. The chloroform layer was then evaporated to dryness using N2 sample 
concentrator. 
 
3.2.8 Sep-Pak Separation of permethylated glycans  
The C18 Sep-Pak® cartridge was primed sequentially with 5 ml methanol, 5ml 
deionized water, 5 ml acetonitrile and 5 ml deionized water. The dried permethylated 
samples were reconstituted in 200 µl of 50% methanol and loaded onto the Sep-Pak® 
cartridges. Elution was performed using 2 ml of 15, 35, 50 and 75% acetonitrile for 
each sample. Each eluted fraction was then collected and evaporated to dryness using 
vacuum centrifuge.  
 
3.2.9 Mass spectrometry analysis 
MALDI-TOF data was acquired on a 5800 MALDI-TOF/TOF mass 
spectrometer (AB Sciex, Foster City, CA) in positive reflectron mode. Permethylated 
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samples were reconstituted in 30 µl of 80% (v/v) methanol in water. 0.5 µl of the 
sample was then spotted on a target plate along with 0.5 µl of matrix (10 mg/ml 2,5-
dihydroxybenzoic acid (Water Corporation, Milford, MA) dissolved in 80% (v/v) 
methanol in water). The 4700 calibration standard kit, calmix (AB Sciex) was used as 
the external calibrant for the MS mode. The mass spectrum of the sample was 
acquired from a mass range of 500 m/z to 5000 m/z with total accumulated shots of 
10000. The laser intensity used for the obtaining the mass spectrum was 5000.  
 
3.2.10 High pH anion exchange chromatography (HPAEC) 
 N-glycans were released from purified recombinant EPO-Fc using trypsin and 
PNGase F digestions as described for the N-glycan profiling using MALDI-TOF/TOF 
mass spectrometry.  N-linked oligosaccharides from Dextra Laboratories were used as 
standards and were prepared by dissolving 20 µg of each standard in 1ml of water. 
The EPO-Fc released N-glycans and oligosaccharide standards were cleaned up using 
a Thermo Hypercarb SPE cartridge according to manufacturer’s instructions. The 
oligosaccharides obtained after cleanup were dried using a Labconco CentriVap 
before reconstituting in 150 µl of water. The Dionex BioLC system (Dionex 
Corporation) with integrated amperometry was used for HPAEC analysis. A PA200 
analytical column (3 × 250 mm) with PA200 guard column (3 x 50mm) and three 
eluents were used for the separation. The eluents were namely 500mM CH3COONa, 
500mM NaOH, and deionised water. The gradient program for the elution of both 
neutral and charged oligosaccharides began with an equilibration period of 25 min 
with 20% NaOH and 80% water, a start injection on isocratic mode for 10 min, 
followed by a ramp gradient for sodium acetate to reach 34% whilst maintaining 
NaOH at 20% until 78 min. The waveform used was E1=+0.05V, t1 = 400 ms; E2 = 
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+0.75V, t2 = 200 ms; E3 = −0.15V, t3 = 400 ms. The flow rate was kept constant at 
0.3 ml/min and the volume of sample/standard injected was 30 µL. The remaining 
sample was retained for further analysis. 
 
3.2.11 Fluorescent staining of intracellular and cell surface Tn antigen by HPA 
 Cells were seeded on glass coverslips at the density of 1×105 cells/ml and 
cultured overnight. Next day, cells were fixed by 4% paraformaldehyde in PBS and 
permeabilized by 0.1% Triton X-100 in PBS. Unoccupied surface was blocked by 
incubating the coverslips in Carbo-Free blocking solution (Vector Laboratories, 
Burlingame, CA). Intracellular Tn antigens was labeled by AlexaFluor 488-
conjugated HPA (Invitrogen, Eugene, OR). The coverslips were washed four times 
before mounted onto glass slides. Images were captured using a Carl Zeiss LSM510 
META confocal microscope. For labeling of cell surface Tn antigen, the 
permeabilization step was omitted. 
 
3.3 Results 
3.3.1 Structural profiling of endogenous N-glycans by MALDI-TOF 
 The five cell lines were cultured in DMEM supplemented with 10% FBS to 
mid-log phase. Monolayers of cells were washed, scraped and pelleted. For each cell 
line, proteins from about 1×107 cells were extracted, reduced and carboxymethylated 
before tryptic digestion. N-glycans were released from the glycopeptides by PNGase 
F treatment. The resulted mixture of N-glycans and peptides (some containing bound 
O-glycans) were loaded onto a C18 Sep-Pak column. N-glycans were eluted with water 
and 5% acetic acid, chemically permethylated, and then purified by a C18 Sep-Pak 
column and fractioned using 15, 35, 50, and 75% acetonitrile (ACN). Finally, 
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permethylated glycans in each fraction was analyzed by MALDI-TOF MS in positive 
ion mode. Glycan species were detected in 35% and 50% ACN fractions. Glycan 
structures were assigned to peaks with intensities above the background level with 
matching compositions using GlycoWorkBench software (Ceroni et al. 2008). Note 
that some peaks with substantial intensities did not match the size of any known 
glycan structure and were thus not annotated. 
 
3.3.1.1 N-Glycome of CHO-K1 
 The CHO-K1 N-glycans eluted by water contained abundant oligomannose-
type structures (m/z = 1171. 2, 1345.2, 1579.3, 1783.3, 1987.3, 2191.4, and 2395.4) in 
the both 35% and 50% ACN fractions (Fig. 3.1). Majority of these structures were not 
core fucosylated. In contrast, the other major peaks, although less abundant than 
oligomannose structures, correspond to predominantly core fucosylated, bi-, tri-, and 
tetra-antennary complex-type structures (assuming the LacNAc (             ) on top of 
the existing two LacNAc form new branches from the mannose (   ) instead of 
forming LacNAc repeats). These complex-type glycans terminated with either Gal or 
Neu5Ac on top of Gal (Neu5Ac number n = 0 – 2). No non-human glycan epitopes 
such as Neu5Gc and Gal-Gal were found. 
 Acetic acid-eluted N-glycans following the elution by water showed a 
different profile with a paucity of oligomannose-type structures in both 35% and 50% 
ACN fractions (Fig. 3.2). The dominant species were complex-type glycans with a 
variable content of sialic acids (n = 0 – 2). Interestingly, the acetic acid-eluted glycans 
contained significant amount of high mass glycans in the 50% ACN fraction that 
contained 3 – 4 LacNAc disaccharide on top of the two LacNAc branches (boxed area 
in Fig. 3.2). Because an N-glycan can contain up to 4 LacNAc units that are directly 
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linked to the two core mannose residues, by assuming a tetra-antennary structure, 
there should be one LacNAc-LacNAc repeat on one of the branch. 
 Overall, the CHO-K1 N-glycome contains abundant oligomannose-type as 
well as complex-type structures with terminal Gal or Neu5Ac. These complex-type 
structures are relatively simple, with a paucity of LacNAc-repeating glycans. No non-





Fig. 3. 1. Mass spectra of N-glycans produced in CHO-K1 cells (water fraction) 
CHO-K1 N-glycans eluted from the C18 column by water were permethylated, fractionated by ACN (15, 35, 50, and 75%) and analyzed by 
MALDI-TOF. Peaks corresponding to N-glycans were found in the 30% and 50% ACN fractions. Major peaks and peaks for structures of 




Fig. 3. 2. Mass spectra of N-glycans produced in CHO-K1 cells (acetic acid fraction) 
CHO-K1 N-glycans eluted from the C18 column by acetic acid after water elution were permethylated, fractionated by ACN (15, 35, 50, and 
75%) and analyzed by MALDI-TOF. Peaks corresponding to N-glycans were found in the 30% and 50% ACN fractions. Major peaks and peaks 
for structures of interest, if any, were described in the text. Note the presence of high molecular weight glycan species in 50% ACN fraction that 
contain 3 – 4 LacNAc repeats (boxed area). Species in the boxed area were enlarged and shown on the right. 
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3.3.1.2 N-Glycome of BHK-21 
 The 35% ACN fraction of water-eluted N-glycans from BHK-21 cells 
contained predominantly oligomannose-type, afucosylated glycans, as well as 
complex-type, bi- and tri-antennary core fucosylated glycans with 0 – 2 Neu5Ac (Fig. 
3.3). Minor peaks corresponding to tri- and tetra-antennary sialylated glycans (n = 1 – 
3) in the high mass region (3500 – 4500) were also detected. The 50% ACN fraction 
contained several dominant species, including a Man3 core N-glycan which was core 
fucosylated (m/z = 1345.5), oligomannose-type structures (m/z = 1783.7, 1987.8, 
2191.9, and 2396.0), as well as mono- and di-sialylated bi-antennary structures (m/z = 
2605.1, 2792.2 and 2966.3). Note the fully sialylated, core fucosylated bi-antennary 
structure at m/z = 2966.3 was the most abundant among all structures, suggesting 
relatively high extent of sialylation in BHK-21 cells. In addition, several peaks with 
lower intensities in the high mass region (m/z = 3200 – 5000) were also annotated. 
Two dominant species within this region were a di-sialylated tetra-antennary glycan 
(m/z = 3415.6) and a fully sialylated tri-antennary glycan (m/z = 3776.7). 
 In comparison, the acetic acid-eluted glycans contained less oligomannose 
structures in both 35% and 50% ACN fractions (Fig. 3.4). The dominant species in the 
35% ACN fraction were complex-type bi-antennary glycans terminated with one 
GlcNAc on each branch (m/z = 1835.8), one Gal on each branch (m/z = 2244.0), one 
Neu5Ac (m/z = 2605.2) or two Neu5Ac residues (m/z = 2966.4). A paucity of tri- and 
tetra-antennary glycans with variable extent of sialylation (n = 0 – 3) were also 
detected. Sialylated species were more enriched in the 50% ACN fraction, with 
dominant structures being mono-sialylated bi-antennary (m/z = 2605.2), fully 
sialylated bi-antennary (m/z = 2966.4), di-sialylated tetra-antennary (m/z = 3415.6), 
and fully sialylated tri-antennary (m/z = 3776.8) glycans. Fully sialylated tetra-
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antennary glycan (m/z = 4413.3) was also detected. The acetic acid-eluted, 50% ACN 
fraction of BHK-21 N-glycans contained a few high mass species with m/z > 4700 
(boxed area in Fig. 3.4 lower panel), corresponding to glycans with 3 – 5 LacNAc 
units on top of the two LacNAc units of a bi-antennary glycan, suggesting at least 1 – 
3 repeating units of LacNAc-LacNAc.  
A peak at m/z = 2996 (marked by arrow in Fig. 3.4) did not match the size of 
any common glycan structure shown in the spectra. This peak sits right next to the 
dominant peak at m/z = 2966 (representing a fully sialylated core fucosylated glycan). 
Re-annotation of this peak by considering non-human structures revealed an unusual 
structure, which was a bi-antennary di-sialylated glycan with core fucose. However, 
one of the sialic acids was Neu5Gc and the other Neu5Ac. We then extended the 
annotation to other peaks that did not match any common glycan structures in the first 
round. Interestingly, many peaks were successfully assigned with N-glycan structures 
comtaining non-human residue NeuGc or motif Gal-Gal. Some peaks (m/z = 285.9, 
2910.3 and 3806.8) (Fig. 3.5 left panel) were unambiguously annotated to be Neu5Gc-
sialylated glycans. Several low abundance species were also identified at the high 
mass region (Fig. 3.5 right panel) that contained Galα(1,3)Gal xenoantigen. However, 
all these non-human glycans were at low abundance and did not constitute a 
significant portion of the BHK N-glycome. 
 Overall, the N-glycome of BHK-21 cells is constituted by mainly bi-, tri-, and 
tetra-antennary sialylated glycans as well as oligomannose-type glycans. This cell line 
is also capable of producing low-abundance non-human glycans containing Neu5Gc 
under our culture conditions and Galα(1,3)Gal epitope which is consistent with our 
GS-IB4 intracellular staining result and a previous report based on lectin-mediated 








Fig. 3. 4. Mass spectra of N-glycans produced in BHK-21 cells (acetic acid fraction) 
Note the presence of high molecular weight glycan species in 50% ACN fraction that contain 3 – 5 LacNAc repeats (boxed area). The peak at 





Fig. 3. 5. Mass spectra of N-glycans produced in BHK-21 cells (other structures) 
Peaks that did not match any common glycan structures in the first round were re-annotated based on knowledge of putative non-human 
structures. Note that all major peaks correspond to either human-like glycan structures or non-glycan substances. Therefore, the non-human 
glycans are of low-abundance. Isobaric structures were arranged vertically. 
59 
 
3.3.1.3 N-Glycome of HEK293 
 The 35% ACN fraction of water-eluted HEK293 N-glycans were dominated 
mainly by oligomannose-type structures (m/z = 1171.4, 1345.5, 1375.5, 1579.6, 
1783.7, 1988.8, 2191.9 and 2396.0) as well as a mono-sialylated bi-antennary 
complex-type structure (m/z = 2605.2) (Fig. 3.6). Bi-, tri- and tetra-antennary 
sialylated glycans were also detected but were of much lower abundance in m/z > 
2700 region. The two oligomannose-type structures (m/z = 2191.9 and 2396.0) were 
also the predominant glycan species the 50% ACN fraction. Another two major peaks 
corresponded to a mono-sialylated bi-antennary glycan (m/z = 2606.1) and a di-
sialylated tetra-antennary glycan (m/z = 3864.9) with intensities about 15 – 20% of 
the peak at m/z = 2396.0 (a Man9 oligomannose glycan). Other peaks corresponding 
to sialylated glycans were also detected (m/z = 2966.0, 3415.6, 3503.7, 3776.8, 4226.1) 
which potentially contained 1 – 3 Neu5Ac residues on 2 – 4 putative branches. 
However, these species were less abundant with relative intensities less than 10% of 
the Man9 glycan peak. 
 Major peaks in the 35% ACN fraction of acetic acid-eluted HEK293 N-
glycans included a Man3 core structure (m/z = 1345.5), structures terminating with 
two or three GlcNAc residues (m/z = 1835.7 and 2080.9, respectively), asialylated 
glycans terminating with variable number of Gal residues (n = 1 – 4) (m/z = 2244.0, 
2285.0, 2489.1, 2693.1, and 3142.4), as well as monosialylated bi-, tri- and tetra-
antennary glycans (2605.1, 3054.4, and 3503.6, respectively) (Fig. 3.7). Note that only 
the peak at m/z = 35036 represented > 10% intensity of the Man3 peak. The 50% 
ACN fraction was much more heterogeneous than the corresponding fraction from 
CHO-K1 and BHK-21 cells. More asialylated glycans were detected at m/z = 2060.1, 
2243.9, 2489.1, 2693.1, 2938.3, and 3142.4, matching bi-, tri- and tetra-antennary 
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structures with terminal GlcNAc, Gal, or both. Sialylated species were mostly mono-
sialylated glycans with 2 – 4 branches (m/z = 2605.1, 2850.2, 3054.4, 3299.5 and 
3415.5), as well as di- and tri-sialylation tetra-antennary glycans (m/z = 3864.8 and 
4226.1, respectively). Glycans with 1 – 4 potential LacNAc-LacNAc repeating units 
were detected in the high mass region (m/z ~ 4200 – 5700) (boxed area in Fig. 3.7 
lower panel).  
 Overall, N-glycans produced by HEK293 are more heterogeneous than those 
produced by CHO-K1 and BHK-21. Complex glycans are predominantly core 
fucosylated. Neu5Ac residue was assigned to all sialylated species, i.e., no Neu5Gc-








Fig. 3. 7. Mass spectra of N-glycans produced in HEK293 cells (acetic acid fraction) 
Note the presence of high molecular weight glycan species in 50% ACN fraction that contain 3 – 5 LacNAc repeats (boxed area). 
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3.3.1.4 N-Glycome of COS-7 
 The 35% ACN fraction of water-eluted COS-7 N-glycans showed a profile 
similar to that of CHO-K1, with a full set of high-abundance oligomannose structures 
(m/z = 1171.5, 1345.5, 1579.6, 1783.8, 1967.9, 2192.0 and 2396.0) (Fig. 3.8). Other 
major peaks included mono-sialylated, bi-antennary glycans with or without core 
fucose (m/z = 2605.2 and 2431.1, respectively). Other detectable glycan species 
included bi- and tri-antennary structures terminated with GlcNAc, Gal, or Neu5Ac (n 
= 0 – 2). But these species formed only a small percentage of total glycans in this 
fraction, indicated by the low peak intensities. In the 50% ACN fraction, the dominant 
species were Man8 glycan (m/z = 2192.0), as well as Man3 (m/z = 1579.7), Man6 
(m/z = 1783.8), Man7 (m/z = 1967.9) and Man9 (m/z =2396.1) glycans. All these 
glycans showed intensities higher than 10% of the Man8 peak. Among other peaks, 
only one showed intensity above 10% of the Man8 peak, which corresponded to a 
mono-sialylated bi-antennary glycan (m/z = 2605.2). Other complex glycans with 2 – 
4 branches were detected with varying number of Neu5Ac (n = 0 – 3) but were of low 
abundance. 
 The 35% ACN fraction of the acetic acid-eluted COS-7 N-glycans contained 
only one dominant glycan species at m/z = 2244.0, corresponding to a di-
galactosylated, core fucosylated, bi-antennary glycan (Fig. 3.9). Other major peaks 
(intensity > 10% of the afore-mentioned peak) included a di-GlcNAcylated, core 
fucosylated glycan (m/z = 1835.8), a di-galactosylated, afucosylated bi-antennary 
glycan (m/z = 2069.9), mono-sialylated bi-antennary glycan (m/z = 2605.2) and tri-
antennary glycan terminated with a Gal on each branch (m/z = 2593.3). Other 
complex-type glycans with 2 – 4 branches and 0 – 2 sialic acids were also detected but 
did not constitute a significant portion of all glycans. In the 50% ACN fraction, three 
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peaks at m/z = 2244.0, 2605.2 and 2693.3 constituted the majority of all glycan 
signals, corresponding to a di-galactosylated bi-antennary glycan,  a mono-sialylated, 
mono-galactosylated bi-antennary glycans, and a tri-galactosylated tri-antennary 
glycan, respectively. Other major peaks (intensity > 10% of the peak at m/z = 2244.0) 
include bi-, tri-, and tetra-antennary glycans with varying number of sialic acids (n = 0 
– 2) which are predominantly core fucosylated (m/z = 2472.1, 2693.3, 2966.4, 3054.4, 
3415.7 and 3503.7) as well as a peak at m/z = 3591.8 matching a glycan with 3 
LacNAc units on top of the two LacNAc on a bi-antennary structure, suggesting at 
least one LacNAc-LacNAc repeat. LacNAc repeating units (n = 3 – 5) can also be 
found in high mass region (m/z ~ 3800 – 5000) at low levels (dash-lined area in Fig. 
3.9), suggesting a paucity of the glycans in COS-7 could contain at least 1 – 3 
LacNAc-LacNAc repeats. The peak at m/z = 2996 found in BHK-21 glycan samples 
was also observed in this fraction, although intensity of this peak was relatively low. 
Nevertheless, the unambiguously assigned structure (enlarged in red boxed area) 
suggested the presence of low abundance Neu5Gc in the N-glycome of COS-7 cells, 









Fig. 3. 9. Mass spectra of N-glycans produced in COS-7 cells (acetic acid fraction) 
Note the presence of high molecular weight glycan species in 50% ACN fraction that contain 3 – 5 LacNAc repeats (dash-lined area) and a di-
sialylated bi-antennary glycan containing one Neu5Gc and one Neu5Ac at m/z = 2996 (enlarged in red box). 
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3.3.1.5 N-Glycome of 3T3 
 The 35% ACN fraction of water-eluted COS-7 N-glycans contained a full set 
of oligomannose-type structures, i.e., Man3 (m/z = 1171.4), Man4 (m/z = 1375.6), 
Man5 (m/z = 1579.7), Man6 (m/z = 1783.8), Man7 (1987.9), Man8 (2192.0) and 
Man9 (2396.1) glycans, constituting a major fraction of all glycan species in this 
fraction (Fig. 3.10). All these oligomannose glycans were afucosylated. Another peak 
at m/z = 1345.6 represented a core fucosylated Man3 structure with significant 
intensity. Other low-abundance but significant peaks corresponded to bi-, tri-, and 
tetra-antennary glycans terminated with GlcNAc (n = 0 – 4), Gal (n = 0 – 3), or 
Neu5Ac (n = 0 – 2). Man6, Man7, Man8, and Man9 also dominated the 50%ACN 
fraction (m/z = 1783.7, 1987.9, 2191.9, and 2396.0, respectively), with a paucity of 
complex-type structures bearing 2 – 4 branches terminated with GlcNAc, Gal, or 
Neu5Ac (n = 0 – 4). Therefore, the water-eluted fraction of 3T3 N-glycans were 
predominantly oligomannose-type. 
 The 35% ACN fraction of acetic acid-eluted 3T3 N-glycans were dominated 
by six species, namely, a Man3 core fucosylated glycan structure (m/z = 1345.5), a 
mono-GlcNAcylated hybrid glycan (m/z = 1590.6), a di-GlcNAcylated bi-antennary 
glycan (m/z = 1835.7), a mono-galactosylated bi-antennary glycan (m/z = 2039.9), 
and two di-galactosylated bi-antennary glycans (m/z = 2069 for afucosylated structure, 
and m/z = 2244.0 for fucosylated structure) (Fig. 3.11). Other oligomannose- and 
complex-type structures were at much lower abundance, including sialylated (Neu5Ac 
= 0 – 3), bi-, tri-, and tetra-antennary structures. A special note here is that major two 
peaks at m/z = 2652.2 and 2809.2 (marked by arrows in Fig. 3.11) could not match the 
any of common structures. These two peaks will be re-annotated and were revealed to 
be glycans bearing non-human structures (see below). The 50% ACN fraction was 
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more heterogeneous, and as a result, more structures were assigned. Note that some 
peaks can correspond to several putative structures which merit further analysis by 
tandem MS/MS. Several major peaks were annotated with common glycan structures, 
namely, m/z = 1835.7 for a di-GlcNAcylated bi-antennary glycan with core fucose, 
m/z = 2605.1 for a bi-antennary core fucosylated glycan terminated with a Neu5Ac 
and a Gal on each branch, m/z = 2966.3 for a di-sialylated core fucosylated bi-
antennary glycan. In the low mass region, two glycans bearing bisecting GlcNAc 
residue were identified (marked by * in Fig. 3.11). In the high mass region, a diverse 
set of unusual structures were identified (marked by # in Fig. 3.11), including multiple 
structures bearing Neu5Gc (structures shown in enlarged Box 1), as well as Gal-Gal 
linkage in terminal sequences (enlarged Box 2), suggesting the presence of α3-
galactose antigenic epitope. 
 As noted above, the mass spectra for acetic acid fraction of 3T3 N-glycans 
contained several peaks that could not be assigned to any common N-glycan 
structures (peaks at m/z = 2652.2 and 2809.2 in Fig 3.11). A careful re-inspection of 
the mass spectra revealed two additional major peaks at m/z = 3305.5 and 3462.6 (Fig. 
3.X), despite at lower abundance, that did not match any common structures. These 
four unannotated peaks were also present in the water fraction at even lower 
abundance. Based on the knowledge that 3T3 cells are capable of synthesizing 
Galα(1,3)Gal linkage, supported by literature (Galili 2006, Tearle et al. 1996), new 
structures were assigned to the peaks previously unannotated peaks (Fig. 3. 11) with 
the consideration of non-human glycan structures containing Neu5Gc and 
Galα(1,3)Gal. The peak at m/z = 2652.2 can correspond to two structures (Box 1 in 
Fig. 3.12), an unusual hybrid structure with two galactosylated branches as well as 
two α2 mannose residues, or a bi-antennary glycan terminated with two layers of 
69 
 
galactose residues (i.e. one Galα(1,3)Gal on each branch). The peak at m/z = 2809.2 
can correspond to a mono-sialylated (Neu5Gc), mono-galactosylated bi-antennary 
glycan with a fucose on the branch, or a monosialylated (Neu5Ac) bi-antennary 
glycan with Galα(1,3)Gal on the other branch (Box 2). In either case, the structure 
contains non-human glycan epitope. The peak at m/z = 3305.5 corresponded to either 
a hybrid-type glycan with two α2 mannose residues and two Galα(1,3)Gal epitopes on 
the other two branches, or a tri-antennary complex-type glycan with a Galα(1,3)Gal 
epitope on each branch (Box 3). The peak at m/z = 3462.6 can match to the sizes of 
four putative structures that are either hybrid-type or tri-antennary glycans (Box 4), all 
bearing Neu5Gc or Galα(1,3)Gal or both. Similarly, other minor peaks were annotated, 
corresponding to a diverse collection of unusual non-human structures with Neu5Gc 
or Galα(1,3)Gal.  
 Overall, the N-glycome of 3T3 is more heterogeneous and contains abundant 
structures bearing Neu5Gc- or Galα(1,3)Gal. It is also noted that the major glycan 
peaks in all fractions were oligomannose-type or complex-type with low sialic acid 








Fig. 3. 11. Mass spectra of N-glycans produced in 3T3 cells (acetic acid fraction) 
Note the presence of glycans species containing bisecting GlcNAc (marked by *). Abundant non-human glycan structures were also detected 




Fig. 3. 12. Mass spectra of N-glycans produced in 3T3 cells (other structures) 
Peaks that did not match any common glycan structures in the first round were re-annotated based on knowledge of putative non-human 
structures. Putative structures for the same peak were arranged vertically. 
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3.3.1.6 Main features of N-glycomes of the five cell lines 
 Profiling of N-glycomes of the five cell lines by MALDI-TOF MS reveals 
several common features among these cell lines: 
i) The 35% ACN fraction of water-eluted glycans from all five cell lines 
were predominantly oligomannose-type with Man6 and Man5 as the 
major species. 
ii) Complex-type glycans were more enriched in the 50% ACN fraction of 
both water and acetic acid-eluted glycans. 
iii) Oligomannose-type glycans were predominantly without core 
fucosylation, whereas complex-type glycans were mostly core-
fucosylated. 
iv) Hybrid-type glycans can be detected in all five cell lines but did not 
constitute a significant fraction of the total glycan pool. 
v) LacNAc repeats were detected at low abundance. 
vi) Neu5Ac was the major form of sialic acid. 
 
Apart from these common features, a strong cell line-dependent pattern of 
glycosylation is also noted during the analysis: 
i) Neu5Gc was not detected in CHO and HEK293 N-glycomes. The 
presence of low-abundance Neu5Gc in BHK-21 and COS-7, which are 
thought to be unable to synthesize Neu5Gc, is mostly likely due to the 
salvage of Neu5Gc from culture media which contained FBS as the 
source of Neu5Gc (Ghaderi et al. 2010). 3T3 cells, on the other hand, 
produced a diverse set of Neu5Gc-containing structures. 
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ii) CHO-K1 and COS-7 N-glycomes were free of Galα(1, 3)Gal epitope. 
BHK-21 cells were found to produce low-abundance Galα(1,3)Gal-
containing glycans. Galα(1,3)Gal-containing glycans constituted a 
significant portion of 3T3 N-glycome, consistent with previous reports 
on mice (McKenzie et al. 1998, Tearle et al. 1996). 
iii) Comparison based on relative peak intensities suggests that BHK-21 
N-glycome has the highest level of sialylation, dominated by di- and 
tri-sialylated species, whereas complex glycans in CHO were mostly 
mono-sialylated or asialylated. HEK293, COS-7 and 3T3 contained 
higher fractions of truncated glycans such as bi- and tri-antennary 
glycans with GlcNAc exposed at one or more branches, suggesting 
lower extent of complete glycosylation.   
 
Because glycans were prepared from whole cell lysates, we postulate that the 
relative abundance of complex-type glycans, especially those of multi-antennary 
structures and with high sialic acid content, was under-represented in this analysis, 
due to the co-extraction of glycans that were still undergoing processing/assembly as 
well as that carried by intracellular glycoproteins (e.g. ER resident proteins). To 
specifically analyze the mature glycan structures on secreted proteins, we later 
performed MALDI-TOF analysis of glycans on a recombinant glycoprotein, EPO-Fc 
(Section 3.3.5). Comparison of relative sialylation extent based MALDI-TOF spectra 
is challenging due to the differential ionization and/or ion abundance. This was 
resolved by chromatographic separation and quantitation of differentially sialylated 




3.3.2 Structural profiling of endogenous O-glycans by MALDI-TOF 
 Proteins extracted from cell lysates were treated with trypsin and PNGase F to 
release N-glycans. The remaining peptides (including O-glycosylated peptides) were 
separated from N-glycans by a C18 column. The O-glycans were liberated from the 
peptides by reductive elimination. After permethylation, the O-glycans were analyzed 
by MALDI-TOF MS.  
 
3.3.2.1 O-Glycome of CHO-K1 
Mass spectrum of endogenous O-glycans in CHO-K1 shows two major peaks that can 
matched to O-glycans, a mono-sialylated core 1 (or sialyl-T antigen (ST)) of m/z ratio 
895.2 and a disialyl-Tn antigen (dST) of 1256.3 (Fig. 3.13). Note that only Neu5Ac 
form of sialic acid was detected. These two O-glycan species are comparable in 
abundance. The other peaks did not match any O-glycans. This shows CHO-K1 O-
glycome is constituted by mono- and di-sialylated core 1 structured. 
  
Fig. 3. 13. Mass spectrum of O-glycans produced in CHO-K1 cells 
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3.3.2.2 O-Glycome of BHK-21 
In BHK-21 cells, more O-glycan structures were detected in the cell lysate 
(Fig. 3.14). ST and dST found in CHO-K1 also represented two dominant structures 
in BHK-21. A few minor peaks were identified that matched the sizes of known O-
glycans, namely asialylated T antigen at m/z = 534.2, Neu5Gc-T antigen (m/z = 
1286.5), as well as some extended core 2 structures at m/z = 1344.6, 1617.7 and 
1705.7. Although intensities of these species were relatively low, they were clearly 
above the noise level, suggesting the real existence of these O-glycan species in BHK-
21 cells. Neu5Gc was detected on several low-abundance structures. By normalizing 
the total intensities of Neu5Gc-containing species to the integrated intensities of all 
annotated peaks, Neu5Gc-containing O-glycans were found to constitute about 5% of 
all O-glycans produced in BHK-21 cells. 
 
Fig. 3. 14. Mass spectrum of O-glycans produced in BHK-21 cells 
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3.3.2.3 O-Glycome of HEK293 
In HEK293 sample (Fig. 3.15), the ratio of ST to dST is about 1:3 as compared 
to around 1:1 in CHO-K1 and 1:1.6 in BHK-21. There are additional three peaks at 
m/z = 983.4, 1344.5 and 1705.7, which represented extended core 2 O-glycans. 
Neu5Gc was detected on several low-abundance structures (m/z = 1286.5, 1374.5, and 
1735.7), possibly due to salvage of Neu5Gc sialic acid from the culture medium 
which contained bovine serum (Ghaderi et al. 2010). These Neu5Gc-containing 
species represented less than 5% of total O-glycan population. Another minor peak 
(m/z = 2154.9) corresponds to an di-sialylated, extended core 2 structure with two 
repeats of LacNAc. 
 
 




3.3.2.4 O-Glycome of COS-7 
The dominant species of COS-7 O-glycome were ST and dST. The ratio of ST 
to dST in COS-7 cells was about 1:2 (Fig. 3.16). Other peaks included dST with one 
or both sialic acids being Neu5Gc (m/z = 1286.5 and 1316.5, respectively) and 
extended core 2 structures (m/z = 1548.6, 1705.7, 1735.7). The largest O-glycan (m/z 
= 1851.8) was unambiguously assigned to an extended core 4 structure (i.e. the 
GalNAc residue attached to Ser/Thr is derivatized by two GlcNAc residues) with a 
fucosylated branch which contained a Lewis x (Lex) epitope. Neu5Gc-containing 
species represented about 10% of total O-glycan population. 
 
 




3.3.2.5 O-Glycome of 3T3  
3T3 O-glycome contained a more heterogeneous set of O-glycans. The 
dominant species were ST and dST structures at about 1:1 ratio (Fig. 3.17). Other 
structures included naked core 1 (or T antigen) (m/z = 534.2), naked core 2 structure 
(m/z = 779.4), and extended core 2 (m/z = 983.5, 1140.5, 1344.6, 1374.7, 1705.8 and 
1735.8). The minor peak at m/z = 738.4 can be assigned to two structures, namely, 
Gal-Gal-GalNAc representing an extended core 1 O-glycan or a Gal-GlcNAc-Gal 
representing a precursor for P1 blood group antigen typically found on glycoceramide. 
The latter structure was then eliminated in the context of O-GalNAc glycosylation. 
Therefore, the peak at m/z = 738.4 was unambiguously annotated as an extended core 
1 O-glycan containing a terminal Gal-Gal epitope (also known as Linear B antigen). 
About 20% of all O-glycans produced in 3T3 contained Neu5Gc, assuming the peak 
at m/z = 1344.6 represents a Neu5Gc-containing glycan.  
 
Fig. 3. 17. Mass spectrum of O-glycans produced in 3T3 cells
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3.3.2.6 Main features of O-glycomes of the five cell lines 
 O-Glycomic analysis of the five cell lines revealed a few common key features: 
i) Mono- and di-sialylated core 1 (i.e., ST and dST) structures were found 
to be the two dominant species of O-glycome for all five cell lines. 
ii) Immunodominant Tn and sialyl-Tn (STn) structures (Nakada et al. 
1994) were not detected in any of the cell lines analyzed (see below). 
 
The five cell lines also displayed substantial differences in their O-glycans: 
i) CHO-K1 produced only ST and dST structures. O-glycans produced by 
the other four cell lines were more heterogeneous with additional core 
2-based structures. 
ii) Neu5Gc was not detected in CHO-K1 O-glycome. The relative 
abundance of NeuGc among the total pool of sialic acids within the O-
glycome was around 5 – 10% in BHK-21, HEK293 and COS-7 cells, 
possibly due to the salvage of Neu5Gc from the culture media, while 
that in 3T3 cells was about 20%, suggesting de novo production of 
Neu5Gc in this cell line. 
 
Because the O-glycans for MS analysis were prepared from whole cell lysates, 
the O-glycomic profiles were expected to include premature O-glycans that were 
extracted from glycoproteins still in the processing/assembly stage. Therefore, fully 
processed, extended O-glycan structures are postulated to be under-represented in the 
O-glycomic profiles shown above. We later expressed and purified recombinant 
MUC1-Fc, a heavily O-glycosylated protein, as a model molecule for O-glycan 
structural analysis (Section 3.3.7). On the other hand, the MALDI-TOF analysis failed 
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to identify Tn antigen, the structure synthesized in the first stage of O-glycosylation, 
due to the detection range of 500 – 5000 m/z (m/z for Tn is about 245). Lectin 
staining was then utilized to ascertain the presence or absence of Tn antigen in the five 
cell lines.  
 
3.3.3 HPA staining of intracellular and cell surface Tn antigen 
 Lectin staining was performed on the five cell lines aiming to provide 
complementary data to the MS analysis. The five mammalian cell lines, namely CHO-
K1, BHK-21, HEK293, COS-7 and 3T3, grown in monolayer on glass coverslips, 
were fixed with or without a subsequent permeabilization step and stained by HPA, a 
lectin that specifically binds to Tn antigen.  
When cells were permeabilized by detergent, juxtanuclear structures 
resembling the Golgi of all five cell lines were positively stained by HPA (Fig. 3.18). 
This is because of the snapshot of O-GalNAc modified proteins in the Golgi by 
fixation before they could be further processed. When glycoproteins are finally 
destined to the cell surface, however, further modification of the O-GalNAc abolishes 
the binding of HPA. Indeed, non-permeabilized CHO-K1 cells were negative for HPA 
staining, suggesting that the O-glycan structures on CHO-K1 cell surface are more 
elaborate than Tn antigen. Consistently, a previous MS-based finding showed that 
recombinant EPO produced in CHO-K1 cells carry predominantly mono- or di-sialyl-
T antigens (Hokke et al. 1995). Similarly, BHK-21, HEK293 and 3T3 cells were 
positively stained by HPA when permeabilized but became HPA-negative when non-
permeabilized, suggesting the absence of Tn antigen on their cell surface. In contrast, 
non-permeabilized COS-7 showed very strong HPA binding at the cell surface, 





Fig. 3. 18. Staining of intracellular and cell surface carbohydrates by HPA 
Cells were seeded on glass coverslips and cultured overnight before fixation. Cells 
were then permeabilized, blocked and staining with AlexaFluor 488-conjugated HPA 
to visualize intracellular structures (upper panel). Specific labeling of cell surface 
carbohydrates was achieved by omitting the permeabilization step (lower panel). 
 
 
3.3.4 Structural characterization of N-glycan on recombinant EPO-Fc 
produced in the five cell lines by MALDI-TOF 
 To specifically compare the N-glycosylation of recombinant glycoproteins 
produced by the five cell lines, an EPO-Fc fusion protein was designed by placing the 
coding sequence of human EPO N-terminally to the human IgG1 hinge region 
followed by Fc region. The O-glycosylation site on EPO, Ser126, was mutated to Val. 
The N-glycosylation site on Fc, Asn297, was mutated to Ala. Such mutations ensure 
that the EPO-Fc fusion protein carries only three N-glycans, all located within the 
EPO region. We have used this fusion protein as a model molecule for 
characterization of CHO glycosylation mutant (Zhang et al. submitted manuscript), 
profiling of N-glycans (Goh et al. 2010), as well as studying sialylation extent (Zhang 
et al. 2010). In this study, construct encoding EPO-Fc was transient transfected into 
the five cell lines. Recombinant EPO-Fc was secreted into the conditioned media (i.e. 
DMEM supplemented with 4% Ultra-Low IgG FBS) and purified by Protein A 
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chromatography. Purified EPO-Fc protein was tryptically digested. N-glycans were 
released by PNGase F, permethylated, and fractionated by a C18 column with 15, 35, 
50 and 75% acetonitrile (ACN). Each fraction was analyzed by MALDI-TOF MS. 
Glycans were identified in 35% and 50% ACN fractions. Only major peaks with at 
least 10% relative intensity and peaks corresponding to non-human structures were 
highlighted in the figures and described below. 
  
3.3.4.1 N-Glycan structures of EPO-Fc produced in CHO-K1  
 The 35% ACN fraction contained mainly asialylated species, represented by 
peaks at m/z = 1579.7 (Man5 glycan), 1835.9 (di-GlcNAcylated glycan), and 2244.0 
(di-galactosylated bi-antennary glycan), as well as a mono-sialylated bi-antennary 
glycan at m/z = 2605.2 (Fig. 3.19). A minor peak corresponding to a mono-sialylated 
(Neu5Gc), hybrid-type glycan at m/z = 2185.99 was also detected. The 50% ACN 
fraction contained mainly sialylated bi, tri- and tetra-antennary glycans including 
highly sialylated tri- and tetra-antennary glycans (sialic acid number n = 3 – 4) (m/z = 
3602, 3776, 4225, and 4586). Neu5Gc was found at low abundance, represented by 
minor peaks at m/z = 2185, 2996, and 3359. The paucity of Neu5Gc was most likely 
due to the salvage of Neu5Gc from the culture media. The high relative intensities of 
peaks for highly sialylated species suggested relative high sialylation extent of EPO-






Fig. 3. 19. Mass spectra of N-glycans released from recombinant EPO-Fc produced in CHO-K1cells 
Peaks representing non-human structures, despite at low levels, were highlighted in yellow and the corresponding structures were boxed. Note 







3.3.4.2 N-Glycan structures of EPO-Fc produced in BHK-21 
 The three major peaks in the 35% ACN fraction did not match the size of any 
putative N-glycan., suggesting low abundance of N-glycans in this fraction (Fig. 3.20). 
In the 50% ACN fraction, several major peaks (m/z = 2966, 3602, 3776 and 4587) 
corresponding to fully sialylated bi-, tri-, and tetra-antennary glycans were detected in 
addition to peaks corresponding to partially sialylated glycans (m/z = 2605 and 3415). 
The minor peak at m/z = 2185 which was detected in CHO-K1 EPO-Fc sample was 
also present in the BHK-21 sample. Overall, the absence of dominant asialylated 
species suggested that EPO-Fc produced by BHK-21 cells contained high content of 





Fig. 3. 20. Mass spectra of N-glycans released from recombinant EPO-Fc produced in BHK-21cells 
The 35% acetonitrile fraction does not contain any major glycan species. The 50% acetonitrile fraction contains mainly fully sialylated, bi-, tri-, 







3.3.4.3 N-Glycan structures of EPO-Fc produced in HEK293 
 Three dominant glycan species were identified in the 35% ACN fraction of 
HEK293 EPO-Fc sample, namely a tri-GlcNAcylated glycan (m/z = 2060), a glycan 
with an additional Gal residue (m/z = 2284), as well as a tetra-GlcNAcylated glycan 
(m/z = 2325) (Fig. 3.21). Exact position of the terminal GlcNAc remained unknown, 
which can be ascertained by tandem MS analysis. The 50% ACN fraction contained a 
few peaks at comparable intensities (m/z = 3503, 3602, 3864, and 4225). Assuming 
the LacNAc on top of the two LacNAc on a bi-antennary glycan forms a new branch 
instead forming LacNAc repeats, these peaks represented tri- and tetra-antennary 
glycans each containing 2 – 3 sialic acids. A minor peak corresponding to a fully 
sialylated tri-antennary glycan was identified which contained one Neu5Gc and two 





Fig. 3. 21. Mass spectra of N-glycans released from recombinant EPO-Fc produced in HEK293 cells 
The 35% acetonitrile fraction contains abundant tri- and tetra-antennary glycans terminated with GlcNAc or Gal. The 50% acetonitrile fraction 
contains mainly fully sialylated, bi-, tri-, and tetra-antennary glycans. Only a minor peak (highlighted in yellow) corresponds to Neu5Gc-







3.3.4.4 N-Glycan structures of EPO-Fc produced in COS-7 
 Contrary to the profile of the BHK-21 sample, glycans released from EPO-Fc 
produced in COS-7 were enriched in the 35% ACN fraction (Fig. 3.22). This fraction 
contained a few major peaks corresponding to predominantly asialylated glycans that 
were high-mannose type (m/z = 1579), complex-type bi-antennary structures 
terminated with GlcNAc (m/z = 1835), or Gal (m/z = 2243 and 2693), or both (m/z = 
2039 and 2284). A mono-sialylated glycan was also detected at m/z = 2605. The peak 
at m/z = 2809 can be assigned to two structures, one containing a Neu5Gc as well as a 
Lex epitope and the other containing a Gal-Gal linkage. This peak was also identified 
in 50% ACN fraction. The only major peak in the 50% ACN fraction did match the 
size of any putative N-glycan. Overall, EPO-Fc produced in COS-7 cells was believed 
to be poorly sialylated due to the low abundance of highly sialylated species in the 
MALDI spectra. Because COS-7 as a monkey cell line is believed unable to produce 
Galα(1,3)Gal structure, the peak at m/z = 2809 most likely represented the Neu5Gc-








Fig. 3. 22. Mass spectra of N-glycans released from recombinant EPO-Fc produced in COS-7 cells 
The 35% acetonitrile fraction contains abundant bi- and tri-antennary glycans terminated with GlcNAc or Gal. In the 50% acetonitrile fraction, 
only one major glycan peak (highlighted in yellow) was detected, corresponding to either a mono-sialylated (Neu5Gc), bi-antennary glycan with 








3.3.4.5 N-Glycan structures of EPO-Fc produced in 3T3 
 The 35% ACN fraction contained predominantly asialylated glycans (m/z = 
2069, 2243, 2325 and 2693) that were bi-, tri- and tetra-antennary glycans terminated 
with Gal or GlcNAc. (Fig. 3.23). Another major peak at m/z = 2605 represented a 
mono-sialylated complex-type glycan. The 50% ACN fraction contained mainly 
asialylated and mono-sialylated glycans (m/z = 2243, 2605, 2693 and 3054). Other 
structures included tri- and tetra-antennary glycans with variable number of sialic acid 
(n = 0 – 3). A minor peak at m/z = 3583 was detected which represented a tetra-
antennary, mono-sialylated glycan with a Gal-Gal linkage suggesting the presence of 
Galα(1,3)Gal epitope in EPO-Fc N-glycans produced in 3T3 cells. No Neu5Gc was 





Fig. 3. 23. Mass spectra of N-glycans released from recombinant EPO-Fc produced in 3T3 cells 
The 35% acetonitrile fraction contains abundant bi- and tri-antennary glycans terminated with GlcNAc or Gal. The 50% acetonitrile fraction 
contains under-sialylated bi-, tri-, and tetra-antennary glycans with exposed Gal termini, as well as fully sialylated tri-antennary glycan. One 
minor glycan peak (highlighted in yellow) corresponding to a tetra-antennary glycan with Gal-Gal terminal sequence (glycan shown in boxed 







3.3.4.6 Main features of N-glycosylation of recombinant EPO-Fc in the five cell lines 
 MALDI characterization of N-glycans revealed several cell line-dependent 
features of EPO-Fc N-glycosylation in the five cell lines: 
i) N-glycans on EPO-Fc were predominantly sialylated in BHK-21 but 
asialylated in COS-7 cells. The other three cell lines produced a range 
of asialylated and sialylated glycans of substantial abundance. 
ii) Complex-type glycans in HEK293 cells were mainly tri- and tetra-
antennary structures while those in BHK-21 and CHO-K1 were mainly 
bi- and tri-antennary structures with relatively less tetra-antennary 
structures. 
iii) Galα(1, 3)Gal structure was unambiguously detected only in 3T3 cells. 
iv) Neu5Gc was unambiguously detected in CHO-K1, BHK-21 and HEK-
293 cells, possibly due to the metabolic source of Neu5Gc from the 
culture media. 
 
Comparison of sialylation extent, a parameter critical for the bioactivity of 
many therapeutic glycoproteins including EPO, is difficult based on MALDI profiles 
due to the lack of a reference peak for normalization. N-glycans released from EPO-
Fc was then analyzed by high pH anion exchange chromatography (HPAEC) for 
quantitation and comparison of differentially sialylated glycans. 
 
3.3.5 Comparative analysis of sialylation of EPO-Fc N-glycans by HPAEC 
 To compare the sialylation capabilities of the five cell lines, N-glycans carried 
by purified EPO-Fc were released by PNGase F treatment and loaded onto a high pH 
anion exchange (HPAEC) column. HPAEC separates the glycans based on their 
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interaction with the column via the hydroxyl groups at high pH. The glycans were 
eluted from the column by an ascending gradient of sodium acetate and fractionated 
into four fractions representing asialo, mono-sialylated, di-sialylated, tri-sialylated, 
and tetra-sialylated glycan by comparing with a reference curve. Ratio of the four 
fractions reflects the relative sialylation extent of N-glycans in a particular cell line.  
 In CHO cells, asialylated and mono-sialylated glycan pools each constituted 
about 19% and 10% of the tool glycan pool (Fig. 3.24 and Table 3.1). Di-, tri- and 
tetra-sialylated glycans constituted 21%, 27% and 23% each. Therefore, a total of 81% 
of all glycans were sialylated. In BHK-21 cells, sialylated species were more enriched 
in tri-sialylated pools, constituting about 34% of all N-glycans on EPO-Fc. The 
sialylated glycans combined constituted 79% of all EPO-Fc N-glycan pool. HEK293 
and COS-7 cells produced less tetra-sialylated EPO-Fc (7% and 9%, respectively). 
The relative abundances of di- and tri-sialylated pools were comparable whereas 
asialylated species constituted higher percentages (37% and 28%) compared to that in 
CHO-K1 and BHK-21. EPO-Fc produced in 3T3 cells were found to contain the 
highest percentage of asialylated glycans (38%) and conversely, the lowest percentage 
of tetra-sialylated glycans (3%) among all five cell lines. The sialylated glycan 
combined constituted only 62% of the total N-glycan pool. 
It was also noted that comparing the sialylation extents simply by considering 
percentage of sialylated glycans did not accommodate the actual number of sialic 
acids. In other words, impact on sialylation by highly sialylated species was under-
represented.  To take into account of this, sialylation index was calculated according 
to the formula below and used to compare the sialylation extent of recombinant EPO-








            Equation 2 
( %Mono/Di/Tri/Tetra = percentage of mono/di/tri/tetra-sialylated glycans) 
 
According to Equation 2, the theoretical maximum of sialylation extent will be 
4 (assuming all the glycans are tetra-antennary, tetra-sialylated). The sialylation 
indices of the EPO-Fc produced in the five cell lines were calculated and shown in 
Table 3.2. Hence, sialylation extent of EPO-Fc samples follows the order: CHO-K1, 




Fig. 3. 24. HPAEC profiling of EPO-Fc sialylation in the five cell lines 
N-glycans were released from purified EPO-Fc produced in CHO-K1 (blue); BHK21 
(brown); 3T3 (orange); HEK293 (pink) and COS7 (black) and fractionated by 
HPAEC into asialo-, mono-, bi-, tir-, and tetrasialylated pools. Abundance of each 
pool was estimated by area under the curve for that pool. Percentage of each pool was 







Table 3. 1. Relative abundance of HPAEC-fractioned N-glycans from 
recombinant EPO-Fc produced in five cell lines 















CHO-K1 19% 10% 21% 27% 23% 81% 
BHK-21 21% 5% 23% 34% 17% 79% 
HEK293 37% 12% 22% 22% 7% 63% 
COS-7 28% 12% 27% 24% 9% 72% 
3T3 38% 20% 20% 19% 3% 62% 
 
Table 3. 2. Sialylation indices of recombinant EPO-Fc in the five cell lines 
EPO-Fc sialylation index of each cell line was calculated using Equation 2. 







3.3.6 Expression, purification, and initial O-glycosylation analysis of 
recombinant MUC1-Fc 
 A MUC1-Fc fusion protein was designed that contains a MUC1 signal peptide, 
a short stretch of tandem repeats, followed by Fc region of human IgG1 including the 
hinge region. The expression construct encoding the MUC1-Fc fusion protein was 
transiently transfected into the five cell lines. Three days after transfection, MUC1-Fc 
that was secreted into the conditioned media was purified by Protein A 
chromatography. Aliquots of the purified MUC-1Fc samples were analyzed by SDS-
PAGE followed by coomassie staining (Fig. 3.25A) and Western blotting using an 




Fig. 3. 25. SDS-PAGE analysis of recombinant MUC1-Fc purified from the five 
cell lines 
Parallel analysis of purified MUC1-Fc from the five cell lines (labeled on the top) was 
performed using 3 – 8% Tris-acetate gels. (A) One gel was subjected to Western 
blotting and recombinant MUC1-Fc was detected using an HRP-conjugated goat anti-
human IgG1 Fc antibody. (B) The other gel was stained with coomassie blue to 
visualize total proteins in each lane.  
 
 In each purified sample, coomassie staining revealed a major band in each lane 
with apparent molecular weight of about 120 – 150 kDa. In addition, a weaker band of 
about 60 kDa also existed in each sample (Fig. 3.25A). Both bands were detected by 
the antibody specific for human IgG1 Fc (Fig. 3.25B), suggesting that the top band 
corresponds to full length recombinant MUC-1 Fc and the lower band is a cleaved 
product of MUC1-Fc containing the Fc and some adjacent sequence, whereas the 
cleaved N-terminal part of MUC1-Fc was lost during the Protein A purification due to 
the lack of Fc region. Nevertheless, the existence of cleaved product does not affect 
the analysis of MUC1 O-glycosylation. Strikingly, there is a huge difference in the 
apparent molecular weight of full length MUC1-Fc, ranging from about 120 kDa in 
CHO-K1, BHK-21 and 3T3 cells, about 140 kDa in COS- 7 cells, to 150 kDa in 
HEK293 cells. The dramatic difference in molecular weight suggested a huge 







Characterization of O-glycan structures by MALDI-TOF MS was not 
completed during the preparation of the thesis. Here, preliminary results from analysis 
of the HEK293 sample are presented. O-glycans were released from 100 µg MUC1-Fc 
purified from HEK293 culture by microwave-assisted reductive elimination, 
permethylated and analyzed by MALDI-TOF MS. Annotation of the mass spectrum 
revealed only four low-intensity peaks at m/z = 967, 1240, 1328 and 1890 that could 
match O-glycan structures, representing a galactosylated core 2, a di-sialyl core 1 
(dST), an extended core 2, and a di-sialyl core 2 structure, respectively (Fig. 3.26). 
Interestingly, these four structures constituted the dominant species in the whole 
cellular O-glycome of HEK293 (Fig. 3.15), in addition to mono-sialyl T antigen 
structure. Therefore, it is tempting to speculate that O-glycosylation of a secrected 
glycoprotein can be largely deduced from the O-glycome profile of the producing cell 
line. 
The relatively low signal intensity of the O-glycans could be due to the 
difficulty in releasing the closely packed O-glycans. In fact, there are five potential O-
glycosylation sites within each tandem repeating sequence of MUC1. Collectively, the 
over 30 O-glycans in the short region could create a molecular mash to resist the 
chemical release. Higher amount of MUC1-Fc protein can be used to yield more O-











Fig. 3. 26. Mass spectra of O-glycans of recombinant MUC1-Fc produced in 
HEK293 cells 
O-glycans released from MUC1-Fc were analyzed by MALDI-TOF MS. The full 
spectrum contained a few minor peaks corresponding to O-glycans.  
 
3.4 Discussion 
Proteins transiting along the secretory pathway are often decorated with 
carbohydrates before destined to the cell surface or secreted into the extracellular 
space. Glycosylation of cell surface proteins contains a wealth of information and 
interaction of glycans with glycan binding proteins expressed by apposing cells 
creates a new dimension of complexity in cellular regulation and response. This idea 
is supported by increasing knowledge of congenital disorder of glycosylation where 
mutation in glycan-related genes often leads to lethality or severe developmental 
defects (Marquardt and Denecke 2003), change of glycosylation pattern during 
immune cell activation and immune response (Irimura et al. 1999, Isenberg 1995, 
Lowe 2001, Marth and Grewal 2008, Tenno et al. 2007), as well as the involvement of 
aberrant glycosylation in diseases such as autoimmunity and cancer (Green et al. 2007, 
Hassinen et al. 2011). A role of glycosylation on secreted proteins has also been 
widely recognized in many aspects including protein folding (Helenius and Aebi 
2001), secretion (McKinnon et al. 2010) and in vivo bioactivity (Sinclair and Elliott 
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2005). Therefore, systematic characterization of glycan structure will greatly facilitate 
the selection of a cell line suitable for producing favorable glycoforms to ensure 
efficacy and safety of glycoprotein-based biopharmaceuticals. Glycomic profile of a 
cell line also represents the baseline of glycosylation status for subsequent 
investigation of glycan regulation and alteration in response to intracellular and 
extracellular cues. 
This study focuses on five mammalian cell lines that are commonly used for 
biotech production of therapeutic glycoprotein and experimental medicine research. 
Systematic profiling of endogenous glycome was performed using MALDI-TOF MS, 
which offers unparalleled sensitivity and rich structural information. N-Glycomes of 
all five cell lines were found to contain mainly oligomannose- and complex-type 
glycans with a paucity of hybrid glycans. Interestingly, all cell lines were found to 
produce N-glycans with at least two LacNAc-LacNAc repeating units in the 50% 
ACN fraction of acetic acid-eluted glycan samples. However, significant differences 
exist both qualitatively and quantitatively in certain glycan structures among the five 
cell lines. By comparing the relative abundance of peaks, it was found that sialylated 
glycans were more enriched in BHK-21 N-glycome than in the other cell lines 
especially 3T3. Non-human glycan signatures including Neu5Gc and Galα(1,3)Gal 
linkage were found in BHK-21, COS-7 and 3T3 N-glycomes but not in CHO-K1 and 
HEK293 glycomes. While the existence of low-abundance Neu5Gc-containing glycan 
could be due to salvage of Neu5Gc from the culture media, multiple structures bearing 
Neu5Gc or Galα(1,3)Gal were detected in BHK-21 and 3T3, suggesting de novo 
synthesis of such immunogenic epitopes. BHK is used for the production of 
recombinant EPO (Fibi et al. 1995) and Factor VIII (Suiter 2002), two glycoproteins 
with huge demand in the drug market (Walsh 2010) whereas 3T3 finds it major 
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application in producing recombinant viruses for gene therapy (Kafri 2004). Because 
reactivity to Neu5Gc and α-Gal counts for 0.1% (Ghaderi et al. 2010)and 1% (Dahl et 
al. 2005) of circulating antibodies respectively in human body, these two epitopes 
must be absent to ensure safety and efficacy of glycoproteins or viral vectors. 
Strategies for removal of α-Gal have be demonstrated by genetic knockout of α-Gal 
transferase (Dahl et al. 2005) or overexpression of α1,2-fucosyltransferase that 
competes with α-Gal transferase for the same glycan substrate (Osman et al. 1997). 
Similar approaches can be applied to targeting the Neu5Gc biosynthetic pathway in 
BHK-21 and 3T3 cells. 
O-glycomes of the five cell lines displayed more qualitative differences. CHO-
K1 produces only two O-glycan structures, namely sialyl-T (ST) and di-sialyl-T (dST) 
antigens. O-glycosylation in the other cell lines are more elaborated, leading to the 
formation of core 2-based structures on top of abundant ST and dST structures. 
Impact of O-glycosylation in the context of therapeutic glycoproteins is less 
elucidated as compared to N-glycosylation. Therefore, structural information of O-
glycans produced in these five cell lines allows for the selection of a suitable 
expression host line towards establishing structure-function relationship of O-
glycosylation.  
  Glycomic profiling using whole cellular protein samples inevitably includes 
premature N- and O-glycans as well as glycans attached to endomembrane or lumenal 
proteins along the secretory pathway. Presence of these species, despite their low 
relative abundance among the total cellular pool of glycans, introduces a subset of 
structures that are not relevant to glycosylation of cell surface and secreted proteins. 
To specifically characterize the glycosylation of secreted glycoproteins, we expressed 
and purified two fusion proteins, EPO-Fc and MUC1-F
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and O-glycosylation in the five cell lines. Mass spectrometry analysis of EPO-Fc N-
glycans showed less heterogeneous structures as compared to the N-glycome of the 
host cell lines. Sialylated species were more enriched in EPO-Fc produced in BHK-21, 
CHO-K1 and HEK293 than in the N-glycomes of these cell lines. Neu5Gc was 
detected in EPO-Fc samples from all cell lines except 3T3. This result appears to be 
puzzling because glycomic profiling of 3T3 cells revealed multiple structures bearing 
Neu5Gc. A plausible explanation is that the sialic acid content of EPO-Fc is low in 
3T3 cells, which reduces the chance of incorporating Neu5Gc into the glycans. On the 
other hand, α-Gal epitope was unambiguously detected in 3T3 EPO-Fc sample but not 
in BHK-21 EPO-Fc sample, although BHK-21 was shown to be capable of expressing 
α-Gal epitope (Fig. 3.5). Taken together, it is practically impossible to predict N-
glycan structures of a particular protein based on the N-glycome profile of the host 
cells. Therefore, N-glycosylation capability of a cell line should be preferably 
demonstrated by analyzing both the endogenous N-glycome and N-glycans on the 
recombinant glycoprotein. In contrast, our initial data on O-glycosylation of 
recombinant MUC1-Fc produced in HEK293 cells showed the identification of four 
out of five O-glycan species that constituted the majority of endogenous HEK293 O-
glycome. It is tempting to speculate that it is possible to predict the O-glycosylation 
structures of recombinant glycoproteins based on the O-glycome profile of the host 
cell line. Alteration of MUC1 O-glycosylation was observed in many types of cancer 
(Tarp and Clausen 2008). Cancer-associated O-glycans, namely Tn, STn and T 
antigens, on top of MUC1 protein backbone, provoke strong immune response and 
has been proposed as a cancer vaccine (Wandall et al. 2010). Under our MS 
conditions, we were not able to detect Tn and STn on MUC1-Fc produced in any of 
the cell lines. However, lectin staining experiment suggested abundant Tn antigen on 
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the surface of COS-7 cells (Fig. 3.18). Hence, O-glycosylation of the five cell lines 
merits further analysis using orthogonal techniques. 
  One major limitation of MALDI-TOF MS is the difficulty in quantitative 
comparison of different glycan species across spectra or separated apart in long range. 
To compare the sialylation extent of recombinant EPO-Fc in the five cell lines, 
HPAEC was employed to complement the MS method. Chromatographic quantitation 
of sialylated glycans showed a significant difference in the sialic acid content of EPO-
Fc produced in the five cell lines which follows the order: BHK-21>CHO-K1>COS-
7>HEK293, 3T3. Although the superior sialylation capability of BHK-21 was evident 
by MS analysis, capabilities of the other four cell lines were difficult to compare 
based on MS data alone. Therefore, a multifaceted analysis using biochemical, mass 
















3.5 Chapter summary 
 Glycosylation of cell surface and secreted proteins critically modulate 
properties and functions of the attached cells. Appreciation of glycan structures will 
facilitate the selection of a cell line with desirable glycosylation pattern. We 
undertook systematic MALDI-TOF analyses of N- and O-glycomes of five commonly 
used mammalian cell lines and found dramatic differences in glycosylation among 
these cell lines. BHK-21 and 3T3 were found to express α-Gal-containing structures, 
raising safety concerns when these cell lines are used for production purposes. 
Neu5Gc was detected in the glycomes of all cell lines (except in the N-glycome of 
HEK293), due to metabolic incorporation of Neu5Gc or de novo synthesis. O-
glycomes of the five cell lines were all dominated by mono-sialyl or di-sialyl T 
antigens. In addition, all cell lines except CHO-K1 were found to produce core2 
structures. Thus, these four cell lines, by comparison with CHO-K1, represent suitable 
expression hosts for dissecting the structure-function relationship of core 1 and core 2 
O-glycans. Sialylation capabilities of the five cell lines were compared by analyzed 
the sialic acid content of recombinant EPO-Fc produced in these cell lines and were 
found to follow the order: CHO-K1, BHK-21>HEK293, COS-7>3T3. Therefore, 
BHK-21 and CHO-K1 are preferred over the other cell lines for the production of 
highly sialylation therapeutic glycoproteins for enhanced circulation and in vivo 
bioactivity. MALDI analysis of EPO-Fc N-glycosylation also revealed abundant 
asialylo-glycans with terminal Man, GlcNAc, or Gal produced in all cell lines. Such 
structural data shed light on molecular targets for glycoengineering in each cell line. 
This will be demonstrated by individual and combinatorial functional expression of 
glycosylation pathway-related genes in these cell lines to enhance the sialylation of 
recombinant EPO in the next chapter.    
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CHAPTER 4: IMPACTS OF GLYCOSYLATION-
RELATED GENES ON SIALYLATION OF 




4.1.1 Glycosylation in the context of biopharmaceutical drugs 
 Glycoproteins constitute a major proportion of the biopharmaceutical drugs 
(Walsh 2010). These glycoproteins are usually recombinantly produced in mammalian 
cell lines which can effectively glycosylate these proteins. Role of glycosylation on 
safety and efficacy of therapeutic glycoprotein was described in Chapter 1. One major 
issue pertinent to glycosylation in the context of therapeutic glycoproteins is the 
extent of sialylation. Impact of sialylation on in vivo circulatory half life and 
bioactivity of glycoproteins has been well documented (Delorme et al. 1992, Morell et 
al. 1971). Because glycosylation is a heterogeneous process leading to the formation 
of a range of glycoforms, it is a requirement by regulatory authority to maintain a 
consistent glycosylation profile of glycoprotein-based drugs (FDA 1996). Control of 
glycosylation, especially sialylation in the cell culture is, therefore, important to 
ensure quality, consistency, and efficacy of recombinant glycoproteins.  
 
4.1.2 Regulation of N-glycosylation at pathway level 
 N-glycosylation entails a series of metabolic reactions mainly 
compartmentalized in the ER and Golgi. Hundreds of genes are dedicated to this 
process (Davies et al. 2005). Broadly, these glycosylation-related genes, or 
glycogenes, encode four major families of proteins: i) glycosidases which trim 
specific residues from the N-glycan, ii) glycosyltransferases which catalyze the 
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formation of specific glycosidic bonds by adding monosaccharide in the form of 
activated nucleotide sugar to acceptor glycans, iii) nucleotide-sugar transporter which 
specifically transport nucleotide sugars synthesized in the cytosol or nucleus into the 
lumen of ER or Golgi, iv) other proteins involved in the metabolism of 
monosaccharide or nucleotide sugars. Many of these proteins function only on 
precursor glycan structures generated by other proteins, while some protein can 
compete for the same glycan substrate. Therefore, these proteins together create a 
complex network of reactions with sequential, parallel or competitive steps, leading to 
the formation of heterogeneous glycan structures as the end products.    
Glycosylation is also dependent on the attached proteins and host cell lines. 
This feature was demonstrated by the glycomic analysis of endogenous protein and 
recombinant EPO-Fc in Chapter 3. While the endogenous glycome contains 
substantial proportion of oligomannose-type glycans in BHK-21 cells, N-glycans 
carried by recombinant EPO-Fc expressed in this cell line were found to be 
predominantly sialylated complex-type. In addition, the dramatic difference in N-
glycosylation among the five cell lines was also observed. The mechanism involved in 
the regulation of N-glycosylation in mammalian cells remains unclear. Two studies at 
transcription level provided insightful evidences for regulation of glycosylation at 
pathway level. Using a focused microarray approach, Comelli et al. (2006a) showed 
that enzymes responsible for N-glycan core structure formation are ubiquitously 
expressed whereas enzymes responsible for N-glycan terminal modification, 
particularly sialyltransferases, are expressed in a tissue-specific manner, correlating 
well with the terminal structures of glycoproteins produced. More recently, Nairn et al. 
(2008) established a medium-throughput quantitative PCR platform and showed that 
in most cases, glycan structural diversity is regulated by transcriptional variability of 
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the corresponding glycan-related genes, or glycogenes. However, functional 
validation of these results has not been performed systematically.  
 
4.1.3 Genetic engineering approaches to enhance sialylation of N-glycans 
Based on the results from transcript profiling, a rational approach to enhance 
N-glycan sialylation is to overexpress the glycogenes that were found in low 
abundance. Indeed, most of the published studies primarily focused on glycogenes 
that act on glycan terminal modifications, for example, galactosyltransferases 
(Weikert et al. 1999), sialyltransferases (Chitlaru et al. 1998, Jeong et al. 2009, Son et 
al. 2011b, Weikert et al. 1999) and CMP-sialic acid transporter (Son et al. 2011b, 
Wong et al. 2006). These approaches all targeted the final steps of N-glycosylation, 
such as the incorporation of Gal and sialic acid, as well as transport of CMP-sialic 
acid. Overexpression of these glycogenes improved sialylation to different extents in 
different cell lines. Impact of upstream glycogenes on sialylation has not been 
elucidated. It should be noted that in the aforementioned studies the functional impact 
of a glycogene was analyzed in cell lines that stably overexpressed this glycogene in a 
recombinant form that were selected from transformed single clones. As a 
consequence of clonal variation, the genetic background of such clones could be 
different from that of the parental wild-type cell lines. Therefore, expression profiles 
of other glycogenes could be changed in these clones. In comparison, transient 
transfection would represent a more accurate method as the readout is from the entire 






4.1.4 Specific aims and outlines   
This study aims to elucidate the mechanism for regulation of N-glycosylation 
at pathway level by systematically analyzing a set of glycogenes. Glycogenes with 
positive impacts on EPO sialylation also represent promising molecular targets for cell 
line engineering towards the production of highly sialylated glycoproteins. The five 
cell lines analyzed in Chapter 3, namely, CHO-K1, BHK-21, HEK293, COS-7 and 
3T3 were included in this study, with the addition of another mammalian cell line NS0. 
NS0 is a murine myeloma cell line that is traditionally used for recombinant antibody 
production (Hermes and Castro 2010, Zhou et al. 1997). Recombinant human EPO 
was used as the model molecule. EPO is heavily glycosylated with 3 N- and 1 O-
glycans. Recombinant EPO produced by cultured mammalian cells is a heterogeneous 
mixture of different glycoforms. Sialylation pattern of EPO can be ascertained by 
isoelectric focusing (IEF) technique which separates different EPO glycoforms based 
on their pI value (Chuan et al. 2006, Lasne et al. 2002, Schriebl et al. 2007). Because 
sialic acid is negatively charged, sialylation extent of EPO is proportional to its ability 
to be focused on the low pH region of an IEF gel.  
First, we cloned 31 glycogenes involved in the mammalian N-glycosylation 
pathway into mammalian expression vector. Collectively, these glycogene expression 
constructs formed the “glycosylation toolbox”. These glycogenes were transiently co-
expressed together with EPO in the six cell lines and their impacts on EPO N-glycan 
sialylation were assessed using the IEF assay. Here we show that overexpression of 
sialyltransferases namely ST3GIII, ST3GIV and ST6GalTI can significantly enhance 
the sialylation profile of EPO in HEK293, COS-7, 3T3 and NS0 cells. Consistently 
with the data from Chapter 3, CHO-K1 and BHK-21 cells were found to produce 
highly sialylated recombinant EPO. Overexpression of none of the 31 glycogenes 
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could further enhance EPO sialylation. Finally, together with results from transcript 
profiling of selected endogenous glycogenes in HEK293, 3T3 and NS0 cells, our 
pathway-focused analysis of glycogenes provided functional insights into the 
regulation mechanism of N-glycosylation at pathway level.  
 
4.2 Experimental procedures 
4.2.1 Transient transfection 
 Cells were seeded into 12-well plates at appropriate densities (see Section 
2.2.2) and cultured overnight. Transfection was performed using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA) for CHO-K1, BHK-21, HEK293, COS-7 and 3T3. NS0 
cells were transfected by electroporation using Nucleofactor C kit and Program T-005 
on Nucleofactor II machine (both from Lonza, Germany) following manufacturer’s 
instructions. For analyzing the impact of a single glycogene, 1 µg of DNA construct 
that encodes human EPO and 1 µg of DNA construct that encodes a glycogene were 
mixed and added into 100 µl Opti-MEM (Invitrogen, Auckland, CA) before mixing 
with an equal volume of Opti-MEM containing 4 µl of Lipofectamine 2000 reagent. 
The plasmid DNA/Lipofectamine mixture was incubated at room temperature for 20 
min and then added into each well of 12-well plates. Media were replaced with fresh 
complete culture media 6 hours later. Conditioned media were collected 48 hours after 
transfection and stored at -20oC for subsequent experiments. For co-transfection of 
constructs in Group A, Group B, or both groups, constructs in group were first mixed 
at equal molar ratio. A volume that contains 1 µg of total glycogene plasmids was 
then mixed with 1 µg of EPO construct. The subsequent transfection procedures are 




4.2.2 IEF/immunoblotting analysis of EPO and EPO-Fc 
 A general IEF protocol based on immobilized pH gradient (IPG) gel was 
described in Section 2.2.7. Briefly, IPG gels with pH gradient 3 – 10 were casted, 
dried, and re-hydrated with a denaturing buffer containing 6M urea. Conditioned 
media containing secreted recombinant human EPO or EPO-Fc molecules were 
desalted by four times of concentration using a 4 ml centrifugal filter unit (Millipore) 
followed by resuspension in 20mM phosphate buffer (pH7.0). Typically, 0.6 – 1 ml of 
the conditioned medium was desalted and finally concentrated to 0.1 – 0.2 ml. EPO 
concentration in each desalted sample was determined by human EPO ELISA kit 
(Roche, Manheim, Germany) and used to normalize the loading. Typically 80 ng of 
EPO was loaded to each lane. However, due to batch-to-batch variation of EPO 
ELISA plates, the optimal amount of EPO could change. The EPO sample was mixed 
with an equal volume of IEF sample buffer and then loaded onto the IEF gel. After 
focusing, the gel was removed from the film backbone and electroblotted against a 
PVDF membrane. EPO bands were detected by incubating the blot with a monoclonal 
EPO antibody and then an HRP-conjugated secondary antibody.   
  
4.2.3 End-point RT-PCR analysis of heterologous glycogene expression 
CHO-K1 cells were transfected with blank pcDNA3.1 vector, Group A or 
Group B mix of plasmids for all genes in the toolbox. Cells were harvested 48 hours 
after transfection. Total RNA was extracted using RNeasy Mini kit (Qiagen, 
Germany). Reverse transcription was done using Moloney murine leukemia virus 
reverse transcriptase (MMLV-RT) and oligo dT(15) (both from Promega, Madison, 
WI). The resultant first-strand cDNA was used as template in PCR amplifications of 
exogenously expressed glycogenes. For each glycogene construct, a specific pair of 
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primers was designed: the forward primer specific for the coding region of a 
glycogene and the reverse primer specific for the vector sequence to yield a PCR 
product of about 500 bp (see Table 4.1 for primer list).  
 






The primer pair was added into each aliquot of PCR reaction mix containing 
the first-strand cDNA template. After amplification, the PCR products were analyzed 
by agarose gel electrophoresis in the presence of ethidium bromide and visualized 
under the UV light using the Gel Doc 2000 system (Bio-Rad, Hercules, CA). As a 
control, primers specific for β-actin were included in all reactions to yield a product of 
about 100bp. To rule out the possible contamination of RNA preparations by co-
isolation of transfected plasmids, the RNA samples were treated with the same 
procedures except that the reverse transcriptase was not added. The “mock” reverse-
transcribed samples were subjected to PCR amplification using primers specific for 
each heterologous glycogenes and the products were subjected to agarose gel 
electrophoresis. No amplified products were detected for any of the glycogenes. 
 
4.2.4 Quantitative RT-PCR (qRT-CPR) profiling of endogenous glycogenes 
Levels of endogenous transcripts of GlcI, ST3GalIII, and ST3GalIV in 
HEK293, 3T3 and NS0 cells were determined using qRT-PCR method according to a 
previously published method with slight modifications (Nairn et al., 2008). Briefly, 
total RNA was extracted using RNeasy kit (Qiagen). First strand cDNA was 
synthesized from 5 µg of total RNA using Moloney murine leukemia virus reverse 
transcriptase (MMLV-RT) and oligo dT(15) (both from Promega). Specific primer 
pairs for the three glycogenes were designed using Primer3 web site (Rozen and 
Skaletsky 2000) based on the following criteria: primer length 19 – 21 bp, product 
size 100 – 150 bp, Tm 59 – 61 oC. Sequences of the primers were listed in Table 4.2. 
Primer specificity was confirmed by melting curve analysis and agarose gel 
electrophoresis. Single PCR products were detected in both experiments, high 
specificity of primer pairs.  
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PCR analysis was done using ABI Prism 7000 qRT-PCR Detection System 
(Applied Biosystems, Foster City, CA). For each reaction of 25 µl, 12.5 µl of 2X 
SYBR Green PCR mastermix (Applied Biosystems) was mixed with 12.5 µl cDNA 
(from 5 µg of total RNA) and 364 nM (final concentration) of forward and reverse 
primers. PCR reaction conditions were as follows: 95 oC for 10 min, followed by 40 
cycles of 95 oC for 15 s and 60 oC for 60 s. Threshold cycle (Ct) was determined using 
ABI Prism 7000 SDS program (Applied Biosystems). All reactions were run in 
triplicates. Primer amplification efficiencies were analyzed by serially diluting the 
cDNA samples. The corresponding average Ct values were plotted against log (cDNA 
amount) and fitted to a linear curve with R2 close to 1. Primer efficiency (E) was 
calculated based on the slope of the linear curve (S) using the following equation: 
110 /1 −= − SE
                         Equation 1                                                                
Efficiencies of all primers were found to be within the range of 1±0.1 (Fig. 4.1 as an 
example and data not shown). Relative transcript abundance was calculated by 
transforming the average Ct values to 2-Ct and normalizing to a house keeping gene, β-






Fig. 4. 1. Primer efficiency test using mouse ST3GalIII as an example 
Ct values of mouse ST3GalIII were plotted against a serial dilution of 3T3 cDNA 
template from 500 ng to 5 ng. The data was fitted to a linear curve with a slope value 
(S) of -3.47. Primer efficiency (E) was calculated using Equation 1 to be 0.94.  
 
4.2.4 Thiobarbituric acid assay 
EPO-Fc expression vector was constructed as previously described (Goh et al. 
2010) and transiently expressed in wild-type HEK293 cells alone or co-transfected 
with ST3GalIII construct. Conditioned media were collected 48 hours after 
transfection. Recombinant EPO-Fc was purified using HiTrap Protein A column (GE 
Healthcare, Uppsala, Sweden). Duplicates of 3.5 µg of purified EPO-Fc protein from 
each transfection were treated with neuraminidase at 37 oC overnight. The released 
sialic acid was quantified using TBA assay (Hammond and Papermaster 1976). 
Briefly, 25 µl of 25 mM periodic acid in 0.125 M HCl was added into the supernatant 
containing free sialic acid and incubated at 37 oC for 30 min before the addition of 40 
µl of 2% sodium arsenite (Sigma, St. Louis, MO) in 0.5 M HCl. The mixture was then 
incubated at room temperature until the yellow color disappeared. 0.4 ml of 0.1 M 
thiobarbituric acid (Sigma, St. Louis, MO) at pH 9 was added and the mixture was 
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heated to 100 oC for 8 min. 1.5 ml of 95% (v/v) butanol with 5% (v/v) HCl and 0.7 ml 
of water was added and the solution was centrifuged at 13000 rpm for 5 min. The 
upper aqueous phase was removed and the absorbance at 549 nm measured. A 
standard curve was generated using 1 – 5 nmol of sialic acid. 
 
4.2.5 Lectin precipitation of glycoproteins 
CHO-K1 cells were transfected with the construct encoding human alone or 
together with the ST6GalI construct. Conditioned media were collected 48 hours after 
transfection. Total protein concentration was determined by Bradford assay (Thermo 
Scientific, Rockford, IL). Conditioned medium containing 20 µg of total protein was 
mixed with 50 µg of MAA or 100 µg of SNA (both from EY Laboratories, San Mateo, 
CA) and topped up with PBS to 100 µl and incubated at 4oC for 48 hours. The 
precipitated lectin-glycoprotein complex was pelleted by centrifugation, washed twice 
in ice-cold PBS and analyzed by SDS-PAGE/Western blotting. Recombinant EPO 
was detected using a monoclonal anti-EPO antibody. 
 
4.3 Results 
4.3.1 Organization and pathway-mapping of the glycosylation toolbox 
First, a simplified pathway diagram depicting the important steps of protein N-
glycosylation in mammalian cells is developed (Fig. 4.2) based on literature review of 
glycosylation in mammalian cells. For the simplicity and clarity purposes, in this 
diagram several parallel or sequential steps were condensed to a single step. These 
include the sequential removal of the two glucose residues by α-glucosidase II, the 
parallel trimming of Man8GlcNAc2 glycan to Man5GlcNAc2 glycan by α-
mannosidase I isoforms, as well as the branching of bi-antennary glycans to tri- and 
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tetra-antennary glycans by GlcNAc transferase IV and V (marked by double-headed 
arrows in the diagram). With the exception of core fucosylation, steps that are not 
necessary for the synthesis of precursor glycans for sialylation were omitted. For 
example, the enzyme N-acetylglucosaminyltransferase III (GnT-III) incorporates a 
bisecting GlcNAc into the (Stanley 2002) was not included because this bisecting 
GlcNAc residue will not be further modified. Similarly, the pathway diagram does not 




Fig. 4. 2. A simplified diagram of mammalian N-glycosylation pathway 
This diagram shows the major steps in N-glycosylation from ER to Golgi. Double-
headed arrows indicate parallel or multi-step reactions. Glycogenes in the toolbox are 
assigned to their cognate reaction steps. Genes that are underlined are included in 






Genes that are involved in the formation of structures shown in the pathway 
diagram were searched from the literature. A total of 31 glycogenes were mapped to 
the diagram, among which we managed to clone 25 cDNAs from either human, mouse, 
or Chinese hamster cells into mammalian expression vectors and obtained the other 6 
from commercial source (IMAGE Consortium distributed by Invitrogen, USA) or 
other researchers (Drs Taniguchi and Stanley). The 31 glycogenes are listed as follows: 
i) glycosidases, including α-glucosidase I (GlcI), the heterodimeric α-glucosidase II 
complex (GlcIIa and GlcIIb) and mannosidases (ManIA-C, ManII, ManIIx, ERMan, 
EndoMan) (Akama et al. 2006, Herscovics 1999, Herscovics 2001, Pelletier et al. 
2000, Trombetta et al. 1996); ii) glycosyltransferases, including N-
acetylglucosaminyltransferases I and II (GnT I and GnT II) (Wang et al. 2002), the 
branch-forming GnT IV (which has two isoforms GnT IVA and GnT IVB) (Yoshida 
et al. 1998) and GnT V (Brockhausen et al. 1988), β1,4-galactosyltransferases 1 – 6 
(B4GalT 1-6) (Hennet 2002), four sialyltransferases that are known to only sialylate 
the Galβ1,4GlcNAc structure in N-glycans (ST6GalI, ST3GalIII, ST3GalIV, 
ST3GalVI) (Comelli et al. 2006a, Harduin-Lepers et al. 2001), and α1,6-
fucosyltransferase (Fut8) (Miyoshi et al. 2008); iii) nucleotide-sugar transporters, 
including UDP-GlcNAc transporter (UGnT), UDP-galactose transporter (UGT), 
CMP-sialic acid transporter (CST) and GDP-fucose transporter (Hirschberg et al. 
1998); and iv) UDP-galactose epimerase (GALE) (Allard et al. 2001). All expression 
constructs contain a CMV promoter, a Kozak sequence (GCCACC) ahead of 
translation start codon (ATG), which is in turn followed by cDNA coding sequence of 
a glycogene from human, mouse, or Chinese hamster because glycogenes are highly 
conserved in these species. Information including cDNA sources, database accession 
number, and annotation of glycogenes was summarized in Table 4.3. 
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Table 4. 3. List of genes included in the current glycosylation toolbox 
cDNAs of 31 glycogenes from mouse, human or Chinese hamster (CH) were either 
purchased from IMAGE Consortium (GlcIIa, GlcIIb, Fut8, ST6GalI, UGnT), 
provided by other researchers (human GnTV by N. Taniguchi; CH GnTV by P. 
Stanley), or cloned from in-house cDNA sources into mammalian expression vectors 



















Class Gene Abbrevation cDNA source GenBank ID Group 
Glycosidases 
Glucosidase I GlcI Mouse BC051949 A 
Glucosidase II alpha subunit GlcIIa Human BC065266 A 
Glucosidase II beta subunit GlcIIb Mouse BC009816 A 
ER-Mannosidase I ERMan Human NM_016219 B 
Golgi endomanosidase EndoMan Human NM_024641 A 
Mannosidase IA ManIA Human NM_005907 A 
Mannosidase IB ManIB Human AF027156 B 
Mannosidase IC ManIC Human AF261655 B 
Mannosidase II ManII Human NM_002372 A 
Mannosidase IIx ManIIx Mouse BC055006 B 
Glycosyl- 
transferases 
N-acetylglucosaminyl transferase I GnT I Human M61829 A 
N-acetylglucosaminyl transferase II GnT II Human BC006390 A 
N-acetylglucosaminyl transferase IV A GnT IVA Human BC064141 A 
N-acetylglucosaminyl transferase IV B GnT IVB Human AB000624 B 
N-acetylglucosaminyl transferase V GnT V CH CGU62587 A 
α1-6 fucosyltransferase Fut8 Mouse BC010666 B 
β1-4 galactosyltransferase I B4GalT1 CH AF318896 A 
β1-4 galactosyltransferase II B4GalT2 CH AY117536 B 
β1-4 galactosyltransferase III B4GalT3 CH AY117537 B 
β1-4 galactosyltransferase IV B4GalT4 CH AY117538  B 
β1-4 galactosyltransferase V B4GalT5 CH AY117539  B 
β1-4 galactosyltransferase VI B4GalT6 CH AF506839 B 
α2-3 sialyltransferase III ST3GalIII Mouse BC006710 B 
α2-3 sialyltransferase IV ST3GalIV CH AY266675 B 
α2-3 sialyltransferase VI ST3GalVI Mouse NM_018784 A 




UDP-N-acetylglucosamine transporter UGnT Mouse BC024110 A 
UDP-galactose transporter UGT CH AF299335  A 
CMP-sialic acid transproter CST CH Y12074 A 
GDP-fucose transporter GFT Human AF323970 B 
Sugar 
metabolism UDP-galactose 4-epimerase GALE Human NM_000403 B 
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The assessment of impacts of individual glycogenes on sialylation was 
preceded by co-expression of groups of glycogenes. To simplify the analysis, the 31 
genes in the toolbox were divided into two groups analogous to conventional library 
screenings (Lubke et al. 2001). With this approach, all the genes in either group can 
be ruled out for further analyses if the group as a whole failed to make an impact on 
sialylation. We chose one gene for each reaction step (marked by underlines in Fig. 
4.2) and categorized them as Group A. In the event a particular reaction can be 
catalyzed by more than one protein, only one (for example, ST3GalVI for the 
formation of  Sia-Gal linkage) was included in the Group A and the others were 
placed in Group B. In addition, three nucleotide-sugar transporters, namely UGnT, 
UGT and CST, were also included in Group A as they transport the essential 
substrates for the formation of sialylated (or its precursor) N-glycans. Thus, the 15 
genes in the Group A were thought to be sufficient to cover the entire N-glycosylation 
pathway as depicted in Fig. 4.2. The remaining 16 genes in the toolbox constitute 
Group B. 
 
4.3.2 Recombinant EPO produced in the six mammalian cell lines show distinct 
IEF profiles, due to differences in sialylation 
Six commonly used mammalian cell lines, CHO-K1, BHK-21, HEK293, COS-
7, 3T3 and NS0 cells were transiently transfected with an expression construct 
encoding human EPO. The conditioned media were collected 48 hours after 
transfection and subjected to IEF analysis followed by immunoblotting and detection 
using an EPO-specific antibody. Fig. 4.3A shows the IEF profiles of recombinant 
EPO produced by the six cell lines. Recombinant EPO produced by different cell lines 
displayed different IEF profiles: EPO produced by BHK-21 cells was resolved into 
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less than 10 bands within a narrow range in the low pH region; CHO-K1-produced 
EPO was similarly resolved, with a few addition bands in the high pH region; EPO 
produced by HEK293, COS-7 and 3T3 showed a wider range of glycoforms that 
spread across most of the pH gradient; EPO produced by NS0 cells was only resolved 
into a few bands in the high pH region. These results suggested that among the six cell 
lines, BHK-21 has the strongest capability of sialylating recombinant EPO, followed 
by CHO cells, whereas HEK293, COS-7 and 3T3 cells are relatively weaker in 
producing highly sialylated EPO glycoforms and NS0 cells are the least capable in 
sialylating recombinant EPO. To ensure that the differences in the IEF profiles were 
indeed caused by differential sialylation of EPO glycans, the conditioned media were 
treated with neuraminidase and subjected to IEF. Neuraminidase-treated EPO in all 
six samples showed the same IEF pattern (Fig. 4.3B). Therefore, using recombinant 
EPO as a model molecule, we showed that sialylation is highly cell line specific. The 
IEF data further supports the choice of CHO-K1 or BHK-21 cells for the production 
of highly sialylated species of recombinant glycoproteins. On the other hand, the other 
four cell lines (HEK293, COS-7, 3T3 and NS0) have suboptimal sialylation 
capabilities. It is then intriguing to understand how the differential sialylation is 
regulated in these cell lines and how we can improve sialylation (or in other words, 
make a shift of EPO IEF profile towards the low pH region) in these cells using our 




Fig. 4. 3. Sialylation patterns of recombinant EPO expressed in six mammalian 
cell lines analyzed by IEF/immunoblotting 
(A) CHO-K1, BHK-21, HEK293, COS-7, 3T3 and NS0 cells were transiently 
transfected with a construct that expresses human EPO. Conditioned media were 
desalted and analyzed by IEF followed by immunoblotting analysis for EPO. (B) 





4.3.3 Combinatorial expression of Group B genes from the glycosylation 
toolbox significantly improved recombinant EPO sialylation in HEK293, 
COS-7, 3T3 and NS0 cells 
Genes in the Group A, Group B or all 31 genes were mixed at equal molar 
ratio and co-transfected with an EPO expression construct into all six cell lines. 
Briefly, for cells cultured in one well of a 12-well plate, a total of 2 µg of DNA 
constructs were used, which includes 1 µg of EPO construct and 1 µg of glycogene 
construct mixture. Therefore, the amount of DNA construct for each glycogene used 
is approximately 1/15 µg for Group A genes, 1/16 µg for Group B genes, and 1/31 µg 
when all 31 genes in the toolbox were used for transfection. 48 hours after transfection, 
recombinant EPO secreted into the conditioned media was quantified by ELISA and 
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equal amount of EPO produced by the same cell line was resolved by an IEF gel. The 
results are shown in Fig. 4.4. “EPO st.” shown in all six gels is the highly sialylated 
clinical EPO produced by Kirin-Amgen Inc. Under our IEF conditions, the Amgen 
EPO was typically resolved into 4 – 5 bands, consistent with results from a previous 
study (Park et al. 2009). Our results show that the sialylation pattern of EPO produced 
by CHO-K1 or BHK-21 cells was not improved by combinatorial overexresssion of 
the genes Group A, Group B or all 31 glycogenes. However, in HEK293 cells, co-
transfection with all 31 genes together clearly improved the sialylation pattern of 
recombinant EPO, as indicated by a decrease of band intensity in the high pH region 
and at the same time an increase of band intensity in the low pH region. 
Overexpression of Group B genes resulted in a similar change in EPO IEF profile in 
HEK293 cells., while overexpression of Group A genes did not affect the EPO 
sialylation pattern, suggesting that the impact on EPO sialylation pattern observed in 
HEK293 cells can be solely attributed to genes in Group B. Similar sialylation pattern 
changes were also observed in COS-7, 3T3 and NS0 cells. In these three cells lines, 
the EPO sialylation patterns were improved when co-transfected with Group B genes. 
Combinatorial overexpression of Group A alone did not improve EPO sialylation in 
these three cell lines. In the present of Group B overexpression, Group A failed to 
further improve EPO sialylation (compare the profile of Lane 4 and Lane 5 of each 
panel). Therefore, none of the Group A genes could directly improve EPO sialylation 
nor could synergize the impact of Group B genes. By this bi-partite screening 
approach, we managed to rule out Group A for further functional analysis. Our efforts 







Fig. 4. 4. Sialylation of recombinant EPO expressed in different cell lines was 
improved by combinatorial overexpression of Group B genes 
Group A, Group B, and all 31 glycogenes were mixed together and co-transfected 
with EPO construct into CHO-K1, BHK-21, HEK293, COS-7, 3T3 and NS0 cells as 
indicated in each gel. Conditioned media were collected and analyzed by 
IEF/immunoblotting 48 hours after transfection. EPO st.: clinical EPO produced by 
Kirin-Amgen Inc. as a standard. “I” stands for EPO produced by host cells that were 
not co-transfected with any glycogene. Group A: EPO produced by cells that were co-
transfected with Group A genes.  Group B: EPO produced by cells that were co-
transfected with Group B genes.  31 genes: EPO produced by cells were co-







The faithful expression of all genes in the toolbox under the combinatorial 
transfection condition was confirmed by RT-PCR and genetic complementation 
experiments demonstrated in CHO-K1 cells. For RT-PCR analysis, mRNAs were 
isolated from CHO cells that were transfected with either Group A genes or Group B 
genes. For each gene a forward primer specific to the coding region was designed. 
One universal reverse primer was designed for all glycogenes in such a way that it 
only binds to the vector-coded 3’ UTR of the heterologous glycogene transcripts. In 
other words, the primer pairs detect only the heterologous glycogenes encoded by the 
toolbox constructs but not the endogenous glycogenes. The RT-PCR results confirmed 
the expression of these genes at the transcription level (Fig. 4A). Each primer pair 
yielded a band around 500 bp from RNA extracted from cells transfected with Group 
A or Group B mixture, which was absent from RNA extracted from cells transfected 
with a blank pcDNA vector. We also ruled out the possibility of contamination by 
plasmid carry-through in the RNA preparations by no RT control experiment (Fig. 
4.5). These results convincingly showed that all the glycogenes in the toolbox can be 
effectively overexpressed by co-transfection. Next, we took the advantage of four 
existing CHO glycosylation mutant lines and performed functional rescue experiments. 
Lec1 cells lack functional GnTI and the glycosylation pathway is terminated at the 
Man5GlcNAc2 stage (Chen and Stanley 2003). In UGT-deficient Lec8 cells, no 
galactose residues can be added to the N-glycans (Deutscher et al. 1984, Oelmann et 
al. 2001). Lec23 lacks GlcI activity (Ray et al. 1991) and MAR11 has a dysfunctional 
CST (Lim et al. 2008). N-glycans produced by these mutant cells are either poorly 
sialylated or not sialylated at all due to the mutations in the N-glycosylation pathway 
prior to the sialylation step. However, the mutant phenotype can be rescued by 
introducing the intact gene into mutant cells. Fig. 4.5B shows the mutant rescue 
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results for Lec1 and Lec8 cells and Fig. 4.5C shows the rescue results for Lec23 and 
MAR-11 cells.  EPO produced in wild-type CHO-K1 cells are shown on the far left in 
both Fig. 4B and 4C as a control. Using Lec1 as an example, Fig. 4.5B shows that 
EPO produced in Lec1 cells was not sialylated (Fig. 4.5B, 2nd lane from left). 
However, EPO sialylation was restored when Lec1 cells were co-transfected with a 
construct encoding human GnTI (lane under “GnTI”). Importantly, EPO sialylation 
was also restored in Lec1 cells that were co-transfected with a mixture of Group A 
genes which contains GnTI and 14 other glycogenes at equal molar ratio (lane under 
“Group A”). Overexpression of Group B genes did not restore EPO sialylation in 
Lec1 cells. When GnTI was excluded in the plasmid mixture, transfection of the 
remaining 14 genes in Group A failed to restore EPO sialylation in Lec1 cells (lane 
under “Group A without GnTI”). These results clearly demonstrated that only GnTI, 
but not other genes in Group A, rescued the sialylation defect in Lec1 cells. Similar 
results were also obtained for the other three mutant CHO lines. UGT restored EPO 
sialylation in Lec8 cells (Fig. 4.5B). GlcI restored EPO sialylation in Lec23 cells (Fig. 
4.5C) and CST restored EPO sialylation in MAR-11 cells (Fig. 4.5C). Importantly, 
these results confirmed that the amount of DNA constructs used in these transfections 
was sufficient to affect EPO sialylation if a corresponding endogenous gene was 
under expressed. In a previous report, we showed that under similar conditions, ng 
level of DNA construct expressing CST was enough to restore EPO sialylation in 
MAR-11 cells (Lim et al. 2008).  Together with the RT-PCR results, we believe that 
each gene in the toolbox was sufficiently expressed under our experimental conditions. 
Therefore, we concluded that none of the genes in Group A, including ST3GalVI, was 




Fig. 4. 5. RT-PCR and mutant rescue assay demonstrate the effective expression 
of glycogenes in the Toolbox  
(A) For RT-PCR, CHO-K1 cells were transiently transfected with empty pcDNA3.1 
vector (denoted as “-”), Group A gene mix (denoted as “+” in the upper two panels), 
or Group B gene mix (denoted as “+” in the lower two panel). Total RNA were 
extracted from the cells 48 hours after transfection. RT-PCR was performed using the 
extracted RNA and primer pair specific for each exogenously expressed glycogene 
(labeled at the top of each panel). Primer pair specific for β-actin was included in each 
reaction to ensure equal loading. (B and C) For mutant rescue assay, mutant CHO 
cells (Lec1 and Lec8 in B, and Lec23 and MAR-11 in C) were co-transfected with 
EPO alone (denoted as “I”) and together the following constructs: gene that is 
defective in each mutants (GnT I, UGT, GlcI, and CST, respectively), Group A gene 
mix, Group B gene mix, and Group A gene mix excluding the gene that is defective in 
the mutant (for example, Group A without GnT I in the case of Lec1). Conditioned 
media were collected and analyzed by IEF/immunoblotting 48 hours after transfection. 
EPO produced by wild-type CHO-K1 cells was included to indicate the normal EPO 





4.3.4 Sialyltransferases in Group B are responsible for the enhancement of 
EPO sialylation in HEK293, COS-7, 3T3 and NS0 cells 
The elimination of Group A genes allowed us to focus our efforts on the other 
16 genes in Group B on their functions on EPO sialylation. To this end, each of these 
glycogenes was individually co-transfected with EPO into HEK293, COS-7, 3T3 and 
NS0 cells. Three sialyltransferases, namely ST6GalI, ST3GalIII and ST3GalIV, were 
found to significantly enhance EPO sialylation in HEK293 cells as shown in Fig. 4.6A. 
The sialylation patterns for EPO samples from cells co-transfected with each of these 
three sialyltransferase constructs were clearly enhanced in comparison to the wild-
type control, but similar to when the cells were co-transfected with all 16 genes in 
Group B. This result suggests that the other glycogenes that are involved in upstream 
steps of glycosylation do not have a synergistic effect when co-transfected with the 
three sialyltransferases. Again, we showed that the change in IEF profile was indeed 
caused by change in EPO sialylation, because when samples were treated with 
neuraminidase, all EPO samples showed the same IEF profiles with only a few bands 
in the basic region as shown in Fig. 4.7A. Individual overexpression of other genes in 
Group B did not change EPO IEF profile compared to that produced by wild-type 
HEK293. A hierarchy seems to exist for the three sialyltransferases on EPO 
sialylation which follows the order: ST3GalIII>ST3GalIV>ST6GalI. In COS-7 cells, 
ST3GalIII, ST3GalIV and ST6GalI also improved the sialylation of EPO in a similar 
pattern, with their impacts following the same order ST3GalIII>ST3GalIV>ST6GalI 
(Fig. 4.6B). In 3T3 and NS0 cells, however, ST6GalI overexpression did not 
significantly enhance EPO sialylation, whereas ST3GalIII and ST3GalIV showed 
strong positive impacts (Fig. 4.6C and 4.6D). Interestingly, overexpression of 
B4GalT2 or B4GalT3 in NS0 cells resulted in a few weak EPO bands in the low pH 
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area (Fig. 4.6D), that were not present on EPO produced by wild-type NS0 cells, 
suggesting that B4GalT2 and B4GalT3 can positively impact EPO sialylation in this 
cell line, although their impacts are much weaker as compared to the two 








Fig. 4. 6. Impact 
of overexpressing 
individual genes 
in Group B on 
EPO sialylation in 
HEK293, COS-7, 
3T3 and NS0 cells 
Cells were co-
transfected with 
EPO and individual 
genes from Group 
B into HEK293 
cells (A), COS-7 
cells (B), 3T3 cells 
(C), and NS0 cells 
(D). Conditioned 
media were 
collected 48 hours 
after transfection 
and analyzed by 
IEF/immunoblottin
g together with a 
clinical EPO 
sample as a control 
(denoted as “EPO 
st.”) and EPO 
produced in wild-
type cells with no 
glycogenes co-
transfected 
(denoted as “I”). 
129 
 
Our toolbox contains four sialyltransferases. The fourth sialyltransferase, 
ST3GalVI, was selected as a representative sialyltransferase and hence placed in 
Group A. As shown previously in Fig. 4.4, combinatorial overexpression of Group A 
genes did not enhance EPO sialylation in any of these cell lines. To analyze the 
impact of ST3GalVI on EPO sialylation more carefully, ST3GalVI was co-transfected 
with the EPO construct into HEK293 cells and the IEF profile of recombinant EPO 
was compared with that of EPO produced by cells co-transfected with one of the three 
Group B sialyltransferases. Consistently, the three Group B sialyltransferases (i.e. 
ST6GalI, ST3GalIII and ST3GalIV) improved the sialylation profile of EPO (Fig. 
4.7A). However, ST3GalVI overexpression had no significant effect on IEF pattern of 
EPO. Similar experiments were also carried out in COS-7 cells and ST3GalVI failed 
to improve sialylation of recombinant EPO in COS-7 cells (data not shown). 
 To demonstrate the sensitivity of EPO IEF assay and to provide quantitative 
data on sialylation enhancement by overexpressing sialyltransferases, we transiently 
transfected HEK293 cells with a construct encoding an EPO-Fc fusion protein with or 
without the construct encoding ST3GalIII. Overexpression of ST3GalIII significantly 
enhanced the sialylation of EPO-Fc in HEK293 cells as shown by 
IEF/immunoblotting (Fig. 4.7B). Recombinant EPO-Fc produced from both 
transfections was purified by Protein A chromatography. The sialic acid contents in 
both samples were quantitated by thiobarbituric acid (TBA) assay. As shown in Fig. 
4.7C, recombinant EPO-Fc produced in wild-type HEK293 cells contained an average 
of 0.21 nmol of sialic acid per µg of EPO-Fc protein, while EPO-Fc produced by 
HEK293 cells that were co-transfected with ST3GalIII construct showed an average 
sialic acid content of 0.25 nmol per µg of EPO-Fc protein. In other words, 
overexpression of ST3GalIII in HEK293 cells resulted in about 19% increase in sialic 
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acid content of recombinant EPO-Fc. This increase is clearly reflected by the shift of 
EPO-Fc glycoforms towards the low pH end (Fig. 4.7B), thus clearly demonstrating 
the sensitivity and reliability of the IEF assay.  
 
Fig. 4. 7. Impact of overexpressing sialyltransferases on sialylation of 
recombinant EPO and EPO-Fc in HEK293 cells  
(A) HEK293 cells were co-transfected with EPO and each of the four 
sialyltransferases. Conditioned media were analyzed by IEF/immunoblotting using an 
EPO-specific antibody or treated with neuraminidase before the IEF analysis. EPO 
produced in wild-type HEK293 cells (denoted as “I”) was included as a control. (B) 
HEK293 cells were transfected with EPO-Fc construct alone or together with 
ST3GalIII construct. Conditioned media were analyzed by IEF/immunoblotting using 
an EPO-specific antibody. (C) HEK293 cells were transfected with EPO-Fc construct 
alone or together with ST3GalIII construct. Conditioned media were purified by 
Protein A column to homogeneity. 3.5 µg of purified EPO-Fc protein from each 
transfection was treated in duplicates with neuraminidase. The released sialic acid 




4.3.5 Overexpression of sialyltransferases and CMP-sialic acid transporter did 
not change the sialylation pattern of recombinant EPO produced by 
CHO-K1 and BHK-21 cells 
Previous IEF experiments showed that CHO-K1 and BHK-21 cells sialylate 
recombinant EPO more effectively than HEK293, COS-7, 3T3 and NS0 cells. 
Overexpression of sialyltransferases significantly improved recombinant EPO 
sialylation in the latter four cell lines, whereas overexpression of Group B genes 
(which contain these sialyltransferases) did not change the sialylation pattern of 
recombinant EPO in CHO-K1 and BHK-21 cells. To further confirm these results, we 
overexpressed all four sialyltransferases in the toolbox as well as CMP-sialic acid 
transporter in CHO-K1 and BHK-21 cells individually and examined their effects on 
EPO sialylation. Neither sialyltransferases nor CMP-sialic acid transporter 
overexpression improved EPO sialylation in CHO-K1 cells (Fig. 4.8A) and BHK-21 
cells (data not shown). Previous reports showed that the ectopic expression of 
ST6GalI in CHO cells altered the terminal sialic acid linkage in N-glycans from α2,3 
to α2,6 bond (Lee et al. 1989). We show by lectin precipitation experiments that 
although ST6GalI did not change the overall EPO sialylation in CHO cells (compare 
lane 2 with lane 1 in Fig. 4.8A), it altered the terminal sialic acid linkage in N-glycans. 
In these experiments, CHO-K1 cells were transfected with the EPO construct in the 
presence or absence of the ST6GalI construct. Conditioned media were collected 48 
hours after transfection. MAA (Maackia amurensis agglutinin) or SNA (Sambucus 
nigra agglutinin) lectins which recognize α2,3- or α2,6-linked sialic acids respectively 
were used to precipitate the glycoproteins predominantly from the serum in the culture 
media with a minor fraction of glycoproteins secreted by the cells including 
recombinant EPO. The lectins bind to the glycoproteins and form large lectin-
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glycoprotein complexes. Recombinant EPO in the precipitated lectin-glycoprotein 
complex was analyzed by Western blot using the anti-EPO antibody. As shown in Fig. 
7B, EPO produced by wild-type CHO cells was only precipitated by MAA but not 
SNA (lanes 1 and 2 in Fig. 4.8B), suggesting that EPO produced by CHO-K1 cells 
contains α2, 3-linked sialic acid but not α2, 6-linked sialic acid. By contrast, EPO 
produced by CHO-K1 cells that were co-transfected with the ST6GalI construct was 
precipitated by both MAA and SNA (lanes 3 and 4 in Fig. 4.8B), indicating the 
presence of both α2,3- and α2,6-linked sialic acids on EPO N-glycans. Therefore, 
ST6GalI was able to compete with ST3Gal transferases for the same sialic acid 
acceptor even though it is unable to alter the overall sialylation extent of recombinant 





Fig. 4. 8. Impact of overexpressing sialyltransferases and CST on EPO sialylation 
in CHO-K1 cells 
(A) CHO-K1 cells were co-transfected with an EPO construct and each of the four 
sialyltransferases or CST. Conditioned media were collected 48 hours after 
transfection and analyzed by IEF/immunoblotting together with EPO produced in 
wild-type CHO-K1 cells (denoted as “I”). (B) CHO-K1 cells were transfected with 
EPO alone or together with ST6GalI. Conditioned media were collected and a small 
aliquot was mixed with MAA or SNA and incubated at 4 oC for 48 hrs. Lectin-
glycoprotein complex was pelleted and subjected to SDS-PAGE/Western blot using 
an EPO-specific antibody. 
 
4.3.6 Endogenous ST3GalIII and ST3GalIV are expressed at low levels in 3T3 
and NS0 cells 
To gain mechanistic insights into the regulation of sialylation in different cell 
lines, and also to explain why overexression of sialyltransferases can improve EPO 
sialylation in some cell lines but not all , we analyzed the endogenous transcript levels 
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of three glycogenes, namely GlcI, ST3GalIII and ST3GalIV in HEK293, 3T3 and NS0 
cells using quantitative real-time PCR (qRT-PCR). GlcI is an upstream glycogene and 
was chosen for comparison. We only focused on HEK293, 3T3 and NS0 because 
glycogene sequence information is not available for monkey (COS-7 cells) and 
hamster (BHK-21 cells). For CHO cells, only a partial sequence is available for 
ST3GalIII in the database. We found that β-actin (ActB) was expressed at similar 
levels in all three cell lines (data not shown). Therefore, ActB was chosen as a house 
keeping gene and its expression level used as a normalizer. As shown in Fig. 4.9, the 
relative transcript abundance of ST3GalIII is significantly lower than that of the 
upstream glycogene GlcI in all three cell lines, consistent with results from two 
previous transcript profiling studies (Comelli et al. 2006a, Nairn et al. 2008). 
ST3GalIV was found to be at lower or comparable level compared with GlcI. These 
results explain why overexpression of ST3GalIII resulted in the most dramatic 
enhancement of EPO sialylation in these cells whereas ST3GalIV overexpression has 
significant but less dramatic effect (Fig. 4.6A, 4.6C and 4.6D). Furthermore, the 
expression level of endogenous ST3GalIII in NS0 cells is significantly lower 
compared to that in HEK293 and 3T3 cells, correlating well with the difference in 
recombinant EPO sialylation profiles in NS0 and the latter two cell lines (Fig. 4.3). It 
is tempting to speculate the sialylation capability of a cell line is primarily regulated 






Fig. 4. 9. qRT-PCR analysis of endogenous transcript levels of GlcI, ST3GalIII, 
and ST3GalIV in HEK293, 3T3 and NS0 cells  
Total RNA was isolated from 3T3 and NS0 cells. For each qRT-PCR reaction, cDNA 
yielded from reverse transcription of 500 ng total RNA was mixed with SYBR Green 
PCR reagent and specific primer pairs. Average Ct value of each reaction was 





N-glycosylation is a heterogeneous and cell type-specific process in 
mammalian cells. As cultured mammalian cells are often used as host cells for the 
production of recombinant glycoproteins, the glycosylation profiles of different cell 
lines represent a vital set of information that would enable researchers to select a line 
that can produce glycoproteins with favorable glycan structures. This study serves two 
main purposes, i) to identify specific glycogenes from our glycosylation toolbox that 
could synergistically improve protein sialylation in these cell lines so that the findings 
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may be applied to the biotech industry, ii) to provide functional insights on the 
regulation of N-glycans by components of the glycosylation machinery.  
Among the six cell lines, BHK-21 cells and CHO cells sialylate recombinant 
EPO most effectively. The IEF profile of EPO produced by BHK-21 cells is very 
close to that of clinical-grade EPO (Fig. 2), whereas EPO produced by NS0 cells 
shows a very poor sialylation profile. Our results therefore show that BHK-21 and 
CHO cells would be good candidate hosts for the production of recombinant EPO, as 
the circulatory half-life of this molecule is primarily determined by the sialic acid 
content (Sinclair and Elliott 2005). This trend of sialylation capabilities among the cell 
lines (except NS0 which was not included in MS and HPAEC analysis) is consistent 
with result from chromatographic analysis (Section 3.3.5). 
N-glycosylation is catalyzed by a diverse array of proteins that act at 
difference stages of N-glycan biosynthesis. Insufficient expression of endogenous 
upstream glycogenes could result in incomplete processing of glycans and thus 
potentially affect the downstream glycosylation. Indeed, this is the case for several 
CHO glycosylation mutants in which inactivation of upstream glycogenes prematurely 
terminates the glycosylation pathway. This is clearly shown in our sialylation 
profiling of recombinant EPO produced in Lec1 and Lec23 mutants, where loss-of-
function in an upstream glycogene (GlcI in Lec23 cells, GnT I in Lec1 cells) 
ultimately leads to a sialylation defect (Fig. 4.5). In wild-type cells and tissues, results 
from transcriptional profiling of glycogenes showed that genes responsible for the 
synthesis of the core structures of O- and N-glycans are ubiquitously expressed at 
similar levels, however glycosyltransferases responsible for synthesizing the terminal 
structures are expressed in a tissue- and cell type-specific manner (Comelli et al. 
2006a, Nairn et al. 2008). However, these reports only analyzed the expression levels 
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of different glycogenes and did not provide any functional information on these genes. 
In this report, these glycogenes were analyzed at a more functional level by assaying 
their effect on sialylation of EPO. We showed that sialylation capability is highly cell 
type specific. Recombinant EPO expressed in the six cell lines are sialylated 
differently with BHK-21 and CHO cells being the best. Expression of ST3GalIII, 
ST3GalIV and ST6GalI resulted in improved sialylation in four cell lines. In contrast, 
overexpression of the upstream glycogenes failed to improve sialylation in all cell 
lines tested. In addition, these upstream genes did not show any synergistic effects 
when co-transfected with sialyltransferases, suggesting that the upstream glycogenes 
are expressed at sufficient levels in these cell lines and therefore can be considered as 
“house keeping” genes. The two genes, ST3GalIII, ST3GalIV, that dramatically 
enhanced EPO sialylation in HEK293, 3T3 and NS0 cells are indeed under expressed 
in these two cell lines (Fig. 4.9). Taken together, our results suggest that the regulation 
of sialylation in these cell lines is regulated by downstream genes, primarily 
sialyltransferases.  
The four sialyltransferases in our glycosylation toolbox were selected from a 
large number of sialyltransferases because they can transfer sialic acid to the Galβ1-
4GlcNAcβ- structure by forming α2,3 or α2,6 linkage (Harduin-Lepers et al. 
2001).As expected, 3 of them are indeed able to improve sialylation of recombinant 
EPO in some of the cell lines. Surprisingly, ST3Gal VI failed to improve EPO 
sialylation in any of these cells even though it has been shown to be able to transfer 
sialic acid to the Galβ1-4GlcNAcβ- structure on glycoproteins (Okajima et al. 1999).   
Overexpression of sialyltransferases represents a promising strategy to 
enhance sialylation of recombinant glycoproteins. Indeed, such overexpression 
approaches focusing on sialyltransferases and CST have been described in several 
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studies. Stable overexpression of ST3GalIII (Jeong et al. 2009, Son et al. 2011b, 
Weikert et al. 1999) and CST (Wong et al. 2006) was found to enhance sialylation of 
different glycoproteins in CHO cells, contrary to our observations which shows that 
the sialylation in CHO cells cannot be further enhanced (Fig. 4.8A). However, data 
presented by these groups were obtained by analyzing the cells derived from stably 
transfected single clones. The genetic backgrounds of such single clones could be 
different from that of the wild-type population. The transient transfection approach 
adopted in this study represents a better strategy for studying the impacts of 
glycogenes in sialylation in a cell line as it is more reflective of population behavior of 
a cell line. Despite the discrepancy, we are still able to establish some positive 
correlations between other published data and our results. Consistent with our findings, 
(Chitlaru et al. 1998) found that the overexpression of ST6GalI in HEK293 cells 
resulted in a significant increase in sialylation of human acetylcholineesterase, 
whereas overexpression of the same gene in CHO cells only marginally improved 
sialylation of interferon-γ (Bragonzi et al. 2000). 
It should be pointed out that all six cell lines used in this research were 
recently obtained from the ATCC (USA) or ECACC (UK). This was to minimize the 
genetic variations between the cells of different sources. For example, since the 
original development of the CHO cells in 1957, it has been cultured in different labs 
around the world for more than 50 years. The “CHO-K1” cells kept in different labs 
can be different in their genetic backgrounds. To illustrate this point, the sialylation 
capability of recombinant EPO of the CHO-K1 cells used in this report seemed to be 
slightly better than that of the CHO-K1 cells used in one of our previous reports (Goh 
et al. 2010). In addition, CHO-K1 cells reported in our previous work are easier to be 
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adapted and cultured in suspension in serum-free medium compared to the CHO-K1 
cells used in this work (data not shown).   
The conventional method to analyze N-glycan structures of a glycoprotein can 
be costly and time-consuming. The IEF/immunoblotting assay offers a simple and 
sensitive assessment on the extent of sialylation on recombinant EPO. This method 
has been proven fairly sensitive using a series of CMP-sialic acid transporter mutants 
(Lim et al. 2008). In this report, the difference in sialylation shown by IEF was 
confirmed by the thiobarbituric acid (TBA) assay analysis (Fig. 6). IEF has been well-
received as a method to compare the degree of sialylation of EPO (Park et al. 2009). 
The World Anti-Doping Agency (WADA) relies on IEF patterns to distinguish human 
EPO from recombinant EPO produced by CHO cells by comparing the sialylation 
patterns (Lasne and de Ceaurriz 2000, Lasne et al. 2007). The IEF/Western blot assay 
has enabled us to perform rapid and semi-quantitative analysis of multiple samples at 
a time (Chan et al. 2010, Goh et al. 2010, Lim et al. 2008). 
Major limitations of IEF include the inability to distinguish human and non-
human sialic acids (i.e. Neu5Ac vs. Neu5Gc), the potential interference of sulfation 
which gives negative charges to the N-glycans similar to sialylation), and qualitative 
but not quantitative data interpretation. However, these limitations can be resolved by 
orthogonal assays such as mass spectrometric or chromatographic determination of 
sialic acids, sialidase treatment prior to IEF to rule of sulfation interference, and 
quantitative sialic acid assays for example thiobarbituric acid assay as described in 
this study. Nevertheless, IEF is still the best choice as a first screening method for the 
study of sialylation owing to its ability to allow for fast, sensitive and medium-




4.5 Chapter summary 
Consistent with the structural data described in Chapter 3, the analysis of EPO 
sialylation in six mammalian cell lines by IEF demonstrates that glycosylation is a 
highly cell line-specific process. CHO-K1 and BHK-21 were found to produce 
recombinant EPO with highest sialic acid content. The sialylation capabilities of 
HEK293, COS-7 and 3T3 are relatively weaker while that of NS0 cells is the weakest. 
To understand how glycans are regulated at glycosylation pathway level, we 
generated a glycosylation toolbox with 31 glycogene expression constructs, and 
dissected the impacts of individual glycogenes on sialylation extent of EPO. Our data 
from the functional expression of glycogenes provided orthogonal proofs to results 
obtained from transcriptional profiling of glycogenes. This work further strengthens 
the notion that glycan structural diversity is mainly a consequence of variable 
expression levels of glycosyltransferases involved in glycan terminal decoration. In 
the case of sialylation, cell lines that express lower level of sialyltransferases were 
found to produce EPO with less sialic acids and overexpression of three 
sialyltransferases in our toolbox led to significantly enhancement of EPO sialylation. 
On the other hand, upstream glycogenes are ubiquitously expressed at sufficient levels, 
hence do not contribute to the regulation of sialylation in all cell lines tested. 
Overexpression of the upstream glycogenes, therefore, cannot synergize the 
sialyltransferases to further enhance sialylation. Our results also provide a general 
guide for selection of cell lines and strategies for improving sialylation of N-




CHAPTER 5: ELUCIDATION OF STRUCTURE-





It is apparent from the Introduction in Chapter 4 that nucleotide-sugar 
transporters (NSTs) are an indispensable group of proteins for glycosylation; they 
transport nucleotide sugars that are synthesized in the cytosol (such as UDP- and 
GDP-sugars) or nucleus (CMP-sialic acid) into the lumen of Golgi apparatus. 
Incorporation of these nucleotide sugars into the acceptor glycans ultimately gives rise 
to glycan structural diversity. The importance of NST proteins in glycosylation can be 
further supported by evidences from three major aspects: first, mutation of NST in 
cultured cells (especially CHO cells) leads to aberrant glycan structures that are 
essentially devoid of the corresponding sugar (Deutscher and Hirschberg 1986, 
Deutscher et al. 1984, Oelmann et al. 2001); second, rare mutations of several NST 
proteins have been reported in humans which led to Congenital Disorder of 
Glycosylation (CDG) (Lubke et al. 2001, Luhn et al. 2001, Martinez-Duncker et al. 
2005), a class of inherited diseases that are often associated with severe 
developmental defects; third, up-regulation of certain NST proteins have been 
implicated in some pathological conditions such as cancer (Irimura et al. 1993, 
Kannagi 1997, Kannagi et al. 2004). 
NST proteins were discovered as a structurally related family of proteins, 
termed Slc35 family for Solute Carrier 35. Despite low level of conservation in 
overall sequences, these proteins contain multiple hydrophobic regions by hydropathy 
prediction. Topology of one Slc35 family member, the CMP-sialic acid transporter 
(CST), was experimental established by epitope insertion at different regions followed 
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immunofluorescent detection by selectively permeabilize the plasma membrane or 
both plasma- and endo- membranes (Eckhardt et al. 1999). These biochemical data 
support a topological model of CST in which there are 10 transmembrane helices 
connected by hydrophilic loops and both N- and C-termini face the cytosolic side. 
Similarly, other NST proteins were predicted to have 6, 8 or 10 transmembrane 
regions with both N- and C-termini in the cytosol. 
Elegant biochemical assays showed that nucleotide-sugar transporters are 
antiporters, i.e. the transport of nucleotide sugar into ER/Golgi lumen is accompanied 
by transport of the corresponding nucleoside monophosphate out of these 
organelles(Gerardy-Schahn et al. 2001). Most NST proteins are highly specific for 
only one particular nucleotide sugar while a few NST proteins show bi-specificity 
when analyzed in vitro (Ashikov et al. 2005). The NST proteins characterized to date 
are localized to either ER or Golgi, usually corresponding to the cellular compartment 
where the cognate nucleotide sugar is incorporated into the glycans (Gerardy-Schahn 
et al. 2001, Liu et al. 2010).   
 
5.1.1 Nucleotide-sugar transporters: phylogeny and sequence alignment 
The availability of genome sequences for many species, such as human, 
drosophila, C. elegans has resulted in identification (including in silico prediction) of 
an increasing number of NSTs. Phylogenetic analysis of annotated and putative Slc35 
family members revealed substantial sequence diversity leading to at least six 
subfamilies A – F ((Ishida and Kawakita 2004). A few selected NSTs representing 
five subfamilies are shown in Fig. 5.1. The GDP-fucose transporter belongs to 
Subfamily C and is alternatively named as Slc35c1. 
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Overall, protein sequences for different NSTs are not highly conserved despite 
the common feature of multiple hydrophobic regions. Fig. 5.2 shows a multiple 
protein sequence alignment of human and mouse transporters for CMP-sialic acid 
(CST), UDP-galactose (UGT), UDP-N-acetylglucosamine (UGnT), and GDP-fucose 
(GFT). It is evident that many of the highly conserved residues are hydrophobic and 
are located in the putative TM helices. Interestingly, Thr at position 319 (consensus 
sequence numbering) are conserved in all transporters suggesting the importance of 
this residue in maintaining the structure, function, or both of NSTs. In fact, mutation 
of this Thr residue to Arg was the molecular signature in one of the CDG patients 
(Lubke et al. 2001). In addition, several Gly residues located between position 180 to 
290 are also conserved in all transporters. Their impacts on activity of transporters 
will be discussed in Section 5.3.5. 
 
Fig. 5. 1. Phylogenetic grouping of nucleotide sequences for selected NSTs 
Note GDP-fucose transporter in Subfamily C. (Adapted from Ishida and Kawakita 
2004) 
 
However, transporters for the same nucleotide sugar are highly conserved 
during the evolution. For example, the protein sequences for GFT are largely 
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conserved from C. elegans to human (Fig. 5.3). Although the level of conservation in 
the N- and C-terminal sequences are substantially lower, a few residues (especially 
some in the C-termini) are still conserved across most of the species, suggesting for a 
role in maintaining the activity of GFT (see Section 5.3.3 and 5.3.4).  
 
Fig. 5. 2. Multiple protein sequence alignment for different NSTs in human and 
mouse 
Protein sequences were retrieved from NCBI GenBank and aligned by Multalin web-
based software. The name of each protein follows the format: Species_NST 
abbreviation_Database Accession No.. Abbreviations for species: Hu, human; Ms, 
mouse. Coloring scheme: red, conserved residues; blue, partially conserved residues; 




Fig. 5. 3. Multiple protein sequence alignment of GDP-fucose transporter from 
different species 
Name of each protein follows the format: Species_Database Accession No.. 
Abbreviations for species: Hu, human; CH, Chinese hamster; Ms, mouse; Rt, rat; Zf, 




5.1.2 GDP-fucose transporter and its implications in diseases 
The membrane topology of GFT by computer prediction is similar to that of 
CMP-sialic acid transporter with 10 transmembrane helices and both N- and C-termini 
facing the cytosol (Lubke et al. 2001, Luhn et al. 2001) (Fig. 5.4).  
 
 
Fig. 5. 4. Putative membrane topology of human GDP-fucose transporter 
Based on the topological model for CMP-sialic acid, the human GFT was predicted to 
contain 10 transmembrane domains (TMD). Amino acid residues within the TMD are 
shown. The conserved TM helical Gly residues were shown in red (see Section 5.3.5). 
The Thr residue that was mutated in one of the CDG-IIc patients was also shown in 
red. Golgi lumen is at the top and cytosolic side is at the bottom. 
 
Immunofluorescence microscopy showed the human and C. elegans GFT both 
localize to the Golgi apparatus (Luhn et al. 2001). This transporter was first identified 
by genetic complementation and library screening approaches to be the causative 
factor for CDG Type IIc (Lubke et al. 2001, Luhn et al. 2001). The clinical features of 
this disease include flat face with puffy eye lids, growth and mental retardation, and 
compromised immunity with recurrent bacterial infections (Becker and Lowe 1999, 
Etzioni et al. 1993). Mutation of the GFT gene causes deficiency in fucosylation of 
glycoconjugates, including selectin ligands, ABO and Lewis blood group antigens 
(Becker and Lowe 1999).  
GFT can also play a role in cancer. It was found that the fucosylated form of 
serum alpha-fetoprotein, termed AFP-L3 fraction, was increased in hepatocellular 
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cancer (HCC) patients (Aoyagi et al. 1985, Aoyagi et al. 2002). Later it was realized 
that the increase in fucosylation was caused by high expression of the GDP-fucose 
transporter (Moriwaki et al. 2007).  
 
5.1.3 Structure-function relationship of nucleotide-sugar transporters 
 Elucidation of the structure-function relationship will provide insights in 
molecular signatures that determine that substrate specificity and transport activity as 
well as motifs that regulate the trafficking and localization of nucleotide-sugar 
transporters. This will ultimately enable the annotation of putative NST proteins based 
on their primary sequences. It will also allow for the engineering of identified NST 
proteins with novel substrate specificity and/or cellular compartmentalization as a 
viable glycoengineering method. As some NST proteins are also implicated in 
pathological conditions, elements critical for their transport activity could represent 
potential targets for inactivating such transporters.  
One major challenge in establishing the structure-function relationship of 
NSTs lies in the fact that NSTs are Type III membrane proteins with multiple 
membrane spanning regions, making the crystallization or reconstitution of these 
proteins in homogeneous solution notoriously difficult. Despite the lack of direct 
structural data, researchers in the field have accumulated a wealth of information on 
the structure-fucntion relationship of NSTs by utilizing heterologous expression 
systems. One commonly used approach is to express variants of an NST protein in 
yeast S. cerevasiae (Aoki et al. 2001, Aoki et al. 2003, Aoki et al. 1999, Ashikov et al. 
2005) which does not have detectable endogenous transport activity for most of the 
nucleotide sugars except GDP-mannose and UDP-glucose. An alternative approach is 
to test the variant constructs in mammalian cell lines that harbor inactivating 
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mutations in the corresponding NSTs (Chan et al. 2010, Kabuss et al. 2005, Lim et al. 
2008, Oelmann et al. 2001). For the heterologous expression system using yeast, NST 
or its variant is expressed in yeast cells. ER or Golgi enriched vesicles (depending on 
the localization of this protein to ER or Golgi) are prepared and incubated with 
radioactively labeled nucleotide sugars. Transport activity is measured by the relative 
radioactivity in the vesicles. For heterologous expression system using mammalian 
glycosylation mutants, the activity of NST is usually indirectly reflected by binding of 
a lectin that positively or negatively probes the corresponding sugar. For example, the 
analysis of a CST variant can be done by expressing the construct in Lec2 (mutant of 
CST) cells, followed by cell staining using peanut agglutinin (PNA), a lectin that 
specifically recognize asialogalactosylated glycoconjugates. 
Among the annotated NST proteins, CMP-sialic acid transporter and UDP-
galactose transporter are relatively better characterized. Results from several labs 
including our own have shown a critical role of the C-terminal sequence for both 
transporters in the localization (Chan et al. 2010, Kabuss et al. 2005, Zhao et al. 2006). 
In addition, we found that four pairs of conserved Gly residues are important for 
maintaining the transporter activity of CST (Lim et al. 2008). In contrast, elements for 
the localization and activity of GDP-fucose transporter are poorly understood.    
 
5.1.4 Specific aims and outlines 
 
 This part of work aims to establish, at least in part, the structure-function 
relationship of the GDP-fucose transporter protein. Previously, we reported a CHO 
glycosylation mutant cell line, MAR-11 (now renamed as CHO-gmt1), which has a 
genetic defect on CMP-sialic acid transporter (Lim et al. 2008). Recently, on the basis 
of this mutant cell lines, we knocked out the gene encoding hamster GDP-fucose 
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transporter using zinc-finger nuclease (ZFN) technology (Zhang et al. submitted 
manuscript). One of the clones, Clone E, isolated after transfecting the ZFN constructs, 
show mutation in both alleles of GFT (Fig. 5.5). One of the alleles (E1) has a 3-bp 
deletion, resulting in mutation of K137-Y138 to one N residue. The other allele E2 
has a 40-bp deletion which resulted in a prematurely truncated GFT product of 172 
amino acids. The different mutations in the two alleles were caused by different DNA 
repair mechanisms after ZFN-mediated DNA breakage at the target loci. Clone E has 
been since renamed as CHO-gmt5 and represents a novel glycosylation mutant cell 
line with double deficiency in both CST and GFT.  
 
 
Fig. 5. 5. Partial genomic DNA sequence alignment of two mutant alleles of GFT 
in CHO-gmt5 with that of wild-type GFT 
In allele E1 of CHO-gmt5, the 3-bp deletion of GFA results in condensation of codons 
AAG TAC (LysTyr) to AAC (Asn). The 40-bp deletion in E2 allele results in a 
premature stop codon downstream (not shown in this figure).  
 
 
The availability of a GFT-/- cell line offers a GFT-null background for 
heterologous expression analysis of human GFT and its variants. In this study, we first 
characterized the N-glycan structures produced by CHO-gmt5 cells. We then 
investigated the impacts of C-terminal sequence and conserved transmembrane helical 
Gly residues on localization and transport activity of GFT. The activity of GFT was 
indirectly reflected by the binding of a fucose-specific lectin, Aleuria Aurantia lectin 
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(AAL), to the CHO-gmt5 cells. Using this system, we successfully identified elements 
located in different regions of GFT with significant impacts on its transport activity. 
 
5.2 Experimental procedures 
5.2.1 Lectin staining of CHO-K1, CHO-gmt1 and CHO-gmt5 cells 
CHO-K1, CHO-gmt1 and CHO-gmt5 cells were seeded at 1×105 cells/ml 
density into 12-well plates with a glass coverslip at the bottom of each well. After 
overnight culture, cells were fixed with 4% paraformaldehyde in PBS for 10 min and 
permeabilized by 0.1% Triton X-100 (Sigma, St. Louis, MO) in PBS for 5 min. After 
washing with PBS twice, cells were blocked with Carbo-Free blocking solution 
(Vector Laboratories, Burlingame, CA) for 30 min. Cells were then briefly rinsed with 
PBS and incubated with PBS containing 1% BSA and biotinylated AAL (Vector 
Laboratories, Burlingame, CA) (5 µg/ml final concentration) for 30 min . The 
coverslips were then washed three times in PBS and incubated with PBS containing 1% 
BSA and AlexaFluor 647-conjugated streptavidin (Invitrogen, Eugene, OR) (5 µg/ml 
final concentration), FITC-conjugated PNA (5 µg/ml final concentration) and Hoechst 
33342 (Invitrogen, Eugene, OR) (2 µg/ml final concentration). Finally, the coverslips 
were washed four times in PBS and then mounted onto glass slides using ProlongGold 
antifade medium (Invitrogen, Eugene, OR) and stored at room temperature overnight 
before long-term storage at 4oC. Fluorescent images were captured by a Carl Zeiss 
LSM510 confocal microscope with a 63× PLAN-Apochromat objective. 
 
5.2.2 Characterization of N-glycans on recombinant EPO-Fc by MALDI-TOF 
 CHO-gmt1 and CHOO-gmt5 cells were seeded into five T175 flasks each at 
2×105 cells/ml (35 ml per flask) and transfected with a construct encoding EPO-Fc by 
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Lipofectamine reagent following procedures described in Section 2.2.4. Recombinant 
EPO-Fc secreted into the protein-free medium during the next three days post 
transfection was purified by Protein A chromatography (Section 2.2.5). N-glycans 
were released from EPO-Fc molecules by PNGase F digestion (Section 3.2.5), 
permethylated (Section 3.2.8), and analyzed by MALDI-TOF MS (Section 3.2.10). 
  
5.2.3 Cloning of human GFT and its variants 
 The human GFT (database accession number: NM_018389) was synthesized 
by RT-PCR. Briefly, RNA was extracted from HEK293 cells using RNeasy Mini Kit 
(Qiagen, Hilden, Germany) according to manufacturer’s instructions. mRNA was 
reverse-transcribed into cDNA using ImProm-II kit (Promega, Madison, WI). cDNA 
encoding GFT was amplified by PCR reaction with primer pair specific for 5’- and 3’-
ends of the coding region. The HA sequence was incorporated into the forward primer. 
The amplified GFT cDNA was digested with HindIII and XhoI (New England Biolabs, 
Ipswich, MA) and ligated into pcDNA3.1(+) vector. GFT variants with mutation in 
the C-terminal sequence (∆C-tail, CST-tail, ∆CT1, ∆CT2, EM/GG, 3K/3G and EM-
CST-tail) were generated by standard PCR or overlap PCR. GFT variants with point 
mutations in the ∆CT2 deletion region or the transmembrane helical regions were 
generated using site-directed mutagenesis kit (Stratagene, Cedar Creek, TX) according 
to manufacturer’s instructions. All constructs contain a Kozak sequence (GCCACC) 
ahead of the start codon and were cloned into pcDNA3.1 (+) vector using HindIII and 
XhoI sites. Coding regions of all constructs were sequenced to rule out unwanted 





Table 5. 1. List of primers for cloning GFT and its variants 
Boxed sequence indicates an HA-tag. Underlined sequences are HindIII and XhoI 










∆C-tail forward: CGCAAGCTTGCCACCATGTAC 
















































G180I forward: CCTGCGGTATCATCATCGGGATCTTCTGGCTTGGTGTGGACC 
reverse: GGTCCACACCAAGCCAGAAGATCCCGATGATGATACCGCAGG 
G180Y forward: CCTGCGGTATCATCATCGGGTACTTCTGGCTTGGTGTGGACC 
reverse: GGTCCACACCAAGCCAGAAGTACCCGATGATGATACCGCAGG 
G198I forward: GAAGGCACCCTGTCGTGGCTGATCACCGTCTTCGGCGTGCTGGC 
reverse: GCCAGCACGCCGAAGACGGTGATCAGCCACGACAGGGTGCCTTC 
G198Y forward: GAAGGCACCCTGTCGTGGCTGTACACCGTCTTCGGCGTGCTGGC 
reverse: GCCAGCACGCCGAAGACGGTGTACAGCCACGACAGGGTGCCTTC 
G277I forward: GACGCTGGGCGGCCTGTTTATCTTTGCCATCGGCTACGTGAC 
reverse: GTCACGTAGCCGATGGCAAAGATAAACAGGCCGCCCAGCGTC 




5.2.4 Immunofluorescent staining for localization and activity of GFT variants 
 CHO-gmt5 cells were plated on glass coverslips in 6-well plates and 
transfected next day using FuGene 6 reagent (Roche, Indianapolis, IN) with plasmid 
constructs for different GFT variants. Two days after transfection, cells were washed 
with PBS, fixed with 4% paraformaldehyde in PBS for 10 min and permeabilized by 
0.1% Triton X-100 (Sigma, St. Louis, MO) in PBS for 5 min. After washing with PBS 
twice, cells were blocked with Carbo-Free blocking solution (Vector Laboratories, 
Burlingame, CA), briefly rinsed with PBS and then incubated with PBS containing 1% 
BSA and a monoclonal anti-HA antibody (5 µg/ml final concentration) as well as a 
Golgi marker antibody at the following dilutions for 1 hour: anti-giantin 1:300, anti-
GM130 1:100, anti-ManII 1:100, anti-B4GalTI 1:50, anti-TNG46 1:100. For 
experiments involving the analysis of GFT activity, biotinylated AAL (5 µg/ml final 
concentration) was included in the primary antibody mixture. The coverslips were 
then washed three times in PBS and incubated with secondary antibodies, i.e. 
AlexaFluor 488 conjugated goat anti-mouse IgG (for the detection of HA-GFT) and 
AlexaFluor 594 conjugated goat anti-rabbit IgG (for the detection of Golgi marker), as 
well as AlexaFluor 647 conjugated-streptavidin for experiments involving 
biotinylated AAL. In all experiments, Hoechst 33342 (Invitrogen, Eugene, OR) at 2 
µg/ml (final concentration) was included in the secondary antibody mixture to stain 
the nuclei. Finally, the coverslips were washed four times in PBS and then mounted 
onto glass slides using ProlongGold antifade medium (Invitrogen, Eugene, OR). 
Images were taken using a Carl Zeiss LSM 510 META confocal microscope with a 
63× PLAN-Apochromat objective (1.40 NA) immersed in oil. All AAL images within 
the same set of experiments were acquired under constant imaging parameters. 
Representative areas were cropped with LSM Image Brower and used to produce the 
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final figures. For localization analysis of GFT, images were taken at 10 successive 
optical slices in the Z-direction (0.41 µm thickness per slice) and used to produce the 
final figure.  
 
5.2.5 FACS analysis of cell surface fucosylation 
CHO-gmt5 cells were transfected with different GFT constructs in 12-well 
plates using FuGene6. Two days after transfection, cells were washed with PBS and 
harvested using PBS containing 2 mM EDTA. After washing with PBS, cells were 
fixed with 4% PFA (diluted from 16% methanol-free PFA, Thermo Scientific) in PBS 
for 10 min. After washing with PBS twice, cells were incubated with Carbo-Free 
blocking solution  for 30 min, and then incubated with PBS containing 1% BSA and 5 
µg/ml biotinylated AAL for 30 min. After 2 washes with PBS, cells were incubated in 
PBS containing 1% BSA and 5 µg/ml Cy3-conjugated streptavidin for 30 min. Finally, 
cells were washed twice in PBS and analyzed by a BD LSR II FACS analyzer. For 
each run, 10,000 events were recorded. AAL-positive region was gated based on 
untransfected CHO-gmt5 cells and cells transfected with a full-length GFT construct. 
Under such gating parameters, CHO-gmt5 cells transfected with a T306R construct 
had <0.5% population in the AAL-positive region. To control for transfection 
efficiency, a separate set of transfections were done with each GFT construct mixed 
with a GFP construct at 10:1 ratio. Cells were stained by the same method described 
above and GFP fluorescence was analyzed by FACS. Similar GFP fluorescence 
profiles (typically 10-14% GFP+ population) were obtained for all transfections, 
suggesting comparable transfection efficiencies for all constructs (data not shown). 
Representative FACS results from the same batch of experiments were used to 




5.3.1 Endogenous and recombinant N-glycans produced by CHO-gmt5 cell are 
free of sialic acid and fucose 
First, it is necessary to show that the knockout of GFT from CHO-gmt1 cells 
really results in double deficiency of sialic acid and fucose in N-glycans produced by 
CHO-gmt5 cells. To this end, lectin staining was performed to gain insights into the 
glycan terminal structures (Fig. 5.6). Cells were labeled with two lectins, PNA which 
recognizes terminal galactose residue, and AAL which recognizes fucose residue. 
Parental and wild-type cell lines, CHO-gmt1 and CHO-K1, were also included in this 
analysis. CHO-K1 is negative for PNA binding due to the capping of galactose 
residues by sialic acids. It is positive for AAL binding because of the abundant 
fucosylation of N-glycans. In contrast, CHO-gmt1 is positive not only for AAL, but 
also for PNA due to the genetic defect in CST leading to production of galactose-
terminated N-glycans. As expected, CHO-gmt5 was shown to be positive for PNA. 
However, it is negative for AAL binding, suggesting the lack of fucosylation due to 
knockout of the GFT gene (note the weak staining of CHO-gmt5 by AAL is the 





Fig. 5. 6. Lectin labeling of carbohydrates in wild-type and mutant CHO cells  
CHO-K1, CHO-gmt1, and CHO-gmt5 cells were seeded on glass coverslips, cultured 
overnight followed by fixation and permeabilization. Terminal galactose residues 
were detected using FITC-conjugated PNA (colored green). Fucose residues were 
detected using biotinylated AAL and AlexaFluor 647-conjugated streptavidin 
(pseudo-colored red). Nuclei were stained by Hoechst 33342 and colored blue. 
 
 
To further characterize the N-glycan structures produced by CHO-gmt5 cells, 
we transiently expressed EPO-Fc fusion protein in CHO-gmt1 and CHO-gmt5 cells 
each cultured in five T-75 flasks in protein-free media. Recombinant EPO-Fc secreted 
into the conditioned media three days after transfection was purified by Protein A 
chromatography. 100 µg of purified EPO-Fc produced by each cell line was subjected 
to PNGase F treatment to release the N-glycans which were then structurally analyzed 
by MALDI-TOF. The mass spectra are as shown in Fig. 5.7. The glycans isolated 
from CHO-gmt1 were mostly fucosylated, and the dominant species were the asialo, 
core-fucosylated galactosyl bi-antennary, tri-antennary and tetra-antennary glycans 
(note the three major peaks in the top mass spectrum). In contrast, the dominant 
species isolated from CHO-gmt5 were the asialo, afucosylated galactosyl bi-antennary, 
tri-antennary and tetra-antennary glycans, correspondingly. Minor peaks 
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corresponding to fucosylated species were observed in CHO-gmt5 sample at residual 
levels, which were also present in conditioned media collected from untransfected 
CHO-gmt5 cells (data not shown), suggesting these residual amounts of fucosylated 
glycans might come from the culture medium. These data clearly demonstrated that 
membrane-bound and secreted glycoproteins expressed by CHO-gmt5 cells are 




Fig. 5. 7. Mass spectra of N-glycans on recombinant EPO-Fc produced in CHO-
gmt1 and CHO-gmt5 cells 
N-glycans isolated from recombinant EPO-Fc produced in CHO-gmt1 and CHO-gmt5 
cells were analyzed by MALDI-TOF. The N-glycans produced by CHO-gmt1 were 
mostly fucosylated, and the dominant species were the asialo, core-fucosylated 
galactosyl bi-, tri- and tetra-antennary glycans. However, the N-glycans produced by 





5.3.2 The human GDP-Fucose transporter is mainly localized to trans-Golgi  
Although the C. elegans and human GFT have been shown to be localized to 
the Golgi apparatus, its distribution in the Golgi cisternae has not been investigated.  
We transiently expressed HA-tagged GFT in HeLa cells and analyzed the distribution 
of GFT by immunofluorescence microscopy. HeLa cells are known to have elaborate 
Golgi structure. By comparing the localization pattern of HA-GFT with defined Golgi 
cisternal markers, sub-Golgi compartmentalization of GFT can be determined. Cells 
were immunostained with an HA-specific antibody as well as antibodies specific for 
Golgi cisternae, namely GM130 for cis-Golgi, ManII for medial-Golgi, B4GalTI for 
trans-Golgi, and TGN46 for trans-Golgi network. Fluorescent images were taken by a 
confocal microscope at different optical sections. Only cells expressing moderate level 
of HA-GFT were analyzed and representative images were shown in Fig. 5.8. GFT 
did not show co-localization with cis-Golgi marker GM130, or with TGN marker 
TGN46. Partial co-localization was detected with medial-Golgi marker ManII and 
high degree of co-localization was seen with trans-Golgi marker B4GalTI. This 
indicates that at steady state, the majority of GFT protein is localized to the trans-
Golgi with a smaller fraction localized to medial-Golgi. This observation is consistent 





Fig. 5. 8. Localization of GFT in the Golgi  
HA-tagged GFT was transiently transfected into HeLa cells and GFT was detected by 
a monoclonal HA antibody (colored green). Golgi compartments were stained by 
antibodies specific for defined Golgi markers, GM130 (cis-Golgi), ManII (medial-
Golgi), B4GalT1 (trans-Golgi) and TGN46 (trans Golgi network, or TGN). All Golgi 
markers were colored red. Nuclei were stained by Hoechst 33342 and colored blue. 
The boxed areas in the merged images were enlarged and shown on the right. Scale 
bar: 20 µm.  
 
5.3.3 The cytosolic C-terminal tail sequence of GFT is critical for its transport 
activity but not localization to the Golgi  
The cytosolic C-terminal tail sequence of CST has been shown to be involved 
in the localization and trafficking of this transporter (Zhao et al. 2006). To determine 
if this feature is conserved in GFT, we made a series of constructs encoding HA-
tagged GFT variants with deletions in the C-terminal tail region (Fig. 5.10A). 
Constructs were transfected into CHO-gmt5 cells. Two days after transfection, cells 
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were fixed and stained with anti-HA antibody as well as an antibody specific for a 
Golgi marker (Giantin) to determine the localization of the GFT variants. Cells were 
counter-stained by biotinylated AAL followed by AlexaFluor 647-conjugated 
streptavidin as an indirect readout for GFT activity. Multiplex fluorescent images 
were taken at constant imaging conditions and shown in Fig. 5.10B. Expression of a 
full-length GFT (FL) restored the fucosylation in transfected CHO-gmt5 cells as 
evident by the strong AAL fluorescence intensity, both in the Golgi and membrane 
regions. Deletion of aa. 341 – 364 (∆C-tail construct) did not change the Golgi 
localization of GFT. However, AAL fluorescence intensity, especially that outside 
Golgi, was greatly reduced. . The partially retained Golgi staining by AAL could be 
due to higher glycoprotein concentration in the Golgi, which serves as a sorting 
station for secreted and membrane proteins, whereas the much larger surface area of 
plasma membrane “diluted” the AAL signal. Consistent with this argument, FACS 
analysis of cell surface fucosylation by AAL staining shows that cells transfected with 
the ∆C-tail construct were essentially free of fucose at the cell surface (Fig. 5.10C and 
see below). The diminished rescue of fucosylation suggests this sequence is critical 
for GFT transport activity. Replacing this sequence with the analogous tail sequence 
of CST (CST-tail) did not restore the fucosylation, suggesting that, unlike CST, the C-
terminal tail of GFT is essential for its activity. To narrow down the critical amino 
acid residue(s), we made two shorter deletions within the GFT C-tail region, aa 356 – 
364 (∆CT1) and aa 341 – 355 (∆CT2). Both variants exhibited similar Golgi-
localization pattern but striking difference in AAL fluorescence intensity. Cells 
expressing ∆CT1 showed AAL intensity comparable to FL-transfected cells, 
suggesting aa. 356 – 364 are dispensable for GFT transport activity. However, cells 
expressing ∆CT2 were negative for AAL binding, except for a basal level of 
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fluorescence in the Golgi area. This result indicates that aa. 341 - 355 are critical for 
the transport activity of GFT. In addition to analyzing the lectin-stained cells under 
the microscope, we also employed FACS to examine the cell surface fucosylation (Fig. 
5.9). CHO-gmt5 cells were transfected with the construct encoding full-length GFT. 
Two days after transfection, cells, in parallel with untransfected CHO-gmt1 and CHO-
gmt5 cells, were fixed but not permeabilized to allow specific labeling of cell surface 
fucose residues by AAL. FACS analysis clearly showed a significant difference in 
AAL-mediated fluorescence between CHO-gmt1 and CHO-gmt5 cells. Transfection 
of GFT construct into CHO-gmt5 cells resulted in restoration of cell surface 
fucosylation in a smaller population of cells. Note that not all CHO-gmt5 cells were 
rescued in terms of fucosylation due to transfection efficiency. Nevertheless, this 
confirmed the fact that GFT is the only gene defective along the fucosylation pathway 
in CHO-gmt5 cells.  
 
Fig. 5. 9. FACS analysis of cell surface fucosylation of CHO-gmt 1 and 5 cells 
CHO-gmt5 cells were transfected with a full-length GFT construct (red line) and 
analyzed for cell surface fucosylation in parallel with untransfected CHO-gmt1 (green 
line) and CHO-gmt5 cells (shaded area) by sequential incubation with biotinylated 




To quantitatively compare the relative activities of different GFT variants, we 
included a GFT construct bearing a T308R, a point mutation previously reported in a 
CDG-IIc patient (Lubke et al. 2001), as a negative control. Cells transfected with the 
FL construct typically show 15 – 20% in the AAL-positive region (Fig. 5.10C). This 
percentage was used to define 100% transport activity (Fig. 5.10D). Under such 
conditions, the activity of GFT (T308R) is close to zero. Consistent with the lectin 
staining results, ∆C-tail and CST-tail GFT variants failed to restore the cell surface 
fucosylation. ∆CT1 showed an activity comparable to FL, whereas ∆CT2 mutant 
completely lost its activity. These results indicate a dispensible role of the C-terminal 
tail in Golgi-targeting of GFT. On the other hand, the C-terminal tail (and specifically 






Fig. 5. 10. The cytosolic C-terminal tail sequence, and more specifically aa 341 – 
355, is essential for GFT transport activity but not its localization to the Golgi 
(A) Schematic representation of GFT constructs with different tail sequences. FL, full-
length GFT; ∆C-tail, GFT with a deletion from aa 341 – 364; CST-tail, replacement of 
aa 341 – 364 with the C-terminal sequence (aa 317 – 336 according to CST 
numbering) of CST;  ∆CT1, GFT with a deletion of aa 356 – 364; ∆CT2, GFT with a 
deletion of aa 341 – 355. All GFT constructs were N-terminally tagged with an HA 
epitope (shown as black boxes). Predicted transmembrane regions are shown as gray 
boxes. (B) Immunofluorescence and lectin staining analyses for localizations and 
activities of GFT variants. CHO-gmt5 cells seeded on glass coverslips were 
transfected with a GFT construct. GFT was detected by a monoclonal HA antibody 
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and colored green. Golgi was marked by antibody specific for giantin and colored red. 
Fucose residues were detected by biotinylated AAL and AlexaFluor 647-conjugated 
streptavidin. Nuclei were stained by Hoechst 33342 and colored blue. Scale bar: 20 
µm. (C) FACS analysis of cell surface fucosylation. CHO-gmt5 cells were transfected 
with a GFT construct and fixed without a permeabilization step two days after 
transfection. Cell surface fucose residues was labeled by biotinylated AAL and Cy3-
conjugated streptavidin. FACS analysis was performed in duplicates on a BD LSR II 
analyzer and representative results were shown. In each histogram plot, shaded area 
shows negative control (untransfected CHO-gmt5 incubated with biotinylated AAL 
and Cy3-conjugated streptavidin). Red line shows the profile of CHO-gmt5 
transfected with the indicated GFT construct. Horizontal line indicates the gate for 
defining the AAL-positive population. (D) Quantification of FACS results. Percentage 
of cells in the gated region (as shown in C) was taken and normalized to that of FL-
transfected cells to indicate the relative transport activity of different C-tail variants. 
Average values are shown. Error bar indicates standard deviation. 
 
 
5.3.4  344EM345 and a cluster of three Lys residues in the C-terminal tail of GFT 
have significant impacts on the activity of GFT  
To pinpoint the exact amino acid residue critical for GFT activity in the ∆CT2 
deletion region, a series of mutant GFT constructs were generated by replacing every 
amino acid in this stretch with a Gly residue. These constructs were then expressed in 
CHO-gmt5 cells and analyzed by immunofluorescence microscopy for their cellular 
localization and AAL-staining for GFT activity. All of these GFT mutants were 
localized to Golgi and shown to be fully functional as evident by strong AAL 
fluorescence intensity both in the Golgi area and on the plasma membrane (Fig. 5.11). 
Therefore, the impact of ∆CT2 could be contributed by a combination of amino acids 




Fig. 5. 11. Single amino acid substitution to Gly in the ∆CT2 deletion region does 
not affect the localization and activity of GFT 
CHO-gmt5 cells were transfected with a GFT construct bearing a single point Gly 
substitution mutation in the ∆CT2 deletion region. GFT was detected by HA-specific 
antibody staining. Golgi was marked by Giantin-specific antibody. Fucose residues 
were labeled by biotinylated AAL and streptavidin conjugated with AlexaFluor-647. 
Scale bar: 20 µm. 
 
Previously, Yoda and co-workers identified a series of Lys residues in the C-
tail region of yeast GDP-mannose transporter (GMT) involved in ER retrieval of this 
protein by binding to COPI coatomer (Abe et al. 2004). They postulated that NSTs 
with a cluster of at least three Lys residues near the membrane spanning region could 
utilize these Lys for ER-Golgi trafficking. GFT was one of such NSTs on their list. 
Interestingly, GFT contains four Lys residues, three of which are located in the ∆CT2 
deletion region. These three Lys were replaced by three Gly residues (3K/3G 
construct illustrated in Fig. 5.12A) to assess their involvement in GFT localization and 
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activity. Immunofluorescence results show that simultaneous mutating the three Lys 
residues to Gly did not affect the Golgi localization of GFT (Fig. 5.12B), consistent 
with the localization pattern of the ∆CT2 variant. However, AAL binding was reduced, 
especially outside the Golgi area. Consistently, FACS analysis of cell surface 
fucosylation showed the activity of GFT with triple LysGly mutations was reduced 
by approximately 50% (Fig. 5.12C and 5.12D).  
Sequence alignment analysis of the GFT proteins identified in all the species in 
the database shows the conservation of 344EM345 motif (data not shown). To test if this 
conserved EM motif is involved in the bioactivity of GFT, we made an EM/GG 
construct by replacing these two conserved amino acids with two Gly residues (Fig. 
5.12A). The EM/GG construct was expressed in CHO-gmt5 cells and found to be 
localized to Golgi (Fig. 5.12B). Activity of this variant was analyzed by lectin staining 
and FACS. Cells expressing EM/GG variant showed AAL fluorescence mainly in the 
Golgi area (Fig. 5.12B). Consistently, the cell surface fucosylation was found to be 
greatly reduced as compared to cells transfected with the FL construct (Fig. 5.12C and 
5.12D). To test if the EM and Lys cluster are two inter-dependent elements for GFT 
activity, we made an additional mutant construct by replacing the C-terminal sequence 
of GFT downstream of the 344EMK346 motif with the analogous region from the CST 
(Fig. 5.12A, shown as EM-CST-tail) and analyzed its localization and bioactivity in 
CHO-gmt5 cells. This GFT variant maintained its localization to the Golgi and did not 
show any compromised activity in AAL binding (Fig. 5.12B – D). In contrast, the 
CST-tail GFT almost completely lost the fucose transport activity (Fig. 4), further 
supporting the importance of the EM motif in maintaining the activity of GFT. 
Therefore, the C-terminal Lys cluster and EM sequence are two independent elements 




Fig. 5. 12. Two elements in the C-terminal tail, a cluster of Lys residues and the 
EM motif, are independently required for the transport activity, but not 
localization of GFT 
(A) Schematic representation of GFT constructs with different tail sequences. FL, full-
length GFT; 3K/3G, a mutant construct with Lys346, Lys347, and Lys355 mutated to Gly 
(underlined); EM/GG, a mutant construct with 344EM345 mutated to GG (underlined); 
EM-CST-tail, replacement of aa 347 – 364 with the corresponding C-terminal 
sequence (aa 320 – 336 according to CST numbering) of CST (CST sequence 
underlined). Note the presence of 344EM345 in the EM-CST-tail construct. All GFT 
constructs were N-terminally tagged with an HA epitope (shown as black boxes). 
Predicted transmembrane regions are shown as gray boxes. (B) Immunofluorescence 
and lectin staining analysis for localization and activity of 3K/3G, EM and EM-CST-
tail variants in CHO-gmt5 cells. Scale bar: 20 µm. (C) FACS analysis of cell surface 
fucosylation. Procedures were described in Fig. 4C. (D) Quantification of FACS 




5.3.5 Three conserved Gly residues in the transmembrane helices have 
differential impacts on the activity of GFT 
Previously, we identified four pairs of Gly in the transmembrane helices of 
CST critical for its transport activity (Lim et al. 2008). Multiple sequence alignment 
of GFT, CST and UGT proteins in human and Chinese hamster show that the first Gly 
in the first, third and fourth pairs are conserved (Fig. 5.13A and data not shown). To 
ascertain the involvement of these three conserved helical Gly residues in the 
transport activity of GFT, we mutated individual Gly to Ile or Tyr. Mutating any of 
the Gly to a bulky amino acid Ile or Tyr did not alter the Golgi localization of GFT. 
However, these mutants displayed dramatic difference in rendering AAL-binding to 
the transfected cells (Fig. 5.13B): G180I mutation resulted in substantial decrease of 
AAL fluorescence intensity, whereas G180Y almost completely abolished AAL 
fluorescence outside Golgi; G198I and G198Y did not affect the AAL binding, 
whereas G277I and G277Y mutations render the GFT nonfunctional as evidenced by 
the loss of AAL fluorescence even in the Golgi area. The results based on lectin-
staining were verified by FACS (Fig. 5.13C and 5.13D). Consistently, G180I mutation 
impaired the transport activity of GFT whereas a more bulky amino acid, Tyr, at this 
position almost completely diminished the activity of GFT. Gly198 is dispensable from 
GFT activity as substitution with Ile or Tyr did not make a significant change in cell 
surface fucosylation. Gly277 was most sensitive to mutation as a substitution with Ile 









Fig. 5. 13. Differential involvement of three Gly residues located in the 
transmembrane helical regions on GFT activity 
(A) Schematic representation of GFT and CST. Gray boxes show predicted 
transmembrane regions in GFT and CST. Three conserved Gly residues in 
transmembrane helices 5, 6 and 8, are indicated. The black boxes indicate an HA tag. 
(B) Immunofluorescence and lectin staining analyses for localization and activity of a 
GFT variant containing GlyIle or GlyTyr substitution at positions 180, 198, and 
277. Scale bar: 20 µm. (C) FACS analysis of cell surface fucosylation. Procedures 
were described in Fig. 4C. (D) Quantification of FACS results. Procedures were 





NST proteins typically contain 6 – 10 membrane-spanning helices with both 
the amino- and carboxyl-termini facing the cytosol. The role of C-terminal tail 
sequence in the trafficking and localization of NST proteins is well established in the 
context of mouse CMP-sialic acid transporter (Zhao et al. 2006), a larger splice 
variant of human UDP-fucose transporter (Kabuss et al. 2005), as well as yeast GDP-
mannose transporter (Abe et al. 2004). Several localization or trafficking-related 
motifs have been identified in the C-terminal tail region. These include ER-export 
motif (II and GV in the context of mouse CST), ER-retention signal (KXK motif in the 
context of human UGT2), and ER-retrieval sequence (Lys cluster in the C-terminal 
tail in the context of yeast GMT). The human GFT also ends with a GV sequence at its 
C-terminus. However, this GV sequence, even in combination with upstream C-
terminal tail sequence, does not function as an ER export signal in the context of GFT 
as deletion of the C-terminal does not change the localization of GFT in CHO-gmt5 
(Fig. 5.10) and HeLa cells (data not shown). Surprisingly, the C-tail deleted, Golgi-
localized GFT mutant almost completely loses its transport activity. The loss of 
transport activity of GFT due to the deletion (or mutation of key residues) of its C-
terminal tail sequence is unlikely a consequence of loss of protein 
stability/conformation, reasons being: i) all of the C-tail mutants we created in this 
work all corrected targeted to Golgi, and ii) all of the GFT mutants were expressed at 
comparable level as compared to FL GFT according to immunofluorescence 
microscopy. By contrast, the C-terminus of CST, although critical for its localization, 
was shown to be partially or completely dispensable for CST activity by lectin 
blotting and isoelectric focusing analysis of the recombinant product (Lim et al. 2008, 
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Zhao et al. 2006). In addition, biological function of human UGT was also shown to 
be independent of the C-terminal tail (Aoki et al. 1999).  
The cluster of Lys in the C-terminal tail region of yeast GMT was shown to 
interact with COPI coatomer and prevents GMT from accumulating in the non-Golgi 
vacuolar structures (Abe et al. 2004). However, we have shown that disruption of the 
conserved Lys cluster in human GFT did not alter its localization to the Golgi (Fig. 
5.12B). But the fact that mutating all three Lys to Gly significantly compromised the 
GFT transport activity suggests these residues could be involved in other interactions, 
which among many possibilities may include the binding or recognition of nucleotide-
sugar or other proteins. 
Our results clearly demonstrated that despite the substantial sequence 
similarity between different transporters, functions of the less conserved tail 
sequences have diverged during evolution. Impacts of the tail sequences on trafficking 
and function of transporters have to be analyzed in a context-dependent manner. On 
the other hand, although it is practically impossible to deduce the specificity of NST 
based on its primary sequence, residues that are conserved between transporters or 
species can provide hints for elements that are critical for the transport activity of NST. 
Here we showed the C-terminal conserved EM residues have dramatic impact on the 
activity of GFT. Again, the potential interacting partners of the conserved sequence 
remain to be elucidated. 
Membrane-spanning helices have also been shown to have dramatic impact on 
the activity and specificity of NST. Domain-swap experiments have clearly shown 
that different transmembrane helices are utilized for CST and UGT (Aoki et al. 2001, 
Aoki et al. 2003). It was also noted that some areas of the helices are rich in Gly, 
which are largely conserved in many NST proteins by multiple sequence alignment 
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(data not shown). One plausible hypothesis is that these Gly residues, due to the lack 
of side chain, contribute to the formation of transmembrane channels to allow for the 
passage of nucleotide-sugars. This idea was tested in our previous work with CST 
(Lim et al. 2008). We showed that mutation of four pairs of Gly to Ala or Ile 
dramatically impair the transport activity of CST. Our results from GFT further 
supported this notion. We noted that the first Gly residues in the first, third and four 
Gly pairs are conserved in GFT. These Gly residues have different impacts on the 
activity of GFT: the Gly located in helix 5 has partial effect, Gly located in helix 6 is 
dispensable, whereas Gly located in helix 8 is essential (Fig. 5.13). Interestingly, the 
Gly pair in helix 8 of CST was shown to have the strongest impact on CST activity 
(Lim et al. 2008). Therefore, the conserved Gly residues in the transmembrane helices 
are generally required for the transport activity of NSTs instead of determinants of 
their specificities. 
Recently, another Slc35 protein, ER-localized Efr in Drosophila (Ishikawa et 
al. 2010) and ERGIC/cis-Golgi-localized mammalian Slc35c2 (Lu et al. 2010), was 
shown to have transport activity for GDP-fucose and regulate the O-fucosylation of 
Notch. Overexpression of Slc35c2 was shown to compete with the canonical GFT and 
have an inhibitory effect on the formation of Lewis x structure but imposes a marginal 
effect on core fucosylation of N-glycans (Lu et al. 2010). We analyzed the localization 
of GFT in HeLa and found it to have more co-localization with trans-Golgi marker 
and to a lesser extent with medial-Golgi marker (Fig. 5.8). Therefore, the spatial 
segregation of Slc35c2 and GFT explains why Slc35c2 regulates fucosylation of 
Notch, which takes place pre-Golgi, and does not affect core fucosylation of N-
glycans. Thus, targeting GFT is necessary and sufficient for regulating core 
fucosylation of N-glycans at membrane transport level. 
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Overexpression of human GDP-fucose transporter has been associated with 
hepatocellular carcinoma (Moriwaki et al. 2007). Tissue-specific inhibition or partial 
blockage of GFT can be a plausible approach for management of this type of cancer. 
Through the identification of C-terminal sequences critical for the transport activity of 
GFT, we postulate that these regions can be served as drug or antibody targets for 
inactivating the human GFT. 
Absence of core fucose on Fc N-glycan has been shown to enhance the ADCC 
effect of IgG1 (Peipp et al. 2008, Shinkawa et al. 2003). CHO GFT-/- cell line has 
been generated by homologous recombination and used as a host cell line for the 
production of fucose-free recombinant antibody (Ishiguro et al. 2010). Absence of 
sialic acid on Fc N-glycan is also favorable for ADCC effect (Anthony et al. 2008, 
Kaneko et al. 2006). It is tempting to speculate that the absence of both fucose and 
sialic acid will offer combinatorial enhancement to the ADCC effect. Our CHO-gmt5 
with double genetic defects in GFT and CST is capable of producing recombinant 
glycoproteins free of fucose and sialic acid and thus, has the potential application for 
the production of recombinant antibodies with improved ADCC effect. In fact, our 
ongoing study has demonstrated that CHO-gmt mutants (including CHO-gmt1 and 5) 
can be adapted to suspension culture in protein-free media with growth profiles 
similar to that of wild-type CHO-K1 cells. 
CHO glycosylation mutants with genetic defects in multiple NSTs (such as 
CST and UGT) have been isolated and reported (Patnaik and Stanley 2006). Our 
CHO-gmt5 is a new addition to this range of mutants and holds promise for further 
targeting of additional NSTs towards a mammalian cell line with minimal NST 




5.5 Chapter summary 
The broad aim of this chapter is to identify elements that regulate the 
localization and bioactivity of proteins in the glycosylation machinery. Among the 
three major classes of proteins involved in the glycosylation pathway, glycosidases 
and glycosyltransferases are more thoroughly investigated with the determination of 
their crystal structures and functional domains. Elements and interaction partners 
crucial for their localization and activity have been largely elucidated. Progress on 
nucleotide-sugar transporters, however, is greatly impeded due to their lack of any 
defined domain except the multiple membrane spanning regions and the extreme 
difficulty in solving their structures. GDP-fucose transporter is essential for 
fucosylation of glycans. Elucidation of its structure-function relationship remains a 
challenge due to the lack of a mutant cell line that carries a dysfunctional GFT gene. 
Our lab recently generated a CHO glycosylation mutant by inactivating the GFT gene 
using zinc-finger nuclease method on the basis of a lectin selected CHO glycosylation 
mutant CHO-gmt1. The resultant cell line, CHO-gmt5, was shown to produce N-
glycans deficient of sialic acid and fucose. The structure-function relationship of GFT 
was studied by expressing different variants of GFT in CHO-gmt5 cells. Different 
from previously studied CMP-sialic acid transporter and UDP-galactose transporter, 
the C-terminal tail of GFT is not required for its Golgi localization but critical for its 
transport activity. In addition, we found that this impact can be independently 
contributed by a cluster of three lysine residues and a Glu-Met sequence within the C-
terminus. Furthermore, we showed that the conserved glycine residues at position 180 
and 277 of GFT have significant impacts on its activity. Absence of sialic acid and 
fucose on Fc N-glycan has been independently shown to enhance the antibody-
dependent cellular cytotoxicity (ADCC). CHO-gmt5 can represent a more 
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advantageous cell line for the production of recombinant antibodies with further 




CHAPTER 6: RNAi SCREENING OF KINASES AND 
PHOSPHOTASES TO IDENTIFY REGULATOR GENES 
OF CELL SURFACE GLYCOSYLATION 
 
6.1 Introduction 
6.1.1 Regulation of glycosylation: insights from beyond the pathway 
 Intracellular cues such as the expression level of glycosyltransferase alone are 
not sufficient to orchestrate glycosylation change in response to environmental stimuli. 
For example, N-glycans undergo dramatic remodeling during the activation of T 
lymphocytes (Comelli et al. 2006b), strongly suggesting the existence of a signaling 
pathway that bridges the extracellular stimulus to intracellular regulator molecules 
which eventually in a way alters the N-glycosylation. Previous studies identified 
several factors beyond the glycosylation pathway that participate in the alteration of 
glycosylation in cancer cells (Gill et al. 2010, Ko et al. 1999, Padro et al. 2011, Son et 
al. 2011a). These factors include transcriptional activators, cytokines, and signaling 
molecules that control the glycosylation by regulating the expression or localization of 
the corresponding glycosyltransferases. Systematic insights pertaining to the 
regulation at higher order remain scant.  
 
6.1.2 RNAi screening as a functional assay to discover novel genes and 
interactions 
 RNA interference (RNAi) is a post transcriptional gene silencing process in 
which endogenous or exogenous double-stranded RNA (dsRNA) was processed into 
short interring RNA (siRNA) or microRNA (miRNA) to block the translation of 
messenger RNA (mRNA) (Hannon 2002). Since its original discovery in C. elegans 
(Fire et al. 1998), RNAi has been widely used in many aspects of biological research. 
176 
 
Because delivery of double-stranded RNA can specifically silence its target gene 
without directly affecting the genetic background in cells or organisms, RNAi is often 
used as a reverse genetic tool to establish the functions of genes. Systematic 
interrogation of genes by library screening using dsRNA in drosophila cell lines or 
siRNA in cultured mammalian cells has led to the identification of novel genes, 
interactions, and pathways in many important areas such as cell cycle control 
(Schmitz et al. 2010), viral infection (Karlas et al. 2010, Panda et al. 2011), protein 
secretion (Bard et al. 2006), endocytosis (Collinet et al. 2010, Moreau et al. 2011), 
and stem cell differentiation (Chia et al. 2010). There are two major types of readouts 
from RNAi screens, homogeneous assay and imaging-based assay (or high-content 
screening). Homogeneous assay often involves luminescent or fluorescent detection of 
the average signal from all cells in a well, for example the use of horse radish 
peroxidase (HRP) as a reporter molecule for protein secretion (Bard et al. 2006) . 
Typically there is only one parameter measured from the whole population of cells 
within a well. Imaging-based high content screening, on the other hand, allows for 
multiplexed detection using different fluorescent dyes with minimal spectral overlap 
(Collinet et al. 2010). In addition to the ability to measure different parameters 
simultaneously, imaging-based assay generates a collection of raw images which 
allows for subsequent re-analysis and quantification by fine-tuning the data 
acquisition algorithm. Moreover, it is possible to analyze each individual cell in a well 
using imaging-based assay. 
  
6.1.3 Specific aims and outlines 
 We decided to perform a discovery-oriented, systematic interrogation of genes 
to identify factors that affect the cell surface glycosylation by an RNAi screening 
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approach. The collection of kinases and phosphotases, or kinome/phosphotome, 
contains many functionally versatile genes involved in key biological processes such 
as signaling, metabolism and cell cycle control and is often screened for prototypic 
optimization and identification of control genes for subsequent genome-wide 
screening (Pelkmans et al. 2005). For this reason, a kinome/phosphotome siRNA 
library was used in our prototypic screen. Due to the difficulty in adapting the mass 
spectrometry or chromatography-based methods in automated, high-throughput 
screening, we took the advantage of carbohydrate-binding proteins, or lectins, to 
specifically label different glycan structures expressed at the HeLa cell surface. 
Among many steps in glycosylation processes, we were interested in the conversion of 
oligomannose-type and hybrid-type N-glycan to complex-type N-glycans as well as 
the fucosylation of glycans. To this end, we selected two lectins, ConA and AAL, 
which bind to oligomannose/hybrid glycans and fucosylated glycans, respectively. 
The feasibility of using fluorescently conjugated lectin to quantitate the relative 
abundance of cell surface glycans was demonstrated using HeLa and CHO 
glycosylation mutant cells, a fluorescence quantification algorithm and control 
siRNAs targeting known genes affecting the steps of interests. Following that, two 
replicates of kinome/phosphotome siRNA library screening were performed on HeLa 
cells. Data analysis revealed that knockdown of several genes led to significant 
change in ConA or AAL binding to the cell surface, suggesting a role of these genes 







6.2 Experimental procedures 
6.2.1 Reverse transfection of siRNA 
 Human kinome/phosphotome siRNA library, originally from Dharmacon (now 
Thermo Scientific, USA), was kindly provided by Dr Frederic Bard (IMCB, 
A*STAR). The library belongs to siGenome®-line of products and was spotted into 
four 384-well plates, contain 972 pools of siRNA. Each pool contains a mixture of 4 
siRNAs targeting the same gene. 
 The four 384-well assay plates were printed with 2.5 µl of 500 nM siRNA 
solution in each well, leaving only column 1, 3, 22, and 24 blank. The four assay 
plates were then stored at – 20 oC. Before the reverse transfection, the assay plates 
were warmed up at room temperature for about 1 hour. 2.5 µl of 500 nM control 
siRNAs were manually spotted into the respective wells according the layout shown 
in Fig. 6.1. Reverse transfection was done using HiPerFect transfection reagent 
(Qiagen, Hilden, Germany). For one well of a 384-well plate, 0.25 µl of HiPerFect 
reagent was diluted in 7.25 µl of Opti-MEM medium, mixed and incubated at room 
temperature for 5 min. The diluted HiPerFect was then dispensed into the 384-well 
plate using Multidrop Combi at 7.5 µl per well. The plate was briefly shaken and 
incubated at room temperature for 20 min. During this incubation period, HeLa cells 
were trypsinized, pelleted by centrifugation and washed. Viable cell density was 
measured by Cedex cell counter. The cell suspension was then diluted to 5×104 
cells/ml. After the 20 min incubation for HiPerFect-siRNA complex formation, the 
diluted HeLa cell suspension was dispensed into the 384-well plate at 40 µl per well 
(i.e. 2000 cells per well). The plate was briefed rocked and incubated in a dedicated 37 




Fig. 6. 1. Layout of a 384-well siRNA library plate 
siRNA was spotted into all wells except wells in Column 3 and 22. Control siRNA 
were manually pipette into these two columns following the arrangement shown in the 
figure. Yellow: GnTI siRNA; blue: non-targeting siRNA; pink: Fut8 siRNA.  
 
6.2.2 Lectin staining of cell surface glycans 
 70 hours after reverse transfection of siRNA, 384-well plates were taken out 
from the incubator. Conditioned media were aspirated using a 12-channel vacuum 
aspirator. All liquid dispensing steps were performed using an automatic liquid 
handler, Multidrop Combi (Thermo Scientific, Finland). Plates were gently washed 
with PBS and then cells were fixed by 2% paraformaldehyde in PBS (diluted from 16% 
methanol-free paraformadehyde, Thermo Scientific, Rockford, IL) at room 
temperature for 20 min. After two times washing with PBS, 40 µl of Carbo-Free 
Blocking solution was added into each well. After 30 min incubation at room 
temperature, the blocking solution was aspirated and 20 µl of PBS containing 5 µg/ml 
of biotinylated AAL (final concentration) was added into each well and incubated for 
30 min. The plates were then washed three times with PBS and 20 µl of PBS 
containing 10 µg/ml AlexaFluor 488-conjugated ConA, 5 µg/ml AlexaFluor 647-
conjugated streptavidin, and 2 µg/ml Hoechst 33342, was added into each well and 
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incubated for 30 min. Finally, the plates were washed five times with PBS and sealed 
with aluminum adhesive film to block out the light at the top. The plates were scanned 
by an automatic high-throughput imaging station within 2 days of staining. 
 
6.2.3 Automated high-content image acquisition and quantification 
 Fluorescent images were acquired using an IX-Ultra automatic confocal 
imaging station (Molecular Devices, USA), equipped with a 20× objective, a robotic 
arm for handling of the plates, a bar code reader for registration of plate ID, and a 
charge-coupled device (CCD) camera for detection of fluorescence.  
 Imaging parameters were first set manually by adjusting detector gain, offset, 
and scanning speed, such that majority of the signals in both positive and negative 
control wells were within 3/4 of the detection range. Images for Hoechst, ConA, and 
AAL were acquired by sequential scanning using appropriate laser lines. The 
objective lens was automatically focused based on nuclear stain (Hoechst channel). 
Two non-overlapping areas (“sites”) in each well were scanned. Under these 
experimental settings, it took around 3 hours to scan one whole 384-well plate, i.e. 
about 12 hours for one set of kinome/phosphotome library accommodated in four 
plates. Two replica batches of the library plates were scanned. 
 Fluorescence intensity at the cell surface was computed based on a built-in 
algorithm, Transfluor HT. In this algorithm, membrane area was defined by 
continuous regions with fluorescence intensity (ConA and AAL channel respectively) 
above a manually set threshold value. Fluorescence intensity was calculated within the 
defined membrane areas and integrated to give the total fluorescence intensity. Total 
membrane area was also calculated. Similarly, signal for the Hoechst channel was 
used to define nuclear region and area from which the cell number was estimated. 
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 6.2.4 Data analysis 
 Because the siRNAs were arranged based on the ontology of their kinase or 
phosphotase targets, normalization using z-score will potentially create bias in plates 
where regulators of glycosylation are more enriched (Moreau et al. 2011). Instead, we 
used a control-based normalization approach in which average fluorescence intensities 
(F) of positive and negative controls were used to define the range of change (Fpc – 
Fnc). Values from experimental wells were similarly compared to negative control to 
calculate individual change of average fluorescence intensity (F – Fnc). Relative fold 
change (RF) was then calculated by normalizing the individual change to the range of 
change:  
                                    					!" = 	
#$#%
#&%$#%
                                       Equation 3 
  
 Primary screening results were sorted by RF values. Cutoff values were 
manually determined based on the distribution of data. Genes associated with RF 
values beyond the cutoff values were considered as potential hits.  
 
6.3 Results 
6.3.1 Proof-of-concept  
 To prove that quantitative difference in cell surface glycan structures can be 
detected by lectin staining, cell surface carbohydrates of two CHO glycosylation 
mutant lines, CHO-gmt1 (GnT-/-) and CHO-gmt5 (GFT-/-), were labeled by 
fluorescently conjugated ConA and AAL and compared to HeLa cells (Fig. 6.2). HeLa 
cell surface was moderately stained by ConA lectin, due to the presence of 
oligomannose-type and bi-antennary glycans. In comparison, ConA fluorescence was 
stronger at the cell surface of CHO-gmt1 cells because GnTI knockout in CHO-gmt1 
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stalls the N-glycosylation at Man5 stage leading to accumulation of oligomannose-
type glycan at its cell surface. On the other hand, HeLa cell surface was strongly 
labeled by AAL, due to the presence of abundant core fucosylated N-glycans. Because 
of the GDP-fucose transporter knockout, AAL failed to stain the cell surface of CHO-
gmt5. The lectin staining protocol was able to label exclusively carbohydrates at the 
cell surface and detect quantitative difference in relative abundance of the cognate 
glycan structures.  
 
Fig. 6. 2. ConA and AAL staining of HeLa and CHO mutant cell lines 
HeLa, CHO-gmt4 (GnTI-/-), and CHO-gmt5 (GFT-/-) cells were seeded in 384-well 
plate and cultured overnight. Next day, cells were fixed by 4% PFA in PBS and 
stained with AlexaFluor 488-conjugated ConA as well as biotinylated AAL. Bound 
AAL was revealed by AlexaFluor 647-conjugated streptavidin. Images were captured 
using Cellomics ArrayScan VTI. Note the bright spots in CHO-gmt5 (GFT-/-) AAL 
channel were background noise possibly caused by AAL aggregates.  
 
 Efficient gene silencing under the transfection protocol was demonstrated 
using a siRNA pool from the library that targets the human GnTI. Reverse 
transfection of this siRNA pool into HeLa cells that stably expressed GnTI-mCherry 
fusion protein resulted in depletion of mCherry signal in majority of the cells under 
the microscope (Fig. 6.3). In comparison, cells treated with a siRNA pool that did not 
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target any gene (“non-targeting siRNA”) showed strong mCherry signal in every cell. 
Thus, using the reverse transfection protocol, potent knockdown was observed at 
protein level.  
 
Fig. 6. 3. Reverse transfection of GnTI siRNA induced potent knockdown of 
GnTI at protein level 
A stable HeLa cell line that expressed GnTI-mCherry was reverse transfected with 
either GnTI siRNA, or non-targeting (denoted as N.T.) siRNA. Two days after 
transfection, nuclei were labeled with Hoeschst 33342. Images were captured with a 
Carl Zeiss AxioVert 200M microscope.  
 
 The effect of GnTI knockdown on ConA binding the cell surface was 
quantitatively assessed using TransfluorHT algorithm. HeLa cells in the well 
receiving GnTI siRNA was strongly stained by ConA and the average ConA 
fluorescence intensity calculated by Equation 3 was over 100. HeLa cells in the well 
treated with non-targeting siRNA showed moderate ConA fluorescence and the 
average intensity was about 60. Therefore, siRNA knockdown of GnTI, a gene that 
critically regulate the conversion of oligomannose-type glycans to complex-type 
glycans, resulted in about 60% increase in ConA fluorescence intensity (Fig. 6.4), 
suggesting an increase in oligomannose-type glycans on the cell surface. Similarly, 
TransfluorHT algorithm was tested for AAL using HeLa and CHO-gmt5 as positive 
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and negative controls. Knockout of GDP-fucose transporter resulted in about 90% 
reduction of AAL binding to the cell surface (Fig. 6.4). The whole process from 
reverse transfection to data acquisition was then applied to the whole library to initiate 
primary screening. 
 
Fig. 6.4. Quantification of ConA and AAL fluorescence intensity at the cell 
surface of HeLa and mutant cells 
HeLa cells were reverse transfected with GnTI siRNA or non-targeting siRNA in a 
384 well plate. The plate was scanned by the IX-Ultra imaging station. Average 
membrane fluorescence intensity (arbitrary fluorescence unit) was quantified by 
measuring the total fluorescence intensity and membrane area within a well.  
 
6.3.3 Primary screens 
 Primary screening of the kinome/phosphotome siRNA library was performed 
in two replicates under identical conditions. Results from the ConA channel and AAL 
channel are separately described here. 
  
6.3.3.1 ConA screens 
 Average membrane ConA fluorescence intensity in each well was calculated 
based on total fluorescence intensity and membrane area quantified by TransfluorHT 
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algorithm. To allow for comparison among different plates, the average intensity was 
normalized to a plate control, i.e. the median value of average fluorescence intensity 
of the negative control wells (containing non-targeting siRNA) to yield relative ConA 
intensity. Results from all siRNA-containing wells were plotted to check for data 
distribution and reproducibility (Fig. 6.5). As expected, relative ConA intensity values 
of all negative control wells were scattered around 1 while values of all positive 
control wells were significantly higher, centering around 1.5 in both replicates. There 
is a good correlation between the two replicates, suggesting overall high 
reproducibility (Fig. 6.5 right). 
 
 
Fig. 6. 5. Results for primary ConA screens 
Relative ConA fluorescence intensity in each well was calculated by normalized the 
average fluorescence intensity to that of the negative control wells and plotted against 
its cumulative well ID for each replicate. To check for reproducibility, relative ConA 
intensity in replicate 1 was plotted against that in replicate 2 of the matching well 
(shown on the right). Red dots indicate values of positive control wells (GnTI siRNA). 
Blue dots indicate values of negative control wells (non-targeting siRNA). Black dots 




 Due to the signal fluctuation in the control wells, relative fold change was used 
as the final score by normalizing the change in relative ConA intensity (F – Fnc) to 
the range of change (Fpc – Fnc). The relative fold change takes into consideration the 
plate-to-plate variation of control well values and thus allows for fair comparison of 
phenotypic change across different plate. By this definition, relative fold change is 
proportional to ConA binding to the cell surface. A high relative fold change value 
implies that knockdown of the corresponding gene results in upregulation of 
oligomannose-type of N-glycans. Relative fold change was calculated for each well 
containing siRNA and ranked in descending order (Fig. 6.6). Such plot for replicate 1 
showed a curve almost linear in the middle, with a concave head and a short convex 
tail, implying that RNAi of genes corresponding to the head region resulted in more 
dramatic increase in ConA binding. This profile was largely conserved in replicate 2. 
To select for hits that resulted in increase in ConA binding, we predetermined a cutoff 
value of 30% relative fold change. siRNAs that resulted in more than 30% relative 
fold change was considered hits. This cutoff line managed to contain all the concave 
head of the curve into the “hit region”. By this selection criterion, 184 and 187 genes 
were considered as hits for replicate 1 and 2, respectively. There was a good 
correlation between replicate 1 and replicate 2 hits with 113 genes (~2/3) conserved in 
the two replicates (Fig. 6.6 right). Interestingly, the top hits in the two replicates were 
identified as the same kinase gene. The other hits were constituted by a variety of 






Fig. 6. 6. Ranking of relative fold change values and selection of hits for the 
ConA screens 
Relative fold change value of each well was calculated by normalizing the change of 
average fluorescence intensity (compared to negative control) to range of change (i.e. 
change of average fluorescence intensity in GnTI siRNA wells compared to negative 
control). Data were arranged in descending order. Genes whose knockdown resulted 
in more than 30% of relative fold change (red line) were selected as hits. Common 
and replicate-specific hits were shown in the pie chart on the right. Among the 180 hit 
in each replicate, 113 hits were conserved. 
 
6.3.3.2 AAL screens 
 α1,6-fucosyltransferase (Fut8) was initially selected as a positive control gene 
for fucosylation. It was expected that knockdown of Fut8 would lead to significant 
decrease of AAL binding to the cell surface. However, knockdown of this gene using 
siRNA pool did not result in substantial decrease of AAL binding (Fig. 6.7). By 
contrast, siRNA targeting of GnTI led to more significant reduction of AAL binding 
to HeLa cell surface. Therefore GnTI was used as the positive control for 
identification of positive regulator genes for fucosylation. 
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 Plots of relative AAL fluorescence intensity in both replicates were shown in 
Fig. 6.7. Values for wells receiving non-targeting siRNA were scattered around 1. 
Well treated with GnTI siRNA showed lower values ranging from 0.7 – 0.9. Well 
treated with Fut8 siRNA showed less significant decrease in AAL fluorescence 
intensity, possibly due to the long half life or resistance to RNAi of the endogenous 
Fut8. Correlation plot suggested overall good reproducibility (Fig. 6.7 right). 
   
 
 
Fig. 6. 7. Results for primary AAL screens 
Relative AAL fluorescence intensity in each well was calculated by normalized the 
average fluorescence intensity to that of the negative control wells and plotted against 
its cumulative well ID for each replicate. To check for reproducibility, relative AAL 
intensity in replicate 1 was plotted against that in replicate 2 of the matching well 
(shown on the right). Red dots indicate values of positive control wells (GnTI siRNA). 
Blue dots indicate values of negative control wells (non-targeting siRNA). Pink dots 
indicate values of Fut8 siRNA treated wells. Black dots indicate values of wells 
containing siRNA constituting the library.  
 
 Data was normalized as described for ConA screens. Basically, relative fold 
change was used as the final score by normalizing the change in relative AAL 
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intensity (F – Fnc) to the range of change (Fpc – Fnc). A high relative fold change 
value implies that knockdown of the corresponding gene results in upregulation of 
fucosylated glycans. Conversely, relative fold change with negative value implies that 
knockdown of the corresponding gene results in downregulation of fucosylated 
glycans. Relative fold change was calculated for each well containing siRNA and 
ranked in ascending order with the initial aim to identify genes that positively regulate 
fucosylation (Fig. 6.6). Such plot for replicate 1 showed a curve almost linear in the 
middle, with a convex head and a concave tail. This profile was largely conserved in 
replicate 2. To select for hits that resulted in decrease in AAL binding, we 
predetermined a cutoff value of -67% relative fold change. siRNAs that resulted in 
more than 67% decrease in relative fold change was considered hits for positive 
regulators of fucosylation. This cutoff line managed to contain all the convex head of 
the curve into the “hit region”. By this selection criterion, 74 and 67 genes were 
considered as hits for replicate 1 and 2, respectively, among which 33 were common 
hits (Fig. 6.6 right). Plotting of relative AAL intensity on siRNA-treated HeLa cell 
surface in Fig. 6.6 revealed several wells with unprecedented increase in AAL binding. 
This suggested that the process of fucosylation, though occurring abundantly in HeLa 
cells, could be negatively regulated at normal physiological state. To identify such 
“negative regulator” genes, we predetermined a cutoff value of 75% relative fold 
change. siRNAs that resulted in more than 75% relative fold change was considered 
hits for negative regulators of fucosylation. This cutoff line managed to contain all the 
concave tail of the curve into the “hit region”. By this selection criterion, 39 and 43 
genes were considered as hits for replicate 1 and 2, respectively, among which 20 
were common hits (Fig. 6.6 right). Hits for positive and negative regulation of 
fucosylation consist of a variation of kinases and phosphotases. Interestingly, some of 
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the identified hits are ontologically or functionally clustered, suggesting a role of 





Fig. 6. 8. Ranking of relative fold change values and selection of hits for the AAL 
screens 
Relative fold change value of each well was calculated by normalizing the change of 
average fluorescence intensity (compared to negative control) to range of change (i.e. 
change of average fluorescence intensity in GnTI siRNA wells compared to negative 
control). Data were arranged in descending order. Genes whose knockdown resulted 
in an increase of more than 75% of relative fold change (red line on the top of each 
plot) were selected as hits as negative regulators of fucosylation. Genes whose 
knockdown resulted in an decrease of more than 67% of relative fold change (red line 
at the bottom of each plot) were selected as hits as positive regulators of fucosylation. 
Common and replicate-specific hits were shown in the pie charts on the right. 33 hits 
for positive regulators were conserved in the two replicates and 20 “negative regulator” 





 One question pertinent to the field of glycobiology is how cells orchestrate the 
glycosylation of their cell surface proteins in response to intracellular and extracellular 
cues. Recent studies suggested that cell surface glycosylation can be regulation by 
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transcriptional control of glycosyltransferases in the context of N-glycosylation 
(Dennis et al. 2009, Lajoie et al. 2009), or by signal-induced translocation of initiation 
enzymes in the context of O-glycosylation (Gill et al. 2010). However, elucidation of 
regulation mechanism for glycosylation at system level remains a challenge. This 
study aims to provide initial clues for the regulation of cell surface glycosylation using 
a functional RNAi screening approach targeting all the kinases and phosphotases. 
Kinome/phosphotome siRNA library was often used for prototypic screening to 
optimize the conditions as well as to identify control genes at lower cost and shorter 
time frame compared to whole genome library (Farhan et al. 2010, Pelkmans et al. 
2005).  Because kinase and phosphotase are central to many key biological processes, 
such as signal transduction, metabolism and membrane trafficking, we postulate that 
regulator genes of glycosylation should be more enriched in the kinome/phosphotome 
as compared to the whole human genome. In fact, results from our primary screens 
showed up to 10% of the kinome/phosphotome genes could be involved in the 
regulation process (see below). By contrast, about 1% open reading frames of the 
human genome are dedicated to glycosylation (Marino et al. 2010).  
 We optimized a lectin staining protocol to specifically label the cell surface 
glycans. On the basis of a built-in algorithm, parameters were optimized to allow for 
sensitive and robust quantification of lectin-mediated fluorescence intensity at the cell 
surface. Despite fluctuation in signal, trend of lectin intensity was reproducibly 
obtained. Using these protocols, we performed RNAi using the kinome/phosphotome 
library. Initial data from the primary screens suggested a huge number of genes (~100) 
seem to affect the binding of ConA to the cell surface. In other words, these genes 
could represent regulator genes that positively control the conversion of 
oligomannose- or hybrid-type N-glycans to complex-type N-glycans. Accumulation of 
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oligomannose-type glycans and conversely, depletion of branched complex-type 
glycans was shown to be associated to autoimmune syndrome similar to lupus in mice 
model (Green et al. 2007). Therefore, the identified putative regulator genes could 
represent interesting molecular targets for studying autoimmune diseases that involve 
aberrant expression of N-glycans. 
 Based on the fact the AAL can strongly label HeLa cell surface, our initial aim 
for AAL screens was to identify genes that positively regulate fucosylation, i.e. 
siRNA silencing of the gene leads to reduction of AAL binding. Interestingly, 
screening the kinome/phosphotome library also revealed a number of genes that 
appeared to negatively regulate the fucosylated. Knockdown of these gene resulted in 
significantly increase in AAL binding to the cell surface. Therefore, selection of hits 
was extended to include both positive and negative regulators. In this regard, we 
identified 33 and 20 hits that were reproducibly in the replicate screens, respectively. 
Upregulation of fucosylation is a well established signature in many types of cancer 
(Aoyagi et al. 2002, Miyoshi et al. 2008). The primary hits for fucosylation regulation 
could represent a set of molecular targets in cancer research. 
 It may be argued that it is too early to conclude the functions of the genes 
based on primary screening results. One major potential pitfall is the off-target effect 
of siRNA which has to be ruled out by complementary assays such as rescue of 
phenotype. The siRNA library used in this study contains pools of multiplex siRNA 
each targeting the same gene. It is envisaged that off-target effect on one siRNA will 
be diluted by the presence of the other three less promiscuous siRNAs. Results from 
similar imaging-based high-throughput RNAi screens showed that majority of the hits 
identified in the primary screen could be validated in secondary assay (Moreau et al. 
2011). Nevertheless, the hits we identified in the primary screens will be subjected to 
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orthogonal assays for validation. Systematic analysis, including pathway association 
and interaction analysis will be performed on the validated hits, which eventually will 
lead to the identification of genes/complexes/pathways that regulate the cell surface 
glycosylation at systems level. Regulator gene identified through this study also 
represents promising targets for genetic engineering of host cell lines for the 
production of glycoproteins with defined, optimal carbohydrate structures. 
 
6.5 Chapter summary 
 Change of cell surface glycosylation has long been observed and well 
documented in cancer and other important physiological response such as 
immunological activation. Insights from the transcriptional regulation of glycogenes 
alone cannot fully decipher the global regulation mechanism that orchestrates the cell 
surface glycosylation. We initiated a high-throughput functional RNAi screen 
targeting all the kinases and phosphotases in the human genome to systematically 
identify regulator genes for cell surface glycosylation. To allow for automated parallel 
analysis of accompanying change in cell surface glycans, we optimized a lectin 
staining based assay using two lectins that recognize two categories of important 
glycan structures, namely ConA for oligomannose- and hybrid-type glycans and AAL 
for fucosylated glycans. Primary screen was performed in two replicates and 
consistent results were obtained pertaining to relative fluorescence intensity of ConA 
and AAL at the cell surface. Analysis of the primary screen data revealed at least 100 
genes with putative functions on conversion of oligomannose- or hybrid-type glycans 
to complex-type glycans. A number of genes appear to positively (n = 33) or 
negatively (n = 20) regulate the fucosylation of cell surface glycans. The primary 
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screens shortlisted a set of putative glycan regulator genes and allows for focused, 




CHAPTER 7: CONCLUSIONS AND 
RECOMMENDATIONS 
 
Protein glycosylation entails a complex network of post translational 
modifications of proteins by carbohydrates. It plays a pivotal role in determining the 
function and fate of glycoproteins and the host cells. Elucidation of the mechanism for 
regulation of glycosylation has been impeded by the challenge in systematic 
characterization of the glycan structures and lack of functional insights into the 
impacts of genes on this process at pathway and systems levels. A multilayered 
approach to decipher the regulation mechanism of glycosylation is presented in this 
thesis. Main findings from this study are summarized below together with 
recommendations for future work. 
 
7.1 Understanding the diversity of glycosylation: Insights from 
glycomic profiling of host cell lines and recombinant glycoproteins 
The first layer of analysis aims to gain insights into the baseline glycosylation 
status of five commonly used mammalian cell lines, namely CHO-K1, BHK-21, 
HEK293, COS-7 and 3T3. Glycomic profiles of endogenous and recombinant 
glycoproteins in these cell lines were systematically characterized by a combination of 
mass spectrometric and chromatographic techniques. N-Glycomes of the five cell 
lines all contained a diverse set of structures including oligomannose-type, hybrid-
type and complex-type glycans. Several immunogenic non-human N-glycan structures 
containing α-Gal epitope were detected in BHK-21 and 3T3 cells, raising safety 
concern when these cell lines are applied for recombinant production of glycoproteins 
and viral vectors. Sialylation extent of N-glycans, a parameter critical for in vivo 
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circulatory half life of glycoproteins, was shown to be highly dependent on the host 
cell lines, which follows the order: BHK-21>CHO>COS-7>HEK293>3T3. The 
difference in O-glycosylation among these cell lines displayed more qualitative 
difference: CHO-K1 O-glycome was found to be relatively simple, containing only 
mono- and di-sialyl T antigens. These two species were the dominant structure in all 
the five cell lines. However, additional core 2-based structures were also detected in 
the other four cell lines, generating a greater heterogeneity in their O-glycomes. The 
glycomic profiling of the five cell lines suggested that protein glycosylation is a 
regulated process. Comparative sialylation analysis suggested BHK-21 and CHO-K1 
are preferred hosts for recombinant production of highly sialylated glycoproteins. 
It was also noted during the annotation of glycan structures in MALDI-TOF 
spectra that many peaks could match multiple structures. An example for such 
ambiguity is the presence of multiple LacNAc units, which can be arranged in parallel 
branches or in connection to each other to form poly-LacNAc motif. Such problem 
can be resolved by tandem MS/MS analysis of fragment ions of the precursor species 
(North et al. 2012). By analyzing the m/z values of fragment ions, some of the 
putative structures for the mother peak can be eliminated. Another challenge is MS 
analysis of glycans is the detection of small O-glycans such as the Tn antigen. In fact, 
MS-based O-glycomic profiling of the five cell lines failed to detect Tn structure, 
despite the high intracellular abundance of this structure as evident in HPA staining 
experiment. A complementary approach to solve this problem is chromatographic 
analysis of O-glycans (Backstrom et al. 2009, Perdivara et al. 2009). In this approach, 
the O-glycans can be labeled at the reducing end and separated by a HPLC system. 
The presence or absence of Tn structure in the five cell lines can be ascertained by 
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comparing the elution profile with that of a reference standard containing Tn 
structures, or by coupling the HPLC to a MS system for detection.  
 
7.2 Regulation of glycosylation at pathway level: Insights from 
functional analysis of pathway-associated glycogenes 
Structural glycomic analysis of EPO-Fc revealed a significant difference in 
sialylation extent of N-glycans in the five cell lines, suggesting an underlying 
mechanism that controls the glycosylation in different cell lines. To investigate the 
impact of different components of the glycosylation pathway on the final repertoire of 
glycan structures, 31 genes that are directly involved in the N-glycosylation pathway 
were cloned and heterologously expressed in the aforementioned five cell lines as well 
as NS0 cells. Impact of these genes on sialylation was revealed by the IEF profile of 
EPO. Overexpression of three sialyltransferases significantly enhanced the sialylation 
of recombinant EPO produced in HEK293, COS-7, 3T3 and NS0 cells. None of these 
genes could enhance EPO sialylation in BHK-21 and CHO-K1 cells. The other 
glycogenes involved in upstream reaction steps could not synergize the effect of these 
sialyltransferases to further enhance sialylation. Transcriptional analysis of 
endogenous glycogene expression showed a relatively low abundance of 
sialyltransferases ST3GalIII in HEK293, 3T3 and NS0 and a relatively high 
abundance of a upstream glycogene, GlcI. The expression level of ST3GalIII in these 
three cell lines positively correlated to EPO sialylation extent. This study represents a 
set of functional, mechanistic insights which supports the notion that glycan structural 
diversity is mainly a consequence of different expression of glycogenes that control 
terminal modifications (Comelli et al. 2006a, Nairn et al. 2008). 
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Significant mass signals corresponding to asialo-glycans were detected in 
recombinant EPO-Fc produced in BHK-21 and CHO-K1 cells. A hypothesis for the 
observation of these asialo-glycans is that glycogenes that act immediately 
downstream of such structures are “insufficiently” expressed and therefore might 
represent “bottlenecks” along the glycosylation pathway towards final sialylation. 
However, here we showed overexpression of any of the pathway-associated glycogene 
could not enhance EPO sialylation in these two cell lines. Therefore, the presence of 
such asialo-glycan structures could be a consequence of glycoprotein escaping from 
downstream modifications or sequestration of asialo-glycans by endogenous lectins 
along the secretory pathway. It is thus anticipated that glycoengineering of BHK and 
CHO by targeting the glycosylation pathway cannot lead to significant improve of 
sialylation. 
A side observation in this study is that overexpressions of some glycogenes 
adversely affected EPO sialylation. It would be interesting to investigate the role of 
these genes on sialylation by a reciprocal approach. Using specific siRNAs, the 
expression of these genes can be reduced and the accompanying effect on EPO 
sialylation can be ascertained by IEF, MALDI-TOF and HPAEC techniques. 
  
7.3 Regulation of glycogene-encoded proteins: Insights from 
structure-function analysis of GDP-fucose transporter 
Localization and structure-function relationship of glycogene-encoded proteins, 
i.e. glycosidases, glycosyltransferases, and nucleotide-sugar transporters, have been a 
long standing question. Such data is essential for understanding the mechanism for 
controlling these proteins in response to physiological change (Gill et al. 2010). While 
recent research has shed light on the essential elements for localization and activity of 
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glycosidases and glycosyltransferases (Breton et al. 1998, Tu and Banfield 2010), 
elucidation of structure-function relationship of nucleotide-sugar transporters remains 
a challenge to the lack of well-defined domain structures. Our lab previously 
generated a CHO glycosylation mutant of GDP-fucose transporter (GFT) (Zhang et al. 
submitted manuscript). On the basis of this mutant, a set of GFT mutant constructs 
harboring mutations introduced to putative key positions were functionally analyzed. 
Through these analyses, we identified a conserved Glu-Met motif and a cluster of Lys 
residues in the C-terminal tail of GFT having a critical impact on the transport activity 
of GFT. In addition, three conserved Gly residues located in different transmembrane 
helices are also essential for GFT activity. The C-terminal motifs and helical Gly 
residues represent conserved and context-dependent elements critical for bioactivity of 
nucleotide-sugar transporters, respectively. These elements could represent promising 
targets for inactivating GFT as a therapeutic approach to block fucosylation 
implicated in hepatocellular cancer (Miyoshi et al. 2008). 
The GDP-fucose transporter purified from rat liver appeared as a homodimer. 
Because of the high homology between rat and human GFT proteins, it is tempting to 
speculate that the human GFT also exists as a homodimer. It will be interesting to 
investigate if such dimerization really occurs in vivo and if the essential motifs on the 
C-terminal are critical for the dimerization process. This hypothesis can be tested 
using bimolecular fluorescence complementation (BiFC) assay, which has been 







7.4 High-order regulation of glycosylation: Insights from 
functional RNAi screens 
Several lines of evidence strongly suggested that glycosylation can be 
regulated at systems level by cellular responses to extracellular stimuli which lead to 
translocation of glycosyltransferase (Gill et al. 2010) or induce its expression (Comelli 
et al. 2006b). As an attempt to systematically identify genes that regulate the cell 
surface glycosylation, we conducted RNAi screens targeting all the kinases and 
phosphotases in the human genome. Using ConA and AAL lectins to specifically label 
oligomannose-type and fucosylated glycans at the cell surface, the primary screening 
results suggested a significant numbers of genes could play a role in the transition of 
oligomannose/hybrid-type glycans to complex-type glycans as well as in fucosylation 
of glycans. Validation of the primary hits was underway during the preparation of the 
thesis. Nevertheless, it appears that multiple kinases and phosphotases can regulate the 
glycosylation process up stream of the glycosylation pathway in response to 
extracellular or intracellular signals. 
Validation of the hits involves the use of deconvoluted siRNAs targeting the 
same gene to rule out possible off-target effect. The imaging-based quantification 
method can be complemented by FACS analysis of lectin binding to cell surface 
glycans. Rescue of phenotype can be performed by expressing siRNA-resistant genes 
in the siRNA-treated cells to confirm the function of such genes. Interaction and 
pathway-associated analysis will aid in elucidation of possible mechanism of the 
validated hits in regulating the cell surface glycosylation. Interactions/pathways that 
are over-represented with validated hits will be subjected to detailed biochemical 




In summary, this multifaceted investigation of glycosylation leads to the 
generation of a rich dataset with potential applications in cell line selection for the 
production of favorable glycoforms, and target selection for effective engineering of 
the glycosylation pathway. This study also sheds light on a mechanistic understanding 
of regulation of glycosylation and glycogene-encoded proteins at pathway and 
systems levels. 
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